

Pasture.
Holdings

LOOKING TO THE FUTURE:

**Our Journey to
*Better Health***



Annual Report 2025

COUNTDOWN TO
30
Pasture.
Group
est. 1996

Mission

From our big-picture strategy to our daily operations, our mission is to:

- Provide creative solutions to health challenges by harnessing science, technology, and meaningful relationships
- Improve quality of life for the community through holistic solutions
- Build healthier, more resilient communities around the world

Our Vision

Merging Empathy with Science: Solutions for Life.

Contents

Corporate Review

- 01** Corporate Profile
- 02** Our Brands and Capabilities
- 04** Chairman's Statement
- 06** Key Milestones
- 07** Financial Highlights
- 08** Investor Relations
- 09** Corporate Information
- 10** Board of Directors
- 12** Executive Team
- 13** Group Structure
- 14** Certifications and Accreditations
- 16** Sustainability Report

Financial Content

- 52** Corporate Governance Report
- 72** Financial Statements
- 118** Statistics of Shareholdings
- 120** Notice of Annual General Meeting
- 126** Disclosure of Information on Directors Seeking Re-Election
- 132** Appendix
Proxy Form

This annual report has been reviewed by the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the sponsor is Mr Shervyn Essex 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Corporate Profile



FY2025 Revenue
US\$12.2 million



FY2025 Net Profit
US\$541 thousand

Leading with a people-first approach grounded in agility, care, and community, Pasture Holdings Ltd. distinguishes itself as a trusted pharmaceuticals and medical supplies distributor. The Company integrates R&D and manufacturing capabilities to deliver innovative healthcare solutions.

Since the Group's founding in 1996, Pasture has grown steadily, expanding from Singapore into over 50 countries. While our reach is now global, we stay grounded in our values, putting people and their health first. We focus on providing lean, effective solutions that meet the needs of our partners, from distributors and governments to institutional customers such as hospitals, pharmacies, and healthcare providers.

In contrast to the traditional pharmaceutical model, we remain adaptable, constantly exploring new ways to improve healthcare access and meet the needs of evolving markets. This includes ventures into B2C segments such as the pet pharmaceuticals market.

Our subsidiaries work together to offer a comprehensive range of products and services. From our innovative Hart-S ODS and other oral disintegrating strip products, to our pet health platform and community, *furlife*, we are constantly driven by the desire to improve lives – be it human or pet.



Our Brands and Capabilities

Our Core, Our Commitment

Pasture's foundation is built on consistency, care, and capability. We continue to invest in the brands and systems that support everyday health. From essential medicines to trusted medical devices, our core portfolio keeps us steady as we grow to serve more across Southeast Asia.

Pasture Mask®

A hallmark of safety and trust, Pasture Mask® includes our range of N95 respirators, surgical N95 respirators, surgical masks, and N95 respirators for general public use. Developed through rigorous R&D and collaboration with certified manufacturers, our masks have been supplied globally in volumes exceeding 100 million units.



With 14 U.S. Food and Drug Administration (“FDA”) clearances and 20 National Institute for Occupational Safety and Health (“NIOSH”) certifications, Pasture Mask® continues to stand for uncompromising quality in respiratory protection. We also hold ISO 13485:2016 certification for the design and development of medical masks, underscoring our adherence to international medical device quality standards.

Pasture+®

Pasture+® is our medical supplies and consumables brand, aimed at empowering healthcare professionals with reliable, essential tools for patient care. Its portfolio covers airway management, diagnostics, IV therapy and vascular access, wound care, urology, incontinence care, personal protective equipment (“PPE”), and more. By continually broadening its range, Pasture+® aspires to support better outcomes in everyday healthcare practice.

DDS – Drug Delivery System

Our proprietary Drug Delivery System (“DDS”) platform is built around Oral Disintegrating Strips (“ODS”), offering a patient-friendly alternative to conventional oral medicines. The first in this range, Hart-S, is being developed for Sildenafil (used in erectile dysfunction), delivering a discreet, convenient, and effective option for patients. DDS reflects our commitment to patient-centric innovation that transforms how medicines fit into daily life.



Innovating for Impact

At Pasture, growth isn't just about scale – it's about intention. We're entering new spaces that align with market needs and our mission to make care more human, accessible, and future-ready.

furlife

furlife is Pasture's pet health and wellness platform, designed to support preventative care, treatment, and responsible ownership. By integrating wellness products and community initiatives, *furlife* extends our healthcare expertise into the lives of companion animals. It reflects our commitment to making quality healthcare accessible – not just for people, but also for the pets we consider family.



Our Capabilities

Beyond our branded products, Pasture provides the backbone services that ensure healthcare solutions reach those who need them.

- **Pharmaceutical Distribution (Wholesale & Drop-Shipment):** Specialised in cold-chain management for temperature-sensitive medicines such as vaccines and oncology treatments, supported by Good Distribution Practice (“GDP”) and Good Distribution Practice for Medical Devices (“GDPMDS”) certified frameworks.
- **Procurement & Warehousing Services:** End-to-end solutions for international ePharmacy businesses, including sourcing, compliance, trans-shipment, and storage – ensuring integrity and efficiency throughout the supply chain.



Chairman's Statement

FY2025 tested our resilience, but Pasture remained profitable, proposed its first dividend, and expanded regionally through strategic partnerships in Malaysia and Thailand. Guided by our belief in 'small pharma, big impact', we continue to deliver healthcare solutions with purpose and care.



Dear Shareholders,

It is my privilege to present Pasture Holdings Ltd's third annual report as a listed company on the SGX-Catalist board, covering the financial year ended 30 June 2025 ("FY2025"). Despite a challenging macroeconomic backdrop, Pasture remained profitable, strengthened its balance sheet, and advanced strategic partnerships across the region.

Financial Discipline and Shareholder Value

Revenue softened this year with the completion of a major government tender and regulatory shifts. Even so, we maintained profitability, improved efficiency, and increased cash reserves while reducing liabilities. A milestone of particular pride is the proposal of our inaugural dividend – our first since IPO. This reflects both our financial resilience and our commitment to delivering shareholder value, even in the face of a challenging macroeconomic environment.

Regional Expansion and Partnerships

We deepened our regional presence through two significant initiatives. In Malaysia, our investment in AP Bioresources Sdn Bhd established a direct operational base, enabling greater access to government tenders and stronger supply chain integration. In Thailand, we signed a term sheet with the Government Pharmaceutical Organisation ("GPO") for the exclusive distribution of Sildenafil (50mg) in the form of our proprietary Oral Disintegrating Strip ("ODS"). Both moves signal our intent to scale in Southeast Asia with agility and purpose.

Chairman's Statement



Innovation and Proprietary Platforms

Our proprietary **ODS** platform, exemplified by HART-S (Sildenafil 50mg), reflects our commitment to advancing innovative drug delivery systems that are discreet, scalable, and patient-friendly. We are also extending this approach to other therapeutic areas, including oncology, while continuing to build value in proprietary brands that form the foundation of our long-term growth. These investments form the foundation of Pasture's long-term growth and reaffirm the commitments made at the time of the IPO: to transform Pasture from a distributor into a platform for healthcare solutions.

Commitment to Community

Our healthcare journey extends beyond profit. *furLife* continues to support pet owners with community initiatives and health products they can trust. This year also saw the launch of our inaugural CSR Day with HCA Hospice, reflecting our ongoing commitment to community care. These initiatives remind us that our purpose lies not only in commercial growth but in meaningful contributions to society.

Looking Ahead

FY2026 will bring both challenges and opportunities. Pasture is well-positioned to operationalise new partnerships, expand our proprietary platforms, and pursue regional growth with discipline. As we approach our 30th anniversary in 2026, we remain guided by our belief in "small pharma, big impact" – delivering healthcare solutions with resilience, innovation, and care.

I extend my deepest appreciation to our employees, partners, and shareholders for your trust and support as we continue this journey together.

LLOYD SOONG

Chairman, Executive Director & CEO

Key Milestones

2025

- **Strengthened regional presence:** Established an operational base in Malaysia to support supply chain integration
- **Growth through strategic investment:** Secured a 50% equity stake in AP Bioresources Sdn Bhd, a medical devices distributor.
- **Expanded access to innovative therapies:** Entered an exclusive distribution agreement with Thailand's Government Pharmaceutical Organisation for our innovative drug delivery system.
- **Scaled proprietary platform:** Commercialised HART-S, Pasture's Oral Disintegrating Strip (sildenafil 50mg), as part of our growing drug delivery portfolio.
- **Returned value to shareholders:** Proposed inaugural dividend subject to shareholders' approval at the forthcoming Annual General Meeting to be convened in October 2025.

2024

- Relocated to a new facility double the previous size
- Partnered with animal welfare organisations to promote responsible pet ownership and engage dog community
- Relunched *furlife* app

2023

- Pasture Holdings Ltd. listed on the Singapore Exchange SGX-Catalist under (SGX:UUK).
- Launched the beta version of "furlife", a mobile application and website designed to provide a comprehensive suite of pet health

2022

- Attained LPPOM MUI Halal certification for nine surgical N95 masks in Indonesia and the Middle East
- Signed private label supply agreement with McKesson Medical-Surgical Inc., a subsidiary of one of the largest global pharmaceutical distribution companies

2021

- Supplied over 100 million Pasture Masks worldwide
- Started an online pharmacy and marketplace for pet pharma and wellness products

2016

- Introduced HART-S, an oral disintegrating drug formulation of sildenafil 50mg.
- Obtained FDA clearance for fourteen N95 respirators and surgical masks

2009

- Became the second globally to receive FDA clearance for two N95 masks for general public use in medical emergencies.

2005

- Developed first proprietary products, anti-viral N95 respirators.
- Launched masks and medical supplies business

2003

- One of the primary suppliers of influenza vaccines to the Singapore government during the SARS outbreak.

1996

- Pasture Pharma incorporated in Singapore.

Financial Highlights

| US\$'000 | FY2025 | FY2024 | FY2023 |
|--|--------|--------|---------|
| Revenue | 12,165 | 14,063 | 9,704 |
| Net Profit After Tax | 541 | 559 | (1,298) |
| Earnings Per Share (“EPS”) per share (USD cents) | 0.41 | 0.42 | (1.15) |
| Net Asset Value (“NAV”) per share (USD cents) | 3.73 | 3.32 | 2.90 |

REVIEW OF FINANCIAL PERFORMANCE

Revenue

In FY2025, the Group recorded revenue of US\$12.2 million and net profit of US\$0.5 million, marking another year of positive earnings despite a slight year-on-year decrease.

Revenue from our Pharmaceutical Wholesale and Drop-shipment segment declined, primarily due to developments in two key markets:

- In Japan, changes in regulatory requirements influenced prescribing practices and procurement patterns, resulting in a transitional shift in product demand.
- In Hong Kong, the decline was due to the completion of a government-linked supply tender, which had contributed significantly to the previous year’s revenue.

Our Masks and Medical Supplies segment continued its gradual recovery with revenue increasing by 38.9% from US\$0.15 million in FY2024 to US\$0.21 million in FY2025.

Revenue by business segment

| US\$'000 | FY2025 | FY2024 | FY2023 |
|--|--------|--------|--------|
| Pharmaceutical wholesale and drop-shipment | 11,798 | 13,860 | 9,645 |
| Mask and medical supplies | 214 | 154 | 45 |
| Other services | 153 | 49 | 14 |

Revenue by geographical

| US\$'000 | FY2025 | FY2024 | FY2023 |
|-----------|--------|--------|--------|
| Canada | 5,653 | 4,971 | 2,232 |
| Japan | 3,977 | 5,590 | 5,937 |
| Hong Kong | 1,830 | 3,076 | 1,167 |
| Singapore | 199 | 140 | 160 |
| Others | 506 | 286 | 208 |

Gross profit and gross profit margin

Gross profit remained stable at US\$3.4 million, despite the decline in revenue, due to improved gross profit margin.

The gross profit margin improved as a result of enhanced operational execution and disciplined cost management across the Group. These efforts focused on strengthening resilience, ensuring supply continuity, and sustaining value delivery to customers, while maintaining the integrity of product quality and positioning.

Financial Highlights

Other income and gains

Other income and gains decreased to US\$0.2 million in FY2025, down from US\$0.3 million in FY2024.

The Group had recovered a long outstanding debt amounting to US\$0.1 million from a customer in FY2025. The Group did not receive any one-off government grants during FY2025. In FY2024, the Group received US\$0.3 million in government grants, relating to the Company's listing on the SGX Catalist Board and for the development of its pet health mobile application.

Operating expenses

Marketing and distribution costs decreased year-on-year by 40.3% from US\$0.13 million to US\$0.08 million due to lower revenue in FY2025.

Administrative expenses remained relatively constant at US\$2.8 million, largely due to fixed costs such as staff costs, statutory expenses and depreciation, which made up around 80% of the total.

There were no significant changes in other losses and finance costs in FY2025.

Profit after tax

As a result of the foregoing, the Group's net profit after tax was consistent with FY2024 performance.

REVIEW OF FINANCIAL POSITION

Assets

Non-current assets as at 30 June 2025 was US\$1.9 million (30 June 2024: US\$2.2 million).

In FY2025, Pasture acquired US\$0.1 million of plant and equipment relating to the new cold chain warehouse and this was set off against depreciation expenses of US\$0.4 million.

Current assets as at 30 June 2025 was US\$8.0 million (30 June 2024: US\$10.3 million).

Inventories, trade receivables and other non-financial assets as at 30 June 2025 decreased to US\$2.4 million (30 June 2024: US\$3.9 million), US\$0.5 million (30 June 2024: US\$1.1 million) and US\$0.2 million (30 June 2024: US\$0.7 million) respectively, in line with the decreased volume in business activities in FY2025.

Liabilities

The Group's non-current liabilities decreased from US\$ 1.7 million in FY2024 to US\$1.3 million in FY2025, mainly due to scheduled repayments of loans and borrowing and lease payments. The lease liabilities relate to the long-term lease of the Group's office and cold chain warehouse located at 2 Corporation Road.

Current liabilities as at 30 June 2025 was US\$3.7 million (30 June 2024: US\$6.5 million).

Non-financial liabilities and trade and other payables decreased to US\$2.7 million (30 June 2024: US\$5.3 million) and US\$0.5 million (30 June 2024: US\$0.7 million) respectively, as a result of decreased volume in business activities in FY2025.

REVIEW OF STATEMENT OF CASH FLOWS

The Group generated a positive net cashflow of US\$0.7 million from operating activities in FY2025 (FY2024: US\$0.8 million) primarily driven by a profit before tax of US\$0.6 million in FY2025 and conservative working capital management.

Net cash flows used in investing activities were minimal in FY2025.

Net cash flows used in financing activities in FY2025 of US\$0.5 million was mainly from the repayment of loans and borrowings and lease payments.

INVESTOR RELATIONS

Pasture is committed to transparent and timely communication with shareholders and stakeholders. Updates are available through our corporate website, and our dedicated investor relations team welcomes inquiries at contact@pasturegroup.com.

Corporate Information

Pasture Holdings Ltd (“**Pasture**” or the “**Company**” or the “**Group**”) (Registration No. 201731601W) was incorporated in Singapore on 3 November 2017 under the Companies Act 1967 as a private limited company, under the name of “Pasture Holdings Pte. Ltd.” On 28 March 2023, the Company was converted into a public limited company and changed its name to “Pasture Holdings Ltd.” and was listed on the Catalist Board (“**Catalist**”) of the Singapore Exchange Securities Trading Limited as Pasture Holdings Ltd. (SGX: UUK.SI) on 9 June 2023.

The principal activities of the Company and its subsidiaries are as follows:

- (a) Wholesale of medicinal and pharmaceutical products (western);
- (b) Wholesale of medical, professional, scientific and precision equipment; and
- (c) Veterinary activities.

Board Of Directors

Soong Chin Kum Jonathan Lloyd
Executive Chairman and Chief Executive Officer
Claire Soong Jia Li
Alternate Director to Soong Chin Kum Jonathan Lloyd
Prashanth Palepu
Non-Executive and Non-Independent Director
Lim Jit Soon
Non-Executive and Lead Independent Director
Teo Kwee Yee
Non-Executive and Independent Director
Low Su-Shing
Non-Executive and Independent Director

Audit Committee

Lim Jit Soon *Chairman*
Teo Kwee Yee *Member*
Low Su-Shing *Member*

Nominating Committee

Teo Kwee Yee *Chairman*
Lim Jit Soon *Member*
Soong Chin Kum Jonathan Lloyd *Member*

Remuneration Committee

Low Su-Shing *Chairman*
Lim Jit Soon *Member*
Prashanth Palepu *Member*

Company Secretary

Peck Jen Jen

Registered Office

2 Corporation Rd, #03-04/05, Corporation Place,
Singapore 618494
Website: <https://pasturegroup.com>

Share Registrar and Share Transfer Office

Tricor Barbinder Share Registration Services
9 Raffles Place #26-01 Republic Plaza
Singapore 048619

External Auditor

RSM SG Assurance LLP
8 Wilkie Road #03-08 Wilkie Edge
Singapore 228095

Partner-in-charge: Yeow Thuan Wee
(Appointed with effect from the financial year ended 30 June 2025)

Internal Auditor

HLS Risk Advisory Services Pte Ltd
331 North Bridge Road #12-03 Odeon Towers
Singapore 188720

Principal Bankers

Standard Chartered Bank (Singapore) Ltd
United Overseas Bank Limited

Catalist Sponsor

PrimePartners Corporate Finance Pte. Ltd.
16 Collyer Quay, #10-00 Collyer Quay Centre,
Singapore 049318

Board of Directors



Mr. Soong Chin Kum Jonathan Lloyd

*Executive Chairman and Chief Executive Officer of Pasture Holdings
Appointed to our Board on 3 November 2017*

Mr. Soong founded the Company in 1996, recognising the unmet need for a distribution company that focused on specialty medications and medical devices. With more than 39 years of experience in the pharmaceutical and medical supplies industries, he oversees the Company's business operations and overall performance. Mr. Soong holds a Master of Business Administration in Strategic Marketing from the University of Hull, England, and has training in Immunology and Organ Transplantation from the University of Texas Medical School at Houston. His personal interests lie in the research and development of innovative healthcare solutions that enhance quality of life.



Mr. Prashanth Palepu

*Non-Executive and Non-Independent Director
Appointed to our Board on 3 November 2017*

Mr. Palepu serves as the Chief Operating Officer at Palepu Pharma Distributors, where he leads critical supply chain operations and drives strategic initiatives across the organisation. He brings deep expertise in logistics and supply chain management. Mr. Palepu is an active member of the Entrepreneurs' Organisation India, where he contributes to a global network of business leaders and entrepreneurs.

Mr. Palepu has a Master of Science in Supply Chain and Logistics Management from the University of Warwick. He is currently pursuing an Executive MBA at the University of Chicago Booth School of Business.



Mr. Lim Jit Soon

*Non-Executive and Lead Independent Director
Appointed to our Board on 29 March 2023*

Mr. Lim is an independent financial advisor, having retired as the Chief Financial Officer of Fuelcore Pte. Ltd. in January 2024. With over 30 years of experience in corporate finance, restructuring, and tax planning, he brings significant expertise in navigating financial challenges and driving strategic initiatives. Mr. Lim is a Chartered Accountant, completing his professional qualifications with the Institute of Chartered Accountants in England and Wales.

Board of Directors



Ms. Low Su-Shing

*Non-Executive and Independent Director
Appointed to our Board on 29 March 2023*

Ms. Low is a biochemist and entrepreneur specialising in biotechnology and life science ventures. As an animal vaccine researcher at NUS laboratories, she co-published several articles in peer reviewed journals. She cofounded StemLife Berhad and as its Managing Director, oversaw its expansion into the largest stem cell bank in Southeast Asia, its public listing, and its eventual strategic sale to a Singapore listed company. Ms. Low is particularly experienced in strategy, operations and marketing. Ms. Low holds a Bachelor of Science with honours in Biochemistry, Molecular Biology & Biotechnology from the University of Bristol, UK.



Ms. Teo Kwee Yee

*Non-Executive and Independent Director
Appointed to our Board on 29 March 2023*

Ms. Teo is currently the head of the corporate and financial services practice group in Harry Elias Partnership LLP. She has over 30 years of experience in advising on landmark transactions in corporate finance, including initial public offerings on the SGX-ST, placements and rights issues, privatisations, compliance and corporate governance issues. Ms. Teo is also a non-executive director and a member of the investment committee and the governance and risk committee of Ren Ci Hospital, a Singapore charity healthcare institution. She is also a member of the investment committee of Singapore Hokkien Huay Kuan and an independent director of The Hokkien Foundation.

Ms. Teo completed her Bachelor of Laws (Hons) at the University of Manchester. She is dually qualified as a barrister and a solicitor of England and Wales and is admitted to the Roll of Solicitors of Hong Kong and to the Singapore Bar.

Executive Team



Mr. Tan Xi Yi

Chief Operating Officer

Mr. Tan oversees corporate strategy, market development, and project management, ensuring operational efficiency and sustainable growth. With over 18 years of experience spanning clinical pharmacy and business strategy in the public and private sectors, Mr. Tan has successfully led new business setups and digital transformation initiatives. He holds a Bachelor of Pharmacy (Honours) and is a registered pharmacist with the Pharmacy Board Malaysia.



Mr. Lee Quang Loong

Chief Financial Officer

Mr. Lee is responsible for the Group's financial management, corporate governance frameworks, and risk management functions. With over 20 years of senior leadership experience, and as CFO in both Main Board and Catalyst companies, Mr. Lee has a proven track record in corporate finance, financial reporting, tax, and audit across the Asia Pacific Region. Mr. Lee obtained his professional accountancy qualification from the Association of Chartered Certified Accountants and is a member of the Institute of Singapore Chartered Accountants.



Ms. Ho Huey-Yi

Chief Pharmacist

Ms. Ho manages the Group's pharmaceutical regulatory affairs, including the supervision of quality management systems. Ms. Ho has over 20 years of experience in the pharmaceutical industry; she plays a crucial role in ensuring compliance and operational excellence. She holds a Bachelor of Science (Pharmacy) from the National University of Singapore and is certified as a registered pharmacist by the Singapore Pharmacy Board.




Ms. Claire Soong Jia Li

*Alternate Director to Lloyd Soong and
Corporate Communications and Marketing Manager*

Ms. Soong leads the Group's corporate communications and public relations, as well as managing digital marketing initiatives including the *fulife* platform. She brings 9 years of experience in marketing, branding, and content strategy, having previously worked with organisations such as Google APAC. Her portfolio includes writing and creative consultancy for editorial publications and local businesses. Beyond her professional work, Ms. Soong volunteers with HCA Hospice, supporting end-of-life patients and their families. She holds a Bachelor of Commerce from McGill University, with a Major in Marketing and a Concentration in Organisational Behaviour.

Group Structure



(a) On 16 July 2025, the Group announced the acquisition of strategic stake in AP Bioresources Sdn Bhd (“**APB**”), a Malaysia-based medical devices distributor. The acquisition was completed on 30 September 2025.

Following the completion of the acquisition of the strategic stake, the Group now holds 50% of the equity interest in APB and has secured Board control of APB in accordance with the terms of the Shareholders’ Agreement cum Share Subscription Agreement.

Certifications and Accreditations

Our Group has received multiple international standard certifications and accreditations from various industry authorities in respect of the quality of our processes and products, which are set out below.

| Certification and Accreditation | Issued to | Issuing Organisation |
|---|---------------------|---|
| Halal Certificate (Halal Decree No. LPPOM-00170140320122) | Pasture Pharma | The Indonesian Council of Ulama (LPPOMMUI) |
| Halal Assurance System Status (No. HS1A25870/012 022/ PAS) | Pasture Pharma | The Assessment Institute for Foods, Drugs and Cosmetics – The Indonesian Council of Ulama (LPPOMMUI) |
| Halal Assurance System Status (No. HS1A25869/012022/ PAS) | Pasture Pharma | The Assessment Institute for Foods, Drugs and Cosmetics – The Indonesian Council of Ulama (LPPOM-MUI) |
| Section 510(k) Pre-Market Notification (No. K020474) | Pasture Pharma | Department of Health & Human Services (Food and Drug Administration) |
| Section 510(k) Pre-Market Notification (No. K083176) | Pasture Pharma | Department of Health & Human Services (Food and Drug Administration) |
| Section 510(k) Pre-Market Notification (No. K141875) | Pasture Pharma | Department of Health & Human Services (Food and Drug Administration) |
| Section 510(k) Pre-Market Notification (No. K141876) | Pasture Pharma | Department of Health & Human Services (Food and Drug Administration) |
| Section 510(k) Pre-Market Notification (No. K152197) | Pasture Pharma | Department of Health & Human Services (Food and Drug Administration) |
| SS 620:2016 (2021) Good Distribution Practice for Medical Devices (Certificate No. 741315) | Pasture Pharma | Guardian Independent Certification Pte Ltd |
| SS 620:2016 (2021) Good Distribution Practice for Medical Devices (Certificate No. 741315A) | Pacific Biosciences | Guardian Independent Certification Pte Ltd |
| SS 620:2016 (2021) Good Distribution Practice for Medical Devices (Certificate No. 741315B) | Pasture PharmaHub | Guardian Independent Certification Pte Ltd |
| ISO13485:2016 (Certificate No. 755641) | Pasture Pharma | Guardian Independent Certification Pte Ltd |

Notes:

(1) There is no term or expiry to the Section 510(k) Pre-Market Notification. For devices which are classified as Class II devices under the U.S. Federal Food, Drug, and Cosmetic Act of 1938 (as amended, the “**FDCA**”), a pre-market notification under Section 510(k) of the FDCA is typically required to be submitted to the FDA, requesting permission to commercially distribute the device. Once the FDA clears the pre-market notification, the manufacturer may bring its product to market in the U.S. pursuant to the Section 510(k) Pre-Market Notification.

| Description | Date/Term |
|--|---|
| Certification that the following products are declared Halal according to Islamic Law: (a) Pasture PM 10 Surgical N95 Respirator; (b) Pasture PM 15 Surgical N95 Respirator; (c) Pasture PM 15s Surgical N95 Respirator; (d) Pasture PM 16 N95 Respirator; (e) Pasture PM 16s N95 Respirator; (f) Pasture PM 17 N95 Respirator; (g) Pasture PM 18 N95 Respirator; (h) Pasture PM 30 N95 Respirator; and (i) Pasture PM V30 N95 Respirator. | 26 January 2022 to 25 January 2026 |
| Implementation of the Halal assurance system in respect of No. 1 Zhonger Street, Guang Gu Industrial Park Chibi High-Tech Zone, Hubei, P.R. China | 26 January 2022 to 25 January 2026 |
| Implementation of the Halal assurance system in respect of ZhuFo Ling Industrial Area, Tang Xia, Dong Guan City, Guang Dong, China | 26 January 2022 to 25 January 2026 |
| Approval of Pasture PM10 N95 Respirator, PM15 N95 Respirator and Pasture PM15s N95 Respirator for commercial distribution in the United States | 23 July 2002 ⁽¹⁾ |
| Approval of Pasture A520G N95 Respirator and Pasture F550G N95 Respirator for commercial distribution in the United States | 23 January 2009 ⁽¹⁾ |
| Approval of Pasture 60S Surgical Mask for commercial distribution in the United States | 5 May 2015 ⁽¹⁾ |
| Approval of Pasture 550S Surgical N95 Respirator, Pasture 550CS Surgical N95 Respirator, Pasture A520S Surgical N95 Respirator, Pasture A520CS Surgical N95 Respirator, Pasture 520S Surgical N95 Respirator and Pasture E520CS Surgical N95 Respirator for commercial distribution in the United States | 28 October 2015 ⁽¹⁾ |
| Approval of Pasture Surgical 3 Ply Medimask for commercial distribution in the United States | 26 August 2016 ⁽¹⁾ |
| Certification that Pasture Pharma has been audited and conforms to the requirements of the Good Distribution Practice for Medical Devices for the import, storage and distribution of active implantable devices, anaesthetic and respiratory devices, dental devices, electro mechanical medical devices, assistive products for persons with disability, non-active implantable devices, ophthalmic and optical devices, reusable devices, single-use devices and in vitro diagnostic devices | 18 October 2024 to 26 December 2026 ⁽²⁾ |
| Certification that Pacific Biosciences has been audited and conforms to the requirements of the Good Distribution Practice for Medical Devices for the import, storage and distribution of active implantable devices, anaesthetic and respiratory devices, dental devices, electro mechanical medical devices, assistive products for persons with disability, non-active implantable devices, ophthalmic and optical devices, reusable devices, single-use devices and in vitro diagnostic devices | 18 October 2024 to 26 December 2026 ⁽²⁾ |
| Certification that Pasture PharmaHub has been audited and conforms to the requirements of the Good Distribution Practice for Medical Devices for the import, storage and distribution of active implantable devices, anaesthetic and respiratory devices, dental devices, electro mechanical medical devices, assistive products for persons with disability, non-active implantable devices, ophthalmic and optical devices, reusable devices, single-use devices and in vitro diagnostic devices | 18 October 2024 to 26 December 2026 ⁽²⁾ |
| Certification that Pasture Pharma has been audited and conforms to the requirements of ISO13485:2016 Quality Management System for design and development, storage and distribution of Medical Mask | 28 August 2025 to 27 August 2028 |

(2) The SS 620:2016 Good Distribution Practice for Medical Devices will be renewed following completion of an audit to be conducted by an independent certification body, which will be submitted to the Health Sciences Authority ("HSA") thereafter. Subject to compliance with the results of such audits, the certification will be periodically extended and/or renewed.

Sustainability Report

1.0 About This Report

2.0 Sustainability Reporting Framework

2.1 Sustainability Policy

2.2 Reporting Scope

2.3 Reporting Process

2.4 Restatements

2.5 Assurance

2.6 Availability

2.7 Feedback and Contacts

3.0 Board Statement

4.0 Our Approach

4.1 Sustainability Strategy

4.2 Sustainability Governance

4.3 Sustainability Committee

4.4 Directors' Training

4.5 Sustainability Risks and Opportunities

4.6 Stakeholder Engagement

4.7 Materiality Assessment

4.8 United Nations Sustainable Development Goals

5.0 Governance

5.1 Corporate Governance

5.2 Code of Conduct

5.3 Anti-Corruption Policy

5.4 Whistleblowing Policy

5.5 Regulatory Compliance

5.6 Board Diversity Policy

6.0 Economic

6.1 Economic Performance

6.2 Product and Service Quality

7.0 Environment

7.1 Energy Consumption

7.2 Greenhouse Gas Emissions

8.0 Our People

8.1 Our Employees

8.2 Diversity

8.3 Parental Leave

8.4 Employee Benefits

8.5 Employee Development

8.6 Performance Management

8.7 New Hires and Turnover

8.8 Human Rights Policy and Non-Discrimination

9.0 Our Communities

9.1 Local Communities

10.0 Our Customers

10.1 Customer Health and Safety

10.2 Customer Privacy

11.0 Our Supply Chain

12.0 Associations and Memberships

13.0 Certifications and Accreditations

14.0 Task Force on Climate-related Financial Disclosures Report

14.1 Climate-Related Risks and Opportunities

14.2 Risk Management

14.3 TCFD Metrics and Targets

About This Report

We are pleased to present the second Sustainability Report of Pasture Holdings Ltd (“**Pasture**”, or the “**Company**”, and together with its subsidiaries, the “**Group**”). This report provides an overview of the Group’s performance related to material environmental, social, and governance (“**ESG**”) issues for financial year from 1 July 2024 to 30 June 2025 (“**FY2025**”).

Sustainability Reporting Framework

This report has been prepared with reference to the Global Reporting Initiative (“**GRI**”) Standards. We use the GRI Standards for preparing our sustainability report due to their international recognition and acceptance by stakeholders. We report on disclosures recommended by the Task Force on Climate-related Financial Disclosures (“**TCFD**”). The report aligns our activities with the United Nations (“**UN**”) Sustainable Development Goals (“**SDGs**”) and is prepared in accordance with Rules 711A and 711B of the Listing Manual Section B: Rules of Catalist of the SGX-ST (“**Catalist Rules**”), detailing our ESG strategies, targets and achievements.

2.1 SUSTAINABILITY POLICY

At Pasture, we are committed to playing a role in improving global health while minimising our environmental and social impact. We have adopted a comprehensive sustainability policy which outlines our commitment to sustainable practices in the pharmaceutical industry and guides our employees, partners, and stakeholders towards a sustainable future. Please refer to our sustainability framework in Section 4.1 Sustainability Strategy of this report to learn more about our policy commitments.

2.2 REPORTING SCOPE

The Sustainability Report of Pasture for FY2025 covers the material ESG factors across the operations of Pasture Group and its three wholly owned subsidiaries, Pasture Pharma Pte Ltd, Pacific Biosciences Pte Ltd and Pasture PharmaHub Pte Ltd.

The Sustainability Report is published annually, and in alignment with the reporting period of our financial statements.

On occasions where data is incomplete or unavailable, we have provided disclosure with supporting explanations and rationales where required.

For comparison, we have included the historical data for financial year ended 30 June 2024, unless stated otherwise.

2.3 REPORTING PROCESS

We follow GRI standards and guidance to identify, assess, prioritise, and validate material ESG topics. The report reflects our stakeholders’ expectations, our understanding of the sustainability context, ESG risks and opportunities, and sustainability trends. The report also aligns with TCFD disclosures.

In preparing the report, we have applied GRI’s principles of accuracy, balance, clarity, comparability, completeness, sustainability context, timeliness, and verifiability to ensure report quality. The data in this report is sourced directly from our primary official records to ensure both accuracy and consistency. For ease of comparison across different years, we have incorporated historical ESG performance data. All financial information is presented in United States Dollars, except where indicated otherwise.

Standards, Frameworks and Guidelines

GRI Standards
 Catalist Rules (711A and 711B) – Sustainability Reporting
 TCFD Recommendations
 UN SDGs
 Greenhouse Gas (“**GHG**”) Protocol

SGX Primary Components

The report comprises the six primary components, as required by the SGX sustainability reporting rules, covering Material ESG factors, Climate-related disclosures, Policies, Practices and Performance Targets, Sustainability Reporting framework and Board statement.

2.4 RESTATEMENTS

This report does not contain any restatements of previously reported information or data.

2.5 ASSURANCE

An independent auditor has reviewed and audited our financial statements.

We maintain an internal control system to validate the accuracy and reliability of our ESG data. We reviewed the overall data collection process internally to ensure data quality and accuracy.

The Sustainability Report for FY2025 has been reviewed by GreenCo ESG Advisory Pte Ltd. for compliance with the disclosure requirements of the Catalist Rules 711A and 711 B and the GRI Standards 2021 - with reference to level of commitment, the 11 recommendations of TCFD and the alignment with the Company's selected UN SDGs.

We have not obtained external assurance for the sustainability information in this report. The possibility of obtaining external verification for our ESG data for future reports remains under consideration.

2.6 AVAILABILITY

The report is available on our website (www.pasturegroup.com) and the SGX website (www.sgx.com).

2.7 FEEDBACK AND CONTACTS

We value and welcome all feedback from stakeholders as they are integral to the continuous improvement of our sustainability actions and reporting.

For comments or questions about this report, please contact us at contact@pasturegroup.com.

Head Office

Pasture Holdings Ltd
2 Corporation Road
#03 – 04/05, Corporation Place
Singapore 618494

Board Statement

The Board of Directors, together with the Executive Chairman & Chief Executive Officer (“**CEO**”), Chief Financial Officer (“**CFO**”), Audit Committee (“**AC**”), and Sustainability Committee, is committed to upholding the highest standards of accountability, transparency, and responsible governance.

As a leading pharmaceutical and medical supply company, we recognise the responsibility that comes with our role. We integrate sustainable practices into our corporate strategy, operations, risk management, and governance frameworks—ensuring we deliver high-quality healthcare solutions while protecting the planet and advancing health equity.

Our Sustainability Report outlines how Pasture identifies and manages ESG risks and opportunities to create long-term value for all stakeholders. The Board has reviewed and endorsed this report, reaffirming its commitment to responsible governance and sustainable growth.

With the global shift toward a low-carbon economy and increasing expectations from investors, regulators, financial institutions, and consumers, Pasture is strengthening its ESG efforts. We are aligning sustainability initiatives with our organisational goals to ensure resilience, relevance, and long-term value creation.

Sustainability and value creation go hand in hand. As we respond to the challenges of today and anticipate those of tomorrow, our approach continues to evolve. The Board extends its appreciation to our stakeholders for their continued support as we advance on our journey toward responsible corporate citizenship and a more sustainable future.

Our Approach

4.1 SUSTAINABILITY STRATEGY

Our sustainability strategy supports the Group’s mission to deliver safe, cost-effective healthcare while reducing environmental impact. We monitor industry developments and address our material ESG priorities by: (1) Engaging stakeholders to understand expectations, (2) Upholding strong governance and ethical standards, (3) Minimising our environmental footprint, and (4) Contributing to economic and community development.


4.2 SUSTAINABILITY GOVERNANCE STRUCTURE

The Board holds overall responsibility for the Group’s sustainability strategy, overseeing material ESG issues, risks, and opportunities. Management implements the strategy, monitors progress, and reports regularly to the Board. The Sustainability Committee (“**SC**”) supports by reviewing ESG impacts, practices, and stakeholder engagement. The Audit Committee (“**AC**”) reviews the adequacy of internal controls and compliance with SGX reporting requirements. Sustainability considerations are embedded into the Group’s strategic direction, with the Board reviewing performance and approving all related disclosures.

4.3 SUSTAINABILITY COMMITTEE

The SC supports the Board by identifying material ESG factors, managing climate-related risks and opportunities, and overseeing the implementation of ESG initiatives and targets, including the annual sustainability report. The SC updates the Board on the progress of climate targets annually.

Chaired by the CEO and led by the CFO, the SC comprises senior leaders and personnel from key functions. The SC reports directly to the CEO. The SC ensures alignment of sustainability policies and targets with the Group's strategic direction, engages stakeholders to integrate their perspectives, and monitors ESG performance through key indicators for reporting to the Board.



4.4 DIRECTORS' TRAINING

The Board stays informed on sustainability trends through training, briefings, webinars, and self-studies. In line with SGX requirements, Directors have also attended the Singapore Institute of Directors' programme on sustainability reporting and ESG essentials.

4.5 SUSTAINABILITY RISKS AND OPPORTUNITIES

The Group manages risks through an enterprise risk management (“ERM”) framework based on the Committee of Sponsoring Organisations of the Treadway Commission Integrated Framework (“**COSO ERM Integrated Framework**”) and global risk insights. The framework defines clear roles, responsibilities, and processes for identifying, assessing, and monitoring risks, with annual reviews by an external advisory firm. Supported by internal controls, policies, and procedures, the ERM framework covers financial, operational, compliance, and IT risks. The Board and management review risks regularly, alongside materiality assessments under GRI Standards, to identify key ESG topics and opportunities.

| Topics | Risks and Challenges | Opportunities |
|--------------------------------------|---|---|
| Compliance with laws and regulations | Keeping abreast of new requirements and ensuring full compliance. | <ul style="list-style-type: none"> • Maintain compliance with Quality, Environment, Health and Safety (“QEHS”) standards and legal obligations. • Improve performance through regular monitoring and review. |
| Climate Change | Understanding policy, legal, and market changes. | <ul style="list-style-type: none"> • Disclose strategies, targets, and performance to stakeholders. • Respond to market demand for sustainable solutions. • Develop policies to reduce emissions. |
| Talent Management & Diversity | Attracting and retaining skilled talent. | <ul style="list-style-type: none"> • Grow and retain professionals aligned with company values. • Develop young talent through fair practices. • Foster an inclusive, diverse workplace. |



4.6 STAKEHOLDER ENGAGEMENT


The Group engages stakeholders who are affected by or can influence our activities to better understand expectations and inform ESG priorities. A mapping exercise, guided by GRI principles and input from senior management, identified key stakeholders across our value chain. We maintain ongoing, meaningful engagement through a range of communication channels to align stakeholder insights with our strategic.

| Stakeholders | Engagement | Expectations | Our Responses |
|---|--|---|---|
| Employees | Appraisals, training, staff events, newsletters, townhalls | Welfare, work-life balance, equal opportunities, occupational health and safety (“OHS”) | Enhanced welfare and benefits, strong OHS, fair employment, skills development |
| Customers | Meetings, ongoing communication, surveys, corporate website | Meeting contractual specifications (quality, timeliness, and performance targets) | Minimum ‘satisfactory’ feedback for completed orders, target zero complaints |
| Government Agencies / Regulators | Updates via training, seminars, correspondence, and discussions with government agencies | Governance, compliance, ethics, anti-corruption | Compliance with Catalist Rules, whistle-blowing, zero corruption target, timely reporting and resolution |
| Shareholders and Investors | Annual reports and general meetings, SGXNet portal, website, investor relations | Transparent reporting, sustainable financial performance, returns | Corporate updates, compliance with Catalist rules, transparent disclosures |
| Suppliers | Regular meetings, site visits, evaluations | Smooth dealings, fair competition, anti-corruption, adherence to agreement terms, meeting payment obligations | Efficiency improvements, performance monitoring, compliance with code of conduct, review and update of Approved Vendor List |
| Communities / Public | Website, internships, local employment, social media | Minimise social/ environmental impact, job creation | Fair employment, regulatory compliance, internship |
| Banks / Financiers | Meetings, annual reports, SGXNet portal | Transparent reporting, compliance covenants, repayment obligations | Compliance with covenants, timely repayment |
| Business Partners | Strategic planning meetings | Joint opportunities, trade growth | Strong partnerships, improved business performance |

4.7 MATERIALITY ASSESSMENT

The Group conducts materiality assessments in line with GRI guidance, identifying and prioritising significant economic, environmental, and social impacts. Internal stakeholders provided input to inform this process.

With support from management and the SC, the Board reviewed and approved the material ESG topics for reporting.



The assessment also considered GRI Reporting Principles, topic standards, and UN SDGs. The following table outlines the material topics identified.

MATERIAL TOPICS

| Material Topics | Management Approach | Our FY2026 Targets |
|----------------------------------|---|--|
| ECONOMIC | | |
| Economic Performance | Generate sustainable value for stakeholders | <ul style="list-style-type: none"> To achieve total economic value distributed of at least USD 14 million |
| ENVIRONMENT | | |
| Energy Consumption | Energy-saving initiatives, Environmental & Climate Policy, QEHS Policy | <ul style="list-style-type: none"> To keep energy consumption intensity within 60 GJ per USD million revenue |
| Greenhouse Gas (“GHG”) Emissions | Reduce carbon intensity under global standards, QEHS Policy | <ul style="list-style-type: none"> To keep GHG emissions intensity within 6.0 tCO₂e / per USD million revenue |
| SOCIAL | | |
| Employment | Attract and retain talent through merit-based and fair employment practices, Diversity & Inclusion Policy | <ul style="list-style-type: none"> To achieve less than 30% turnover rate |
| Training and Education | Provide training aligned to employee needs | <ul style="list-style-type: none"> To have minimum 8 hours training per employee |
| Non-Discrimination | Equal opportunity career advancement, Human Rights Policy in place | <ul style="list-style-type: none"> To maintain zero incidents of discrimination |
| Anti-corruption | Uphold integrity, Group Anti-bribery and Corruption Policy, Code of Conduct Policy, Whistleblowing Policy | <ul style="list-style-type: none"> To maintain zero incidents and public cases concerning corruption |
| Diversity | Promote workforce and board diversity, Group Inclusion Policy | <ul style="list-style-type: none"> To have at least 35% of female employees to achieve a more balanced workforce |
| Regulatory Compliance | Comply with all laws, QEHS Policy | <ul style="list-style-type: none"> To maintain zero incidents of non-compliance |
| Customer Health and Safety | Comply with product health and safety regulations, QEHS Policy | <ul style="list-style-type: none"> To maintain zero incidents of non-compliance with regulations and/ or voluntary codes concerning the health and safety impacts of our products |

4.8 UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS



Adopted by all United Nations (“UN”) Member States in 2015, the 2030 Agenda and its Sustainable Development Goals (“SDG”) guide global action on 17 key issues. Pasture supports this agenda by integrating relevant SDGs into our sustainability strategy and reporting to reflect our contribution to sustainable development.

CONTRIBUTING TO THE UN SUSTAINABLE DEVELOPMENT GOALS

| Material ESG Topics | SDGs Supported |
|-----------------------------------|--|
| Economic Performance |   |
| Energy Consumption |     |
| GHG Emissions |    |
| Employment |     |
| Training and Education |     |
| Non-Discrimination |   |
| Anti-corruption |  |
| Diversity |   |
| Regulatory Compliance |  |
| Local Communities |   |
| Customer Health and Safety |  |

Governance

MATERIAL TOPICS

-  Anti-Corruption
-  Diversity

SDG GOALS



5.1 CORPORATE GOVERNANCE

At Pasture, we believe that strong corporate governance and transparency are essential to building trust with our stakeholders and ensuring long-term sustainability. We are committed to integrity, fairness, and accountability in all that we do, guided by the principles of the Singapore Code of Corporate Governance 2018. Our policies and processes are clearly defined and consistently applied, enabling responsible decision-making that safeguards the interests of our employees, customers, partners, and the wider community. More information can be found in our Corporate Governance section in the FY2025 Annual Report.

5.2 CODE OF CONDUCT

The Group's Business Code of Conduct and Ethics ("**the Code**") defines the standards of behaviour expected of all employees and reflects our commitment to integrity, fairness, and accountability. It applies across all interactions with customers, suppliers, competitors, colleagues, and the wider community, helping to build and maintain trust with our stakeholders.

All new employees receive training on the Code during onboarding, reinforcing our corporate values and ethical principles. The Code provides guidance on key areas including compliance with laws, conflicts of interest, anti-bribery and corruption, workplace conduct, health and safety, protection of company assets and information, as well as channels for reporting violations—ensuring responsible decision-making that safeguards the interests of our employees, partners, and the broader community.



5.3 ANTI-CORRUPTION POLICY

The Group maintains a strict zero-tolerance policy against corruption, bribery, fraud, and money laundering, recognising that such practices undermine stakeholder trust, damage our reputation, and pose significant legal and financial risks. To safeguard our stakeholders and ensure smooth operations, we have implemented a comprehensive anti-corruption policy applicable to all employees, directors, suppliers, and business partners. Any unethical conduct may result in formal disciplinary action, including dismissal, and our practices are regularly reviewed for continuous improvement.


The policy has been communicated to all employees and directors, with the Board also completing dedicated anti-corruption training to reinforce ethical standards across the Group.

| Material Topic | FY2025 Target | FY2025 Performance | FY2026 Target |
|-----------------|--|---|--|
| Anti-Corruption | To maintain no incidents of corruption | Target met – No incidents of corruption | To maintain no incidents of corruption |

5.4 WHISTLEBLOWING POLICY

In line with our commitment to transparency, accountability, and integrity, Pasture has established a robust Whistleblowing Policy. This policy provides employees and external parties with a secure and confidential channel to report concerns related to financial reporting irregularities or other malpractice, with assurance of protection against retaliation. The policy is accessible on our website at www.pasturegroup.com/investors.

In FY2025, we are pleased to report:



Our target set for FY2025 have been met, and we aim to maintain this zero record across all areas for FY2026.

5.5 REGULATORY COMPLIANCE

At Pasture, we are committed to full compliance with all applicable laws and regulations in the jurisdictions where we operate. Regulatory compliance underpins our sustainable growth and enables us to deliver long-term value to shareholders and stakeholders. We take proactive measures to manage legal risks and continuously monitor our performance.

Our regulatory policies and procedures are regularly reviewed to ensure they remain aligned with evolving legislative requirements. Employees receive comprehensive training to understand and adhere to these standards. For transparency, we publicly disclose significant instances of non-compliance—defined as cases resulting in fines exceeding S\$50,000 or suspension of business operations.

| Material Topic | FY2025 Target | FY2025 Performance | FY2026 Target |
|-----------------------|--|---|--|
| Regulatory Compliance | To maintain no incidents of non-compliance involving significant fines or non-monetary sanctions | Target met - No incidents of non-compliance involving significant fines or non-monetary sanctions | To maintain no incidents of non-compliance involving significant fines or non-monetary sanctions |

5.6 BOARD DIVERSITY POLICY

Pasture's Board Diversity Policy emphasises a balanced mix of skills, experience, and perspectives to foster constructive debate, prevent groupthink, and leverage the collective expertise of its directors.

An effective Board comprises individuals with complementary professional qualifications, regional and global business experience, industry knowledge, and diverse backgrounds in gender, geography, nationality, tenure, and seniority. These factors are carefully considered to achieve balanced representation wherever possible.

Recognising the importance of gender diversity, the Board aims to maintain at least one female director. Presently, 2 of the 5 directors (40%) are female, while 3 directors (60%) are above the age of 50.

To support this objective, we have implemented key measures:



External search consultants are required to include female candidates when identifying potential directors.

The Nomination Committee places strong emphasis on diversity and representation in its selection process.

Pasture has met its FY2025 target of maintaining at least one female director. For FY2026, the Board targets to continue maintaining at least one female director.

Economic

MATERIAL TOPICS



Economic Performance

SDG GOALS



6.1 ECONOMIC PERFORMANCE

Good economic performance and continued value creation for our stakeholders are essential to our business. They are also primary concerns for our investors and shareholders. Detailed disclosure of our financial performance is provided in the financial section of our AR FY2025.

| Material Topic | FY2025 Target | FY2025 Performance | FY2026 Target |
|----------------------|--|---|--|
| Economic Performance | To achieve total economic value distributed of at least USD 14 million | Total economic value distributed of USD 11.5 million was achieved | To achieve total economic value distributed of at least USD 14 million |

The decrease in total economic value from USD 13.6 million in FY2024 to USD 11.5 million in FY2025 was mainly due to the decline in revenue, stemming from a weaker performance in the second half of FY2025. Changes in regulatory requirements in the second half of FY2025 influenced prescribing practices and procurement patterns which resulted in a transitional shift in product demand leading to a drop in revenue. This was further impacted by the completion of a government-linked supply tender, which had contributed significantly to FY2024's revenue. This was further impacted by the completion of a government-linked supply tender, which had contributed significantly to FY2024's revenue.

The following is a summary of the direct economic value generated and distributed in FY2025 in comparison with previous year.

| | Economic Performance Indicators | Payment to | FY2025 (USD'000) | FY2024 (USD'000) |
|---|---|-----------------|------------------|------------------|
| 1 | Revenue (economic value generated) | N/A | 12,165 | 14,063 |
| 2 | Cost of sales ¹ | Suppliers | 8,770 | 10,597 |
| 3 | Profit before tax | N/A | 569 | 643 |
| 4 | Total operating expenses ² | Other suppliers | 1,039 | 1,207 |
| 5 | Staff costs | Employees | 1,562 | 1,577 |
| 6 | Income tax expense | Government | 28 | 84 |
| 7 | Finance costs | Bankers | 91 | 85 |
| 8 | Dividends paid to shareholders | Shareholders | - | - |
| 9 | Total economic value distributed ³ | | 11,490 | 13,550 |

1 Excluding staff costs recorded under cost of sales

2 Excluding depreciation expense and staff costs recorded under administrative expenses

3 Calculated based on the computation of Items 2 and 4 – 8.

6.2 PRODUCT AND SERVICE QUALITY

Quality is at the core of our operations, with a strong focus on meeting contractual standards in both product and service delivery. We engage customers through multiple touchpoints and collect customer feedback to drive improvements.

Our targets are to achieve minimum “satisfactory” feedback from the customers. In FY2025, Pasture attained full customer satisfaction, with 100% rating our performance as “satisfactory” or better. We aim to maintain the same target for FY2026.

Environment

MATERIAL TOPICS



Energy Consumption



GHG Emissions

SDG GOALS



Environmental sustainability is integral to our business of providing effective solutions to partners including governments, distributors, and healthcare providers. While our operational carbon footprint is modest, we are committed to supporting national and global climate action.

Our climate policy encompasses commitments to reducing greenhouse gas emissions and embracing responsible packaging practices. Key initiatives include improving energy efficiency, using renewable electricity where possible, adopting sustainable packaging materials, operating within a green building, and optimising transportation routes to minimise environmental impact.

Our strategy focuses on addressing short-term climate-related risks and opportunities, while also monitoring medium and long term risks to develop appropriate responses. In the short term, we are prioritising compliance with mandatory climate-related reporting and aligning with the TCFD Recommendations. This report adheres to the TCFD's structured framework, covering four core areas: governance, strategy, risk management, and metrics and targets. The details of each category are set out in the sections that follow.

We believe making a difference begins with communicating our values with stakeholders. At Pasture, we actively encourage recycling by ongoing promotion of the 3Rs: Reduce, Reuse and Recycle among our employees.

Our planned environmental targets are:

| Material Topic | | FY2025 Target | FY2025 Performance | FY2026 Target |
|--------------------|--|---|---|---|
| Energy Consumption | Intensity (GJ per USD Million revenue) | To keep energy consumption intensity within 30 GJ per USD million revenue | Our consumption was 55.6 GJ per USD million revenue | To keep energy consumption intensity within 60 GJ per USD million revenue |
| GHG Emissions | CO ₂ Intensity (kg per USD million revenue) | To keep GHG emissions intensity within 4.0 tCO ₂ e per USD million revenue | Our GHG emission intensity increased to 5.9 tCO ₂ e per USD million revenue due to increase in purchased electricity | To keep GHG emissions intensity within 6.0 tCO ₂ e per USD million revenue |

Our Group reports consolidated energy consumption and carbon emissions for all the entities within the Group as all these entities are under the Group's operational and financial control.

7.1 ENERGY CONSUMPTION

Our energy consumption is relatively low, mainly arising from essential operations such as lighting, office equipment, and transport for product distribution. Nonetheless, we actively track and monitor usage, with a continual focus on improving energy efficiency across our operations.

The increase in energy consumption in FY2025 was driven by higher purchased electricity resulting from the Group's relocation to a larger office and cold chain warehouse in April 2024, together with a full year of utility expenses being reflected in FY2025 compared to a partial year in FY2024. In addition, the decline in revenue also resulted in higher energy consumption relative to revenue when compared to FY2024.

| | FY2025 | FY2024 |
|---|---------|--------|
| Electricity Purchase (kWh) | 155,311 | 94,925 |
| Fuel Consumption (Petrol) from Motor Vehicles (litres) | 3,145 | 3,805 |
| Energy Consumption (GJ) | 676 | 483 |
| Revenue (USD Million) | 12.2 | 14.1 |
| Energy Consumption Intensity (GJ per USD Million revenue) | 55.4 | 34.3 |

7.2 GREENHOUSE GAS EMISSIONS





Carbon emissions at Pasture mainly come from our consumption of electricity and fuel consumption from motor vehicles. We use globally recognised GHG Protocol guidelines to measure and disclose our carbon emissions. We currently report our scope 1 and scope 2 GHG emissions associated with our operations. At present, Scope 3 is not disclosed due to data limitations. Measuring and reporting our Scope 3 emissions remains under consideration for future reports.

CARBON EMISSIONS SUMMARY (tCO₂e)

| | FY2025 | FY2024 |
|--|--------|--------|
| Direct (Scope 1) GHG emissions | | |
| Mobile Combustion – Petrol | 7.3 | 8.8 |
| Energy indirect (Scope 2) GHG emissions | | |
| Purchased Electricity | 64.7 | 39.6 |
| Total Carbon Emissions (Scope 1 + Scope 2) | 72.0 | 48.4 |
| Carbon Emission Intensity (tCO ₂ e per USD Million Revenue) | 5.9 | 3.4 |

Our People

MATERIAL TOPICS

-  Employment
-  Training and Education
-  Non-Discrimination
-  Diversity

SDG GOALS



At Pasture, we recognise that our people are the foundation of our long-term success and growth. Our goal is to foster a workplace where employees feel valued, supported, and proud to be part of the organisation.

| Material Topic | FY2025 Target | FY2025 Performance | FY2026 Target |
|------------------------|--|---|--|
| Employment | Below 30% turnover rate | Target achieved – 24% turnover rate | To achieve less than 30% turnover rate |
| Training and Education | At least 8 hours of training per employee per year | Target achieved – 100% participation, with average 17.9 hours per employee | To have minimum 8 hours training per employee |
| Non-discrimination | To maintain no incidents of discrimination | Target met – No incidents of discrimination | To maintain zero incidents of discrimination |
| Diversity | To have at least 35% female employees to achieve a more balanced workforce | Target met – Percentage of female employees: Total workforce: 76% Senior Management: 40% Board of Directors: 40% | To have at least 35% female employees to achieve a more balanced workforce |

8.1 OUR EMPLOYEES

Despite the broader decline in Singapore’s net employment outlook, as published by *The Straits Times* on 09 September 2025⁽¹⁾, Pasture maintained a positive trajectory in workforce growth. At the close of FY2025, we recorded a total workforce of 25 employees. 88% were full-time employees, with Singapore accounting for 100% of our total number of employees.

Pasture continues to extend re-employment opportunities to eligible employees who reached the statutory retirement age, but were certified medically fit and able to contribute meaningfully to the organisation. At the close of FY2025, there were 3 staff above the retirement age (63 years and above), who are still hired and contributing to the Group. This practice remains consistent with the Retirement and Re-Employment Policy outlined in our Employee Handbook.

Looking ahead, Pasture remains committed to strengthening our talent base, through the retention of experienced employees, while also investing in workforce development initiatives to ensure long-term organisational resilience and growth.



(1) <https://www.straitstimes.com/business/singapore-q4-hiring-outlook-falls-below-global-average-but-logistics-and-healthcare-outperform>

8.2 DIVERSITY

At Pasture, we are committed to building a workplace where diversity and inclusion are more than policies—they are central to how we grow, innovate, and succeed together. Every employee, regardless of race, gender, age, sexual orientation, disability, religion, or ethnic background, is valued, respected, and provided with the opportunities and support needed to realise their full potential.

In FY2025, our workforce reflected this commitment: 52% were employees aged 30 to 50, while 24% were under 30, and 24% were over 50. Women comprised 76% of our workforce, representing 100% of middle management and 40% of senior management roles. These figures highlight the breadth of experience, perspectives, and leadership that drive our organisation forward.

| | FY2025 | | FY2024 | |
|--|--------|--------|--------|--------|
| | Male | Female | Male | Female |
| Number of Employees | 6 | 19 | 8 | 16 |
| Gender Diversity by Employment Category | | | | |
| Senior Management | 3 | 2 | 3 | 2 |
| Middle Management | 0 | 3 | 0 | 2 |
| Others | 3 | 14 | 5 | 12 |
| Employees by Age Group | | | | |
| Below 30 | 6 | | 7 | |
| 30 – 50 | 13 | | 12 | |
| Above 50 | 6 | | 5 | |
| Employees by Nationalities | | | | |
| Singapore Citizens | 20 | | 19 | |
| Other Nationalities | 5 | | 5 | |



Looking forward, we are focused on creating measurable impact by increasing representation, particularly of women in leadership, and fostering meaningful collaboration across all career stages. Through targeted development programs, mentorship, and clear diversity and inclusion objectives, we aim to cultivate an environment where every employee is empowered to grow, contribute fully, and thrive—ensuring that Pasture remains a place where talent and potential can flourish without barriers.

8.3 PARENTAL LEAVE

We are committed to promoting a supportive, family friendly workplace culture. We believe that offering parental leave is vital as it supports employees' work-life balance and contributes to their overall well-being and job satisfaction.

Our parental leave-related disclosures are presented in the table below.

| | FY2025 | | | FY2024 | | |
|--|--------|--------|-------|--------|--------|-------|
| | Male | Female | Total | Male | Female | Total |
| Employees entitled to parental leave | 0 | 5 | 5 | 0 | 4 | 4 |
| Employees who took parental leave | 0 | 5 | 5 | 0 | 4 | 4 |
| Employees who returned to work after parental leave ended | 0 | 5 | 5 | 0 | 4 | 4 |
| Employees still employed 12 months after returning from parental leave | 0 | 4 | 4 | 0 | 2 | 2 |
| Return-to-work rate | N/A | 100% | 100% | N/A | 100% | 100% |
| Retention rate | N/A | 80% | 80% | N/A | 50% | 50% |

8.4 EMPLOYEE BENEFITS

We are committed to the health and well-being of our employees, providing essential health services and comprehensive benefits—including insurance, healthcare, and parental leave—in full compliance with local regulations, focusing on initiatives that enhance well-being, engagement, and career growth. By investing in our people, we foster a thriving, resilient workforce and a culture where every individual can reach their full potential.

8.5 EMPLOYEE DEVELOPMENT

At Pasture, we believe our people are our greatest asset, and investing in their growth is central to our long-term success. We provide regular training opportunities that not only enhance technical skills but also support employees' confidence, career development, and ability to contribute meaningfully to the organisation. We focus on equipping our workforce with knowledge that is essential for both professional advancement and the critical standards of our industry.

In FY2025, all employees participated in training, contributing to a total of 448 training hours. Male employees accounted for 186.5 hours (averaging 31.1 hours per employee), while female employees completed 261.5 hours (averaging 13.8 hours per employee).

Senior Executives were provided a total of 146.5 training hours, while Mid-Level Executives and Operational Employees were provided a total of 301.5 training hours. Overall, each employee received an average of 17.9 training hours, representing a substantial 85% increase compared to the previous fiscal year. The Group has become more aware of training requirements and targets and has implemented structured planning to ensure staff complete the minimum required training hours.

Looking ahead, we aim to continue maintaining a minimum of 8 training hours per employee for FY2026. This commitment will not only strengthen compliance and operational efficiency but also drive continuous improvement, support innovation, and reinforce the trust our customers place in us to deliver with reliability and excellence.

8.6 PERFORMANCE MANAGEMENT

Pasture is committed to supporting our employees' personal and professional growth through structured performance management. As part of this commitment, we conduct annual performance appraisals for all employees, ensuring that each individual's contributions are assessed fairly and objectively.

In FY2025, every employee—100% of our workforce—participated in the appraisal process, reinforcing our dedication to continuous development and creating opportunities for career progression.

Looking ahead, our target for FY2026 is to maintain full participation in the performance appraisal process, with 100% of employees actively engaged. This reflects our ongoing commitment to fostering a culture of continuous feedback, growth, and professional development across the organisation.

8.7 NEW HIRES AND TURNOVER

We continue to attract diverse talent to support our business growth. In FY2025, we hired 5 new employees, representing a hiring rate of 20%, with women accounting for 80% of the intake. By age group, 60% of the new hires were employees aged 30 to 50, while 20% were under 30, and 20% were over 50.

To strengthen workforce stability, we focus on minimising employee turnover through competitive compensation, career development opportunities, employee engagement initiatives, and a positive workplace culture. In FY2025, our overall turnover rate stood at 24%, reflecting a 5% reduction in attrition compared to the previous fiscal year.

| | FY2025 | FY2024 |
|---------------------------------------|------------|------------|
| EMPLOYMENT RATE | 20% | 38% |
| New Hires by Gender | | |
| Male | 1 | 3 |
| Female | 4 | 6 |
| New Hires by Age Group | | |
| Below 30 | 1 | 3 |
| 30 – 50 | 3 | 5 |
| Above 50 | 1 | 1 |
| EMPLOYEE TURNOVER RATE | 24% | 29% |
| Employee Turnover by Gender | | |
| Male | 3 | 2 |
| Female | 3 | 5 |
| Employee Turnover by Age Group | | |
| Below 30 | 3 | 2 |
| 30 – 50 | 3 | 3 |
| Above 50 | 0 | 2 |

8.8 HUMAN RIGHTS POLICY AND NON-DISCRIMINATION

We are committed to upholding internationally recognised human rights principles, as outlined in the United Nations’ Universal Declaration of Human Rights and the International Labour Organization’s (“ILO”) core labour standards, across all our operations and supply chains. We strictly prohibit child labour, forced labour, and modern slavery. Our goal is to maintain fair and respectful workplaces that are free from discrimination and harassment.

We also respect our employees’ rights to join unions and engage in collective bargaining in accordance with national laws. While our employees are currently not covered by a collective bargaining agreement, we are committed to providing competitive wages and benefits. Our HR policies promote equal opportunities for all employees, regardless of race, gender, religion, ethnicity, nationality, cultural background, sexual orientation, or any other characteristic.

Pasture maintains a zero-tolerance approach to child labour, forced labour, and unlawful discrimination. The target of zero incidents of discrimination and no employees below the age of 16 was achieved during the reporting period. Looking ahead, our target is to maintain zero incidents of discrimination and child labour.

Our Communities

MATERIAL TOPICS

 Local Communities

SDG GOALS



9.1 LOCAL COMMUNITIES

We believe thriving businesses depend on thriving communities. In FY2025, Pasture continued to create positive impact through initiatives that support both people and pets, achieving full group participation in local community activities.

We organised a corporate social responsibility (“**CSR**”) day at HCA Hospice Care. Approximately 40% of the Group employees participate in the event, which translated to S\$1,600 man hours cost. Furthermore, we engaged the pet community through group pet walks, encouraging health, responsible ownership, and strong social connections among pet owners. We continued to hire fresh graduates with limited experience to support youth employment and invest in long-term skills development. In addition, we support employees who choose to further their education, recognising the value of continuous learning in building both personal and organisational growth.


To uplift the local economy, we work with local vendors and third parties wherever possible, reflecting our commitment to supporting homegrown businesses. Through our *furlife* platform, we share AVS-supported educational content and guidelines to promote responsible pet ownership and enhance community well-being.

We also provided internship roles for students in FY2025. Internship opportunities are a powerful tool in achieving inclusive and equitable quality education and promoting lifelong learning. By providing hands-on experience, building industry-relevant skills, expanding professional networks, and fostering an inclusive environment for diverse learners, internships help ensure that all students, regardless of background, have the opportunity to succeed and continue their educational journeys.



Our Customers

MATERIAL TOPICS

 Customer Health and Safety

SDG GOALS



10.1 CUSTOMER HEALTH AND SAFETY

Pasture is committed to maintaining the quality and safety of our health products and services, ensuring compliance with all relevant laws and regulations in the markets where we operate. We strictly adhere to the Health Sciences Authority's ("HSA") standards for Good Distribution Practice ("GDP") and are certified with Good Distribution Practice for Medical Devices. This includes wholesale, distribution, and both primary and secondary assembly of these products.

Strict quality control processes govern our internal operations and supply chain, with non-conforming items promptly removed. Vendors are assessed for compliance with international standards, including GDP, Good Manufacturing Practice ("GMP"), and other good practices relevant to the pharmaceutical industry.

Our enterprise resource system ("ERP") enables real-time inventory management in our warehouse and production areas, ensuring efficient and precise handling of inventories. We ensure product safety and quality through testing by independent, accredited third-party labs and regular audits by internal teams and authorities like HSA.

We aim to maintain zero incidents of non-compliance with regulations and industry standards. In FY2025, there were no audit findings or health and safety-related non-compliance.

| Material Topic | FY2025 Target | FY2025 Performance | FY2026 Target |
|--------------------------------|--|---|--|
| Customer and Health and Safety | To maintain no incidents of non-compliance | Target met – No incidents of non-compliance | To maintain no incidents of non-compliance |

10.2 CUSTOMER PRIVACY

At Pasture, we are committed to protecting the privacy of our customers and employees. We handle personal data responsibly and securely, in compliance with the Personal Data Protection Act of Singapore. Our Data Protection policy guides employees in proper data handling, with regular training and reminders for staff who manage customer data.

The Board of directors, supported by management, oversee our data protection policies and addresses any issues of non-compliance or data breaches. Management undergoes annual training to ensure they are well equipped for their responsibilities.

There were no substantiated complaints of customer privacy breaches in FY2025. Our ongoing target is to always maintain zero incidents of customer privacy breaches.

Our Supply Chain

We embed social and environmental principles in sourcing and expect suppliers to meet our ethical and regulatory standards. Vendor selection includes checks on accreditations, compliance, quality, and reputation, with regular due diligence covering GMP, ISO, and HACCP certifications. Approved vendors are periodically evaluated for cost-effectiveness and efficiency.

Our supply chain includes contract manufacturers for proprietary brands and pharmaceutical principals supplying finished goods, mainly from Europe and the United States. We build long-term partnerships to ensure quality, reliability, and transparency, with related costs reflected under cost of goods sold in our Profit and Loss Statement.

Associations and Memberships

We continue to engage with industry organisations, including the Singapore Business Federation, to address issues material to our business and stakeholders. This participation enables us to stay informed on industry developments and foster valuable connections with peers.

Certifications and Accreditations

In FY2025, Pasture maintained international certifications and accreditations that recognise the quality of our processes and products.

Further details are available in the Certifications and Accreditations section of our FY2025 Annual Report.

Task Force On Climate-Related Financial Disclosures Report

We consider 0-5 years to be short-term, 6-10 years as mid-term and more than 10 years to be a long-term horizon. Our strategic approach over these time horizons to address climate-related risks and opportunities identified through scenario analysis is described below.

Short Term

We expect an increase in regulatory demands and a heightened expectation from stakeholders for comprehensive reporting of GHG emissions, as well as detailed disclosure regarding climate-related risks and opportunities and their potential financial impact on our business in the short, medium, and long term. Our short-term strategic plan involves measuring and reporting a comprehensive inventory of our GHG emissions. This inventory will include scope 1 and scope 2 emissions across all our business segments, and will be aligned with the standards set by the GHG Protocol. At present, our sustainability report already includes scope 1 and scope 2 emissions. Measuring and reporting scope 3 emissions remain under consideration for future reports. In addition, we plan to establish emission reduction goals along with a defined timeline for achieving these reductions.

Medium Term

We will explore potential roadmaps for the decarbonisation of our operations. Scope 2 emissions, arising from purchased electricity, account for more than 80% of our combined scope 1 and scope 2 emissions. We would explore options for switching to renewable electricity to reduce our scope 2 emissions. Scope 1 emissions, which were less than 20% of the total, originate from the use of petrol in our company vehicle. We will examine the feasibility of transitioning to electric or hybrid vehicles to minimise the scope 1 emissions.

We will also continue to enhance our understanding of anticipated new diseases born out of climate change to source supplies from our brand partners to meet demands for medication.

Long Term

Our long-term strategy would be to achieve net-zero emissions for our direct operations and establish Pasture as a low-emissions, climate-resilient Group.

Climate Change and Healthcare

Pasture acknowledges our responsibility in addressing climate change, despite our relatively modest carbon footprint. We are keenly aware that climate change is one of the most pressing challenges of the 21st century, with far-reaching impacts on human health. As part of our commitment to improving the quality of life for patients and communities, we are dedicated to supporting climate change mitigation. We strive to ensure that our business remains sustainable and resilient, while caring for the health of those affected by diseases and illnesses linked to extreme climatic shifts.

The health implications of climate change are wide-ranging and severe. Elevated global temperatures may lead to a rise in the prevalence of vector-borne diseases such as dengue, malaria, chikungunya, and Zika, increasing the demand for robust preventive and therapeutic interventions. Furthermore, intensified weather events — including storms, cyclones, and flooding — can contribute to water system disruptions and contamination, compounding public health risks.

The International Panel on Climate Change (“**IPCC**”)’s Sixth Assessment Report (“**AR6**”) underscores that extreme weather events are already causing cascading and compounding health risks in all inhabited regions. These risks are projected to intensify with further global warming. Without effective adaptation, the incidence of climate-sensitive diseases — such as those that are food-borne, water-borne, and vector-borne — is expected to rise, placing additional strain on public health systems worldwide.

In addition, we acknowledge the growing body of evidence linking climate change to adverse mental health outcomes. These include the psychological impacts of extreme weather events, displacement, migration, food insecurity, and the breakdown of health and social care systems. Furthermore, economic hardship, social disruption, and the increasing prevalence of climate anxiety and ecological grief contribute to a rising mental health burden.

To ensure a proactive and scalable response to the growing market demand for medical supplies, it is essential to strategically align and collaborate with brand partners.

We acknowledge the vulnerabilities that climate change introduces to the pharmaceutical industry's global supply chains. Increasingly volatile weather conditions can disrupt the flow of goods, creating bottlenecks that affect all stages — from raw material sourcing to end-product distribution. These disruptions may lead to delays in raw material supply, unplanned production downtime, transportation interruptions, and cold chain storage failures. Limited flexibility in diversifying supply chains could result in stock unavailability, ultimately impacting both patient access and Group's revenue.

Scenario Analysis

Following TCFD's recommendations, we have considered two key climate scenarios from the Shared Socioeconomic Pathways ("**SSP**") used in IPCC's AR6. This analysis assists us to assess how climate change may impact our business in the short, medium and long term.

For this analysis, we focus on SSP1-2.6 and SSP3-7.0 scenarios.

SSP1-2.6, a low warming scenario, follows a very stringent pathway requiring severe carbon dioxide ("**CO₂**") emissions cuts to keep warming below 2°C compared with pre-industrial levels reaching net-zero in the second half of the century.

SSP3-7.0, a medium to high warming scenario, doubling CO₂ emissions and temperatures from the current level by the year 2100, average temperature rising by 3.6°C.

These SSPs provide insights into how shifts in factors such as population, economic growth, education, urbanisation, and technological advancement that could influence future greenhouse gas emissions, offering narratives of potential pathways to various levels of warming.

We have also considered the corresponding Representative Concentration Pathways ("**RCP**") scenarios used in the IPCC's fifth Assessment Report ("**AR5**") which focus solely on atmospheric greenhouse gas concentrations. Together, SSPs and RCPs offer a more comprehensive understanding of plausible futures.

SSP1-2.6 corresponds to RCP 2.6 while SSP3-7.0 corresponds to somewhere between RCP 6.0 and RCP 8.5. We find SSP1-2.6/RCP 2.6 useful for assessing climate-related transition risks and SSP3-7.0/RCP 6.0 more appropriate for assessing climate-related physical risks.

SSP Scenario Narratives

The SSPs provide a narrative of how the world could reach certain levels of warming, and outline how shifts in population, economy, education, urbanisation, and technology could impact greenhouse gas emissions and influence global warming levels. The two SSP narratives we have examined are summarised below.

| SSP | SSP Narratives |
|----------|---|
| SSP1-2.6 | Sustainability: In this scenario, global CO ₂ emissions are significantly reduced, though slower, achieving net-zero post-2050 by following socio-economic shifts towards sustainability, stabilising temperatures at about 1.8°C higher by century's end. |
| SSP3-7.0 | Regional Rivalry: In this scenario, emissions and temperatures consistently rise, with CO ₂ emissions doubling by 2100. Nations focus more on competitiveness, emphasising national security and self-sufficiency in food. Average temperatures increase by 3.6°C by century's end. |

The above mentioned SSP climate scenarios used in the IPCC's AR6 lead to the following warming futures:

| SSPS | SSP Description | Nearest RCPs | RCP Description | Best Estimate (°C) | | |
|----------|-------------------------|--------------|-----------------------------|-----------------------|----------------------|-----------------------|
| | | | | Near term (2021–2040) | Mid term (2041–2060) | Long term (2081–2100) |
| SSP1-2.6 | Sustainability | RCP 2.6 | Global Warming Slowing Down | 1.5 | 1.7 | 1.8 |
| SSP3-7.0 | Regional Rivalry | RCP 6.0 | Global Warming increasing | 1.5 | 2.1 | 3.6 |

Source: IPCC AR6 (Climate Change 2021, The Physical Science Basis)



Impact of Changing Climate on Human Health

The IPCC's AR6 report provides useful insights into the potential impacts of climate change on human health that are relevant to the healthcare sector, and valuable to us as a pharmaceutical and consumer healthcare company positioned within the industry.

The IPCC's AR6 report (Working Group II: Impacts, adaptation and vulnerability) states that climate change has increased wildlife diseases. Temperature rise and more brutal extreme weather events have played a role in the emergence of new diseases in new areas, according to experimental studies. The report adds that there is evidence that climate change has helped vector-borne diseases that infect humans to expand in countries close to the Arctic.


In Asia, climate change is increasing risks to human health by increasing exposure and vulnerability to extreme weather events such as heatwaves, flooding and drought, and air pollutants, increasing vector and water-borne diseases, undernutrition, mental disorders and allergic diseases. Waterborne diseases, such as diarrhoea, leptospirosis and typhoid fever, can increase in incidence following heavy rainfall, tropical cyclones and flooding events.

One of the more obvious impacts of climate change on human health is extreme heat – which is linked to severe dehydration, organ failure, cardiovascular disease and even death, the report says. Although, the impacts of heat stress are not spread equally across the world. Weather conditions have been linked to negative impacts on mental health. The report says that increasing temperatures are linked to higher hospital admissions for mood and behavioural disorders, “experiences of anxiety, depression, and acute stress” and suicide rates.

Climate change is “increasingly hindering efforts” to meet the nutritional and calorific needs of humanity. In addition to the risk of reduced agricultural yields due to climate change, the report highlights that increased CO₂ levels have been found to diminish key nutrients such as protein, iron, and zinc in numerous plants, with the extent of this reduction varying across different species. Continued increases in CO₂ levels are projected to cause reductions “in a wide range of minerals and nutrients” of 5-10%, depending on the crop. The report states that South and Southeast Asia are projected to be among the regions at highest risk for reduced dietary iron intake among women of childbearing age and children under five years due to elevated CO₂ concentrations.

The climate is also a driving factor in the spread of a range of diseases, the report says. For example, the range of mosquitoes is expanding as temperatures rise, allowing mosquito-borne diseases such as dengue fever and malaria, to spread to new areas. The report projects that climate change will increase the risk of dengue fever in all continents. It also indicates that rising temperatures combined with an increase in heavy rainfall and flooding is already increasing the incidence of diarrheal diseases such as cholera.

Pasture acknowledges the necessity of decisive mitigation and adaptation measures, especially those enacted by policy makers, in reducing GHG emissions to minimise the adverse effects of climate change.



14.1 CLIMATE-RELATED RISKS AND OPPORTUNITIES

The Group incorporates climate considerations into financial planning through risk management, supply chain planning and long term investment decisions. Our initial, qualitative scenario analysis is based on the above-mentioned pathways. An overview of the analysis relevant to our business is presented below. The Group shall include quantified assessments in future reports but considers its current climate strategy resilient to actual and potential risks and opportunities.

CLIMATE-RELATED RISKS

| Risk Type | Potential Financial Impacts | Financial Impact Category | Time Horizon |
|---|--|---------------------------|----------------------|
| PHYSICAL RISK | | | |
| Acute <i>Increased severity of extreme weather events such as cyclones and floods</i> | <ul style="list-style-type: none"> An increased risk of severe weather events such as floods and cyclones can disrupt our supply chains, as well as the manufacturing and distribution operations of our brand partners. These disruptions can lead to reduced stock availability and delivery delays, resulting in potential revenue loss and decreased customer satisfaction. Our distribution and logistics operations in Singapore may be impacted by extreme weather events, which could disrupt deliveries to our customers. Extreme weather events, such as floods and cyclones, can impact the manufacturing sites of our suppliers and brand partners, leading to disruptions or delays in the supply of products to us. | Revenue | Long term |
| Chronic <i>Rising sea levels, rising average temperatures</i> | <ul style="list-style-type: none"> Pharmaceuticals and medications require strict temperature control to preserve their quality. With rising temperatures and more frequent heatwaves, it is critical for us as a distributor to assess and mitigate risks to ensure the safe and efficient delivery of products while maintaining their integrity. Implementing stricter temperature control measures may also increase the costs associated with the storage and transportation of medicines. A warming climate poses risks to our brand partners and suppliers situated in coastal flood-prone areas, potentially disrupting product deliveries. | Revenue | Long term |
| TRANSITION RISK | | | |
| Policy and Legal | <ul style="list-style-type: none"> Mandatory climate reporting regulations, stricter energy efficiency standards, and the introduction of carbon taxes may lead to increased operational costs. Stricter regulations aimed at reducing packaging waste can increase our compliance obligations, thereby escalating legal risks and associated costs. Regulatory non-compliance can lead to increased operational costs. | Expenditure | Short to Medium term |
| Market | <ul style="list-style-type: none"> Consumers are increasingly expecting eco-friendly packaging for our products. Failing to meet these expectations could harm our reputation and negatively impact our brand equity. | Assets: Intangibles | Long term |
| Reputation | <ul style="list-style-type: none"> An increasing number of stakeholders, including investors, may expect detailed disclosures about climate-related risks. Inadequate disclosure about our climate risks and strategy and lower ESG ratings can affect our reputation. | Assets: Intangibles | Short to Medium term |
| CLIMATE RELATED OPPORTUNITIES | | | |
| Resource Efficiency | <ul style="list-style-type: none"> Improving energy efficiency across our operations presents an opportunity to reduce costs substantially, particularly amid rising energy prices. | Expenditure | Short to Medium term |
| Energy Sources | <ul style="list-style-type: none"> Adopting renewable energy sources, such as solar power, can enhance our energy resilience while reducing both energy costs and our carbon footprint. | Expenditure | Short to Medium term |
| Products and Services | <ul style="list-style-type: none"> There is an increased demand for healthcare products to treat diseases exacerbated by rising temperatures and extreme weather conditions, including heat stress, mosquito-borne diseases, and water-borne illnesses. | Revenue | Medium to Long term |

14.2 RISK MANAGEMENT

At Pasture, the Board is responsible for managing risks, including ESG and climate-related risks. The Board is assisted by the AC, which helps oversee the Group's risk management framework and policies. The Board acknowledges the critical need for a robust system of risk management and internal controls, essential for protecting the interests of shareholders and the assets of the Group.

The Group has developed an ERM framework based on the COSO ERM Integrated Framework and the risk categories were derived from the insights by Gartner Risk Management Council, and the World Economic Forum Global Risk Report. This has involved the creation of a Risk Management Policy and a risk organisation structure with clearly defined roles and responsibilities. Additionally, a Risk Management Process has been implemented to enable the Group to continuously assess, manage, report, and monitor risks. Management is informed regularly through regular internal reporting process. These reports are further reviewed by independent external parties annually. An annual review of the ERM framework is conducted by an external risk advisory firm.

Climate risks are prioritised based on likelihood and severity of impact, aligned with the Group's ERM framework. Climate risks are managed through mitigation where possible.

Looking ahead, our aim is to enhance the ERM by strengthening our overall approach to risk management.

Identifying and Managing Climate-related ESG Risks

We use materiality assessment, to identify, evaluate, and prioritise our ESG impacts and risks. We have initiated a progressive climate scenario analysis, guided by the TCFD recommendations. The scenario analysis is crucial for enhancing our understanding of climate-related risks and their potential financial repercussions on our business operations, including those of our brand partners and suppliers. We recognise that climate risks could potentially impact various aspects of our business, such as revenue streams, operational processes, supply chain dynamics, stakeholder engagement, and investor communication. Beyond physical risks, we anticipate facing challenges such as stricter emission reporting regulations, mandatory climate risk reporting, and increased energy costs stemming from carbon taxes. In light of these considerations, it is imperative for our business strategy, both in the medium and long term, to focus on reducing our carbon footprint, preparing for the impacts on our brand partners and supply chains, and seizing emerging opportunities in the transition to a low-carbon economy.

Read more about our Risk Management in the Corporate Governance section in the FY2025 Annual Report.

14.3 TCFD METRICS AND TARGETS

We currently report our scope 1 and scope 2 GHG emissions associated with our operations. Measuring and reporting our Scope 3 emissions remains under consideration for future reports.

Read more about our Energy Usage and GHG Emissions in section 7.0 Environment of this Sustainability Report.

Next Steps

We are committed to deepening our knowledge and understanding of climate-related risks and opportunities and their potential financial impacts on our business. We plan to conduct further scenario analysis to assess potential physical and transition risks, as well as opportunities, for our business. Concurrently, we plan to bolster climate literacy at both the Board and management levels through climate related training.

GRI Content Index

Statement of Use

Pasture Holdings Ltd has reported with reference to the GRI Standards for the period 1 July 2024 to 30 June 2025.

| | |
|---------------------------------|---|
| GRI 1 Used | GRI 1: Foundation 2021 |
| Applicable GRI Sector Standards | Not applicable as a GRI sector standard is not available for our industry |

| GRI Standard | Disclosure | Location |
|---|---|--|
| GRI 2: GENERAL DISCLOSURES 2021 | | |
| Organisational Details and Reporting Practices | | |
| GRI 2-1 | Organisational details | Section 1.0 – About This Report |
| GRI 2-2 | Entities included in the organisation’s sustainability reporting | Section 2.2 – Reporting Scope |
| GRI 2-3 | Reporting period, frequency and contact point | Section 1.0 – About This Report Section 2.2 – Reporting Scope Section 2.7 – Feedback and Contacts |
| GRI 2-4 | Restatements of information | Section 2.4 – Restatements |
| GRI 2-5 | External assurance | Section 2.5 – Assurance |
| Activities and Workers | | |
| GRI 2-6 | Activities, value chain and other business relationships | AR FY 2025 – Corporate Profile, Our Brands, Corporate Information |
| GRI 2-7 | Employees | Section 8.1 – Our Employees Section 8.2 – Diversity |
| GRI 2-8 | Workers who are not employees | Section 8.1 – Our Employees |
| Governance | | |
| GRI 2-9 | Governance structure and composition | AR FY2025 – Corporate Governance Report Section 4.2 – Sustainability Governance Section 5.6 – Board Diversity Policy |
| GRI 2-10 | Nomination and selection of the highest governance body | AR FY2025 – Corporate Governance Report |
| GRI 2-11 | Chair of the highest governance body | AR FY2025 – Corporate Governance Report |
| GRI 2-12 | Role of the highest governance body in overseeing the management of impacts | AR FY2025 – Corporate Governance Report Section 4.3 – Sustainability Committee |
| GRI 2-13 | Delegation of responsibility for managing impacts | AR FY2025 – Corporate Governance Report Section 4.3 – Sustainability Committee |

GRI Content Index

| GRI Standard | Disclosure | Location |
|---|---|--|
| GRI 2-14 | Role of the highest governance body in sustainability reporting | Section 4.2 – Sustainability Governance Section 4.3 – Sustainability Committee Section 4.7 – Materiality Assessment |
| GRI 2-15 | Conflicts of interest | AR FY2025 – Corporate Governance Report Section 5.0 – Governance |
| GRI 2-16 | Communication of critical concerns | Section 5.0 – Governance |
| GRI 2-17 | Collective knowledge of the highest governance body | AR FY2025 – Corporate Governance Report |
| GRI 2-18 | Evaluation of the performance of the highest governance body | AR FY2025 – Corporate Governance Report |
| GRI 2-19 | Remuneration policies | AR FY2025 – Corporate Governance Report |
| GRI 2-20 | Process to determine remuneration | AR FY2025 – Corporate Governance Report |
| GRI 2-21 | Annual total compensation ratio | AR FY2025 – Corporate Governance Report |
| Strategies, Policies and Practices | | |
| GRI 2-22 | Statement on sustainable development strategy | Section 3.0 – Board Statement |
| GRI 2-23 | Policy commitments | Section 4.8 – United Nations Sustainable Development Goals Section 5.0 – Governance Section 8.8 – Human Rights Policy and Non Discrimination |
| GRI 2-24 | Embedding policy commitments | Section 4.8 – United Nations Sustainable Development Goals Section 5.0 – Governance Section 8.0 – Our People |
| GRI 2-25 | Processes to remediate negative impacts | Section 8.8 – Human Rights Policy and Non Discrimination |
| GRI 2-26 | Mechanisms for seeking advice and raising concerns | Section 5.4 – Whistle Blowing Policy |
| GRI 2-27 | Compliance with laws and regulations | Section 5.0 – Governance |
| GRI 2-28 | Membership associations | Section 12 – Associations and Memberships |
| Stakeholder Engagement | | |
| GRI 2-29 | Approach to stakeholder engagement | Section 4.6 – Stakeholder Engagement |
| GRI 2-30 | Collective bargaining agreements | Section 8.8 – Human Rights Policy and Non Discrimination |
| Material Topics | | |
| GRI 3-1 | Process to determine material topics | Section 4.6 – Stakeholder Engagement Section 4.7 – Materiality Assessment |
| GRI 3-2 | List of material topics | Section 4.7 – Materiality Assessment |

| GRI Standard | Disclosure | Location |
|--------------------------------------|--|---|
| ECONOMIC TOPICS | | |
| Economic Performance | | |
| GRI 3: Material topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 6.1 – Economic Performance |
| GRI 201: Economic Performance 2016 | 201-1 Direct economic value generated and distributed | Section 6.1 – Economic Performance |
| ENVIRONMENT TOPICS | | |
| Energy | | |
| GRI 3: Material topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 7.0 – Environment |
| GRI 302: Energy 2016 | 302-1 Energy Consumption within the organisation 302-3 Energy Intensity | Section 7.1 – Energy Consumption |
| Emissions | | |
| GRI 3: Material topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 7.0 – Environment |
| GRI 305: Emissions 2016 | 305-1 Direct (Scope 1) GHG Emissions 305-2 Energy Indirect (Scope 2) GHG Emissions 305-4 GHG Emission Intensity | Section 7.2 – Greenhouse Gas Emissions |
| SOCIAL TOPICS | | |
| Employment | | |
| GRI 3: Material topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 8.0 – Our People |
| GRI 401: Employment 2016 | 401-1 New employee hires and employee turnover 401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees 401-3 Parental leave | Section 8.7 – New Hires and Turnover Section 8.4 – Employee Benefits Section 8.3 – Parental Leave |
| Training and Education | | |
| GRI 3: Material topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 8.5 – Employee Development |
| GRI 404: Training and Education 2016 | 404-1 Average hours of training per year per employee 404-3 Percentage of employees receiving regular performance and career development reviews | Section 8.5 – Employee Development Section 8.6 – Performance Management |

GRI Content Index

| GRI Standard | Disclosure | Location |
|---|---|---|
| DIVERSITY AND EQUAL OPPORTUNITIES | | |
| GRI 3: Material topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 8.2 – Diversity Section 8.8 – Human Rights Policy and Non Discrimination |
| GRI 405: Diversity and Equal Opportunity 2016 | 405-1 Diversity of governance bodies and employees | Section 5.6 – Board Diversity Policy Section 8.2 – Diversity |
| Non-Discrimination | | |
| GRI 3: Material topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 8.0 – Our People |
| GRI 406: Non-discrimination 2016 | 406-1 Incidents of discrimination and corrective actions taken | Section 8.8 – Human Rights Policy and Non-Discrimination |
| Local Communities | | |
| GRI 3: Material topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 9.0 – Our Communities |
| GRI 413: Local-Communities 2016 | 413-1 Operations with local community engagement, impact assessments, and development programs | Section 9.1 – Local Communities |
| Customer Health and Safety | | |
| GRI 3: Material topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 10.1 – Customer Health and Safety |
| GRI 416: Customer Health and Safety 2016 | 416-2 Incidents of non-compliance concerning the health and safety impacts of products and services | Section 10.1 – Customer Health and Safety |

| GRI Standard | Disclosure | Location |
|--------------------------------------|---|--|
| GOVERNANCE | | |
| Anti-corruption | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 5.3 – Anti-Corruption Policy |
| GRI 205: Anti-corruption 2016 | 205-2 Communication and training about anti-corruption policies and procedures 205-3 Confirmed incidents of corruption and actions taken | Section 5.3 – Anti-Corruption Policy |
| Customer Privacy | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 10.2 – Customer Privacy |
| GRI 418: Customer Privacy 2016 | 418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data | Section 10.2 – Customer Privacy |
| OTHER NON-GRI MATERIAL TOPICS | | |
| Regulatory Compliance | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Section 4.7 – Materiality Assessment Section 5.5 – Regulatory Compliance |
| Incidents of non-compliance | Incidents of significant non-compliance with applicable regulations | Section 5.5 – Regulatory Compliance |

TCFD Disclosures

This report is aligned with the TCFD recommendations. The following table indicates the location our TCFD disclosures.

| Number | Disclosures | Location |
|----------------------------|---|---|
| GOVERNANCE | | |
| TCFD 1(a) | Describe the Board's oversight of climate-related risks and opportunities. | Section 4.2 – Sustainability Governance Section 4.3 – Sustainability Committee Section 14.2 – Risk Management |
| TCFD 1(b) | Describe management's role in assessing and managing climate-related risks and opportunities. | Section 4.2 – Sustainability Governance Section 4.3 – Sustainability Committee Section 14.2 – Risk Management |
| STRATEGY | | |
| TCFD 2(a) | Describe the climate-related risks and opportunities the organisation has identified over the short, medium, and long term. | Section 4.5 – Sustainability Risks and Opportunities Section 14.1 – Climate-Related Risks and Opportunities |
| TCFD 2(b) | Describe the impact of climate-related risks and opportunities on the organisation's businesses, strategy, and financial planning. | Section 14.1 – Climate-Related Risks and Opportunities |
| TCFD 2(c) | Describe the resilience of the organisation's strategy, taking into consideration different climate-related scenarios, including a 2°C or lower scenario. | Section 14 – TCFD Report, Climate Change and Healthcare |
| RISK MANAGEMENT | | |
| TCFD 3(a) | Describe the organisation's processes for identifying and assessing climate-related risks. | Section 14.1 Climate-Related Risks and Opportunities Section 14.2 Risk Management |
| TCFD 3(b) | Describe the organisation's processes for managing climate-related risks. | Section 14.2 –Risk Management |
| TCFD 3(c) | Describe how processes for identifying, assessing, and managing climate-related risks are integrated into the organisation's overall risk management. | Section 14.2 –Risk Management |
| METRICS AND TARGETS | | |
| TCFD 4(a) | Disclose the metrics used by the organisation to assess climate-related risks and opportunities in line with its strategy and risk management process. | Section 14.3 – TCFD Metrics and Targets |
| TCFD 4(b) | Disclose Scope 1, Scope 2, and, if appropriate, Scope 3 greenhouse gas (GHG) emissions and the related risks. | Section 7.2 – Greenhouse Gas Emissions |
| TCFD 4(c) | Describe the targets used by the organisation to manage climate-related risks and opportunities and performance against targets. | Section 14.2 – Risk Management Section 7.0 - Environment |

CORPORATE GOVERNANCE REPORT

Pasture Holdings Ltd. (the “**Company**” or “**Pasture**”) and its subsidiaries (the “**Group**”) are committed to maintaining a high standard of corporate governance within the Group. The Company believes that good corporate governance is essential for preserving the interests of all stakeholders and strengthening investors’ confidence in the Group thereby enhancing long-term shareholders’ value.

This report outlines the Company’s corporate governance practices that were in place for the financial year ended 30 June 2025 (“**FY2025**”) with specific reference made to the principles and provisions of the Code of Corporate Governance 2018 (the “**Code**”), which forms part of the continuing obligations of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) (“**Catalist Rules**”). Pursuant to Rule 710 of the Catalist Rules, the Board confirms that the Company has complied with the principles as set out in the Code for FY2025. In respect of any deviation from provisions of the Code, appropriate disclosures and explanations are provided in this report in accordance with the requirements of the Catalist Rules.

BOARD MATTERS

Principle 1: The Board’s Conduct of its Affairs

The Company is headed by an effective Board which is collectively responsible and works with Management for the long-term success of the Company.

The business and affairs of the Group are managed under the direction of the Board which works with Management to achieve long-term sustainable and successful performance. Directors are obliged to objectively discharge their duties and responsibilities at all times in the best interest of the Company. The Board sets the tone from the top and has put in place a Code of Conduct and Ethics to guide all employees in carrying out their duties and responsibilities to the highest standards of personal and corporate integrity. Directors facing conflicts of interest recuse themselves from discussions and decisions involving the issues of conflict.

Apart from its statutory duties and responsibilities, the key functions of the Board are as follows:

- To provide entrepreneurial leadership, set strategic objectives, and ensure that the necessary financial and human resources are in place for the Group to meet its objectives;
- To review management performance;
- To establish a framework of prudent and effective controls which enables risks to be assessed and managed, including safeguarding shareholders’ interests and the Group’s assets;
- To set the Group’s values and standards (including ethical standards), and ensure that obligations to shareholders and other stakeholders are understood and met; and
- To consider sustainability issues, e.g. environmental and social factors, as part of its strategic formulation.

Matters requiring the Board’s decision and approval include:

- The Group’s strategic plans;
- Material investments, acquisitions and divestments of the Group;
- Major banking facilities and funding proposals;
- Annual budgets and financial plans of the Group, including capital expenditure;

CORPORATE GOVERNANCE REPORT

- Annual and half yearly financial reports;
- Share issuance and recommendation of payment of dividends;
- Risk management strategies and execution;
- Interested party transactions;
- Appointment of directors and executive officers, including review of their performance and remuneration packages;
- Appointment and removal of the company secretary; and
- Any other matters required to be considered or approved by the Board as required by legislation or regulations.

To assist the Board in executing its responsibilities, the Board is supported by the Audit Committee, Nominating Committee and Remuneration Committee. These Committees function within clear written terms of reference, which are reviewed on a regular basis, to ensure effectiveness of each Committee. Any changes to the terms of reference for any Board Committee require the approval of the Board.

The Executive Directors are appointed by way of service agreements while the non-executive directors are appointed by way of letters of appointment. The duties and responsibilities of directors are clearly set out in these service agreements and letters of appointments respectively. The Company arranges orientation program as well as meetings with senior management to familiarise new directors with the Group's business activities and strategic priorities of the Group as well as roles and responsibilities of board members and governance matters. This ensures that directors understand the Company's business and their duties. For newly-appointed directors who do not have prior experience as a director of a public listed company in Singapore, they will attend mandatory training on the roles and responsibilities of a director of a SGX-listed company as prescribed by the SGX within one year from their respective appointment dates pursuant to Rule 406(3)(a) of the Catalist Rules. As at the date of this report, all directors of the Company has completed the mandatory training requirements, including the mandatory sustainability training, prescribed by Rule 406(3)(a) of the Catalist Rules. As and where appropriate, the Company will also fund trainings for directors to develop and maintain their skills and knowledge. Relevant courses include seminars conducted by the SID or other training institutes. The Company will also work closely with its professional advisors to provide its directors with updates on changes to relevant laws, regulations and accounting standards.

In FY2025, the directors have been provided with briefings and/or updates on (i) the developments in financial reporting standards by the external auditors; (ii) changes in the relevant laws and regulations pertaining to the Group's business and changing commercial risks and business conditions of the Group by the Management during the Board and/or Board Committee meetings; and (iii) updates on the changes in Catalist Rules and the SGX-ST's guidance notes by the Company's sponsor.

Directors attend and actively participate in Board and Board Committee meetings. Formal Board meetings are held at least twice a year and ad-hoc meetings are convened when required. The Company's Constitution allows a Board meeting to be conducted through electronic means such as telephone and video conferences. All Board and Board Committees' meetings for FY2025 have been scheduled well in advance in consultation with the directors to ensure maximum attendance. Ad-hoc meetings will be convened where circumstances require as such.

CORPORATE GOVERNANCE REPORT

The number of meetings held by the Board and Board Committees and attendance thereat in FY2025 is disclosed below:

| Name of Directors | Board Meetings | | Audit Committee Meetings | | Nominating Committee Meetings | | Remuneration Committee Meetings | |
|--|----------------|----------|--------------------------|------------------|-------------------------------|------------------|---------------------------------|------------------|
| | Held | Attended | Held | Attended | Held | Attended | Held | Attended |
| Number of meetings attended | | | | | | | | |
| Soong Chin Kum Jonathan Lloyd | 2 | 2 | 2 ⁽¹⁾ | 2 ⁽¹⁾ | 1 | 1 | 2 ⁽¹⁾ | 2 ⁽¹⁾ |
| Claire Soong Jia Li (alternate director to Soong Chin Kum Jonathan Lloyd) | 2 | 2 | 2 ⁽¹⁾ | 2 ⁽¹⁾ | 1 ⁽¹⁾ | 1 ⁽¹⁾ | 1 ⁽¹⁾ | 1 ⁽¹⁾ |
| Prashanth Palepu | 2 | 2 | 2 ⁽¹⁾ | 2 ⁽¹⁾ | 1 ⁽¹⁾ | 1 ⁽¹⁾ | 2 | 2 |
| Lim Jit Soon | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 |
| Teo Kwee Yee | 2 | 2 | 2 | 2 | 1 | 1 | 1 ⁽¹⁾ | 1 ⁽¹⁾ |
| Low Su-Shing | 2 | 2 | 2 | 2 | 1 ⁽¹⁾ | 1 ⁽¹⁾ | 2 | 2 |

⁽¹⁾ Attendance of Director (who is not a member) by invitation of the Board Committee.

Management provides directors with complete, adequate and timely information of all material events and transactions as and when they occur or prior to meetings to enable them to make informed decisions and discharge their duties and responsibilities. Requests for information from the Board are dealt with promptly by the Management.

Directors have separate and independent access to Management, the company secretary, and external advisers (where necessary) at the Company's expense.

Principle 2: Board Composition and Guidance

The Board has an appropriate level of independence and diversity of thought and background in its composition to enable it to make decisions in the best interests of the company.

The Board currently comprises five* directors and the majority of whom are independent and non-executive directors.

* This does not include Ms Claire Soong Jia Li, the Alternate Director to Soong Chin Kum Jonathan Lloyd

The criteria for independence are defined in the Code and the independence of each of the directors is reviewed by the Nominating Committee. In accordance with the Code, the Board considers an "independent" director as one who is independent in conduct, character and judgement, and has no relationship with the Company, its related corporations, its substantial shareholders or its officers that could interfere, or be reasonably perceived to interfere, with the exercise of the director's independent business judgement in the best interests of the company. The independence of each director is reviewed annually and as and when circumstances require by the Nominating Committee based on the guidelines set forth in the Code and the Catalist Rules.

The Board has examined its size to determine the impact of the number upon effectiveness, and is of the view that the current Board size of five directors is appropriate and facilitates effective decision-making, after taking into account the scope and nature of the operations of the Group.

CORPORATE GOVERNANCE REPORT

In addition, in line with the Board's diversity policy, the Nominating Committee reviews the Board composition annually to ensure that the Board comprises directors who as a group provide an appropriate balance and mix of skills, knowledge and experience and gender diversity so as to avoid groupthink and foster constructive debate so that the Group can benefit from their collective expertise.

Details of the Board composition at the day of this report are as follows:

Board Independence and Length of Service

| | Independent Directors | Non-Independent Directors |
|--|-----------------------|---------------------------|
| Served more than 3 years and up to 9 years | - | 2 |
| Served less than 3 years | 3 | - |

Gender Diversity

| | | |
|--------|---|-----|
| Male | 3 | 60% |
| Female | 2 | 40% |

Directors' Age Group

| | |
|---------------|---|
| Below 45 | 1 |
| 45 to 55; and | 1 |
| 55 and above | 3 |

Directors' Educational Background

| | |
|----------|---|
| Legal | 1 |
| Finance | 1 |
| Science | 1 |
| Business | 2 |

Directors' Area of Expertise

The Board comprises Directors who have skills and domain knowledge across corporate finance, legal, operational management, mergers and acquisitions, health research and life sciences.

In terms of experience, the Directors collectively have experience in general business management, have served on public listed company boards and have vast international geographic experience.

The NC and Board have determined and are satisfied that the current Board has an appropriate balance of diversity in terms of knowledge, skills, age and experience to facilitate effective decision-making to meet the Group's operational and business needs and enables Management to benefit from a diverse and objective external perspective on issues raised before the Board. Each Director has been appointed on the strength of his calibre, experience and ability to contribute to the Group and its business.

Independent directors, led by the Lead Independent Director, meet regularly without the presence of Management. The Lead Independent Director serves as chairman of such meetings and provides feedback to the Chairman accordingly.

CORPORATE GOVERNANCE REPORT

Principle 3: Chairman and Chief Executive Officer

There is a clear division of responsibilities between the leadership of the Board and Management, and no one individual has unfettered powers of decision-making.

Mr. Soong Chin Kum Jonathan Lloyd is both the Chairman and Chief Executive Officer (“CEO”) of the Company. The Board believes that there is no need for the role of Chairman and the CEO to be separated as there is a good balance of power with majority of the Board comprising independent directors and all Board Committees are chaired by independent directors.

As Chairman of the Board, Mr Soong Chin Kum Jonathan Lloyd’s duties and responsibilities include:

- overseeing the smooth functioning of the Board and ensuring that directors receive complete, adequate and timely information;
- setting the agenda and ensuring that adequate time is available for discussion of all agenda items, in particular strategic issues;
- promoting a culture of openness and debate at the Board;
- ensuring effective communication by the Board and the Management with shareholders;
- encouraging constructive relations within the Board and between the Board and Management;
- facilitating the effective contribution of non-executive directors, in particular; and promoting high standards of corporate governance.

In addition, as CEO of the Group, he assumes responsibility for running the day-to-day business of the Group; ensures implementation of policies and strategy across the Group as set by the Board; manages the Management team; and leads the development of the Group’s strategic direction including identifying and assessing risks and opportunities for the growth of its business and reviewing the performance of its existing businesses.

In accordance with the Code, the Company has appointed a Lead Independent Director, Mr Lim Jit Soon, who would be available to shareholders where they have concerns and for which contact through the normal channels of communication with the Chairman or Management are inappropriate or inadequate.

Principle 4: Board Membership

The Board has a formal and transparent process for the appointment and re-appointment of directors, taking into account the need for progressive renewal of the Board.

The Board has established a Nominating Committee (“NC”) to make recommendations to the Board on all Board appointments. The NC comprises three Directors, the majority of whom, including the NC Chairman, are independent Directors. The Lead Independent Director is also a member of the NC.

The NC comprises:

Teo Kwee Yee - Chairman
Lim Jit Soon
Soong Chin Kum Jonathan Lloyd

CORPORATE GOVERNANCE REPORT

The duties and responsibilities of the NC, under its terms of reference, are as follows:

- (a) recommending to the Board the appointment and re-appointment of directors, alternate directors (if any) and executive officers, including re-nominations of existing directors for re-election in accordance with the constitution of the Company, taking into account the director's contribution and performance;
- (b) reviewing and approving any new employment of persons related to the directors and substantial shareholders and proposed terms of their employment;
- (c) determining on an annual basis whether or not a director is independent with reference to the Code of Corporate Governance and Rules of Catalist;
- (d) reviewing and deciding whether or not a director is able to and has been adequately carrying out his duties as director, having regard to the competing time commitments that are faced by the director when serving on multiple boards and discharging his duties towards other principal commitments;
- (e) reviewing the training and professional development programs of the Board, its Board Committees and directors;
- (f) reviewing succession plans for directors and Key Management Personnel;
- (g) reviewing the structure, size and composition (including skills, qualification, experience, core competencies and diversity) and knowledge of the Group that the Board requires to function competently and efficiently;
- (h) reviewing the directors' mix of skills, experience, core competencies and knowledge of the Group that the Board requires to function competently and efficiently;
- (i) determining and recommending to the Board the maximum number of listed company board representations which any director may hold and disclosing this in the Company's annual report; and
- (j) developing a process for evaluation of the performance of the Board as a whole and its Committees, and assessing the contribution of each director to the effectiveness of the Board.

The NC has in place a formal process for the selection, appointment and re-appointment of directors to the Board. In sourcing for new directors, the NC will tap on recommendations of the Company's sponsor and the directors' personal contacts for potential candidates, postings via Singapore Institute of Directors ("SID") and engagement of executive recruitment consultants. In the selection process, the NC considers attributes such as balance and diversity of skills vis-à-vis existing Board members, industry knowledge, requirements of the Group and time commitment, etc. Background checks are also carried out on the shortlisted candidates. The NC meets with the shortlisted Board candidates to assess their suitability and availability before making recommendations to the Board for its consideration and approval. The NC ensures that new directors are aware of their duties and obligations.

The NC determines annually, and as and when circumstances require, if a director is independent in accordance with the guidelines stipulated in the Code and the Catalist Rules. The NC also decides whether directors, who have multiple board representations, have sufficient time and attention given to the affairs of the Company. Key information regarding directors, including their directorships in listed companies and principal commitments, is set out in the Annual Report under "Board of Directors".

CORPORATE GOVERNANCE REPORT

According to the Company's Constitution, every director shall retire from office at least once every three years and for this purpose, at each Annual General Meeting ("AGM"), one-third of the directors shall retire from office by rotation. The retiring directors are eligible to offer themselves for re-election. The Company's Constitution further states that new directors appointed by the Board shall hold office until the next AGM and shall then be eligible for re-election.

Each member of the NC shall abstain from voting on any resolutions in respect of his re-nomination as a director.

The NC, having considered the attendance and participation of the following directors at Board and Board Committees meetings, in particular, their contributions to the business and operations of the Company as well as Board processes, had recommended to the Board the re-election of the Director, Ms. Teo Kwee Yee and Ms. Low Su-Shing ("**Retiring Directors**"), who will be retiring pursuant to Regulation 111 of the Constitution of the Company at the forthcoming AGM.

If re-elected as a director of the Company:

- (a) Ms. Teo Kwee Yee will remain as Independent Director, Chairman of NC and member of AC; and
- (b) Ms. Low Su-Shing will remain as Independent Director and Chairman of RC and member of AC.

Ms. Teo Kwee Yee and Ms. Low Su-Shing will be considered independent for the purposes of Rule 704(7) of the Catalist Rules.

The maximum number of listed company board representations that any director may hold is not more than five directorships. Currently, none of the Directors holds more than the stipulated maximum number of directorships in listed companies.

Principle 5: Board Performance

The Board undertakes a formal annual assessment of its effectiveness as a whole, and that of each of its board committees and individual directors.

A formal assessment process is in place to assess the effectiveness of the Board as a whole and its Board Committees and for assessing the contribution by the Chairman and each individual director to the effectiveness of the Board.

The NC has adopted the performance evaluation forms recommended by the Singapore Institute of Directors. The evaluations are conducted annually. As part of the process, the directors completed the evaluation forms which were collated by the Company Secretary, who then summarised the results of the evaluation and presented it to the NC. Recommendations for improvement were then submitted to the Board for discussion and for implementation in areas where the performance and effectiveness could be enhanced.

Board Performance Criteria

The Board is evaluated based on the following four categories:

- Structure – Board's size, composition, independence and diversity
- Strategy and performance – engaging and providing insightful inputs to the Company's long-term strategy
- Governance and organisation – reviewing the risk management and internal controls of the Group

CORPORATE GOVERNANCE REPORT

- Board function and team dynamics – timely availability of information, board members' interaction as a group and accountability of management.

Board Committee Performance Criteria

Each Board Committee is evaluated based on the following:

- Structure
- Level of commitment (including frequency of meetings, attendance and preparation for meetings)
- Training and resources available to assist the Committee in discharging its duties
- Ability to fulfill its roles and responsibilities as set out in the Committee's terms of reference
- Relationship with the Board and communication with shareholders

Directors' Performance Criteria

Performance evaluation of individual directors is conducted annually through peer appraisal, together with the Board's evaluation. The performance criteria for assessing individual directors is based on the following:

- Board contribution – understanding and contributing to the Company's corporate objectives, strategic plans, key issues and mandates
- Leadership – contributes to corporate leadership with professional character and integrity
- Strategy and risk management – upholding effective governance of the Company
- Communication skills – ability to communicate concerns and ideas clearly and provide balanced arguments
- Director's duties – attendance, preparation for meetings and keeping abreast with corporate and other regulatory developments
- Knowledge – up-to-date knowledge and experience to discharge his role and responsibility
- Interpersonal relationships – effective interactions with other directors, senior management and professional advisers

The evaluation of the Board is to be performed annually by having all members complete Board and individual directors' evaluation questionnaires individually based on the above assessment parameters.

The NC has reviewed the overall performance of the Board and its Committees for FY2025, taking into account their roles, responsibilities, and the conduct of affairs, and is of the view that the Board has performed satisfactorily as a whole. The NC has also assessed the performance of each individual director, considering factors such as attendance, expertise, adequacy of preparation for meetings, and contribution to Board discussions during FY2025, and is likewise of the view that each director has performed satisfactorily.

All NC members abstained from the review and voting process in relation to their own performance assessments. The Company did not engage an external facilitator for the evaluation process.

CORPORATE GOVERNANCE REPORT

REMUNERATION MATTERS

Principle 6: Procedures for Developing Remuneration Policies

The Board has a formal and transparent procedure for developing policies on director and executive remuneration, and for fixing the remuneration packages of individual directors and key management personnel. No director is involved in deciding his or her own remuneration.

The Remuneration Committee (“RC”) is established to review and recommend to the Board a general framework of remuneration for the Board and key management personnel. The RC also reviews and recommends to the Board the specific remuneration packages for each director as well as for the key management personnel. The RC covers all aspects of remuneration, including but not limited to director’s fees, salaries, allowances, bonuses, options, share-based incentives and awards, and benefits-in-kind. No director is involved in deciding his or her own remuneration.

The RC comprises three independent directors, namely:

Low Su-Shing – Chairman
Lim Jit Soon
Prashanth Palepu

The duties and responsibilities of the RC, under its terms of reference, are as follows:

- (a) review and approve the Company’s policy for determining executive remuneration including the remuneration of the chief executive officer, executive directors, and key management executives (the “**Senior Management Executives**”);
- (b) review the on-going appropriateness and relevance of the executive remuneration policy and other benefit programmes;
- (c) consider, review and approve and/or vary (if necessary) the entire specific remuneration package and service contract terms for each Senior Management Executive and any employee related to the directors, chief executive officer or substantial shareholders, if any (including salaries, allowances, bonuses, payments, options, benefits-in-kind, retirement rights, severance packages and service contracts);
- (d) consider and approve termination payments, retirement payments, gratuities, ex-gratia payments, severance payments and other similar payments to Senior Management Executives and employees related to the directors, chief executive officer or substantial shareholders, if any;
- (e) obtain reliable, up-to-date information on the remuneration practices of other companies and the relevant market benchmarks through the appointment of external consultants. Such information can also be obtained by commissioning or purchasing any appropriate reports, surveys or information. These will be at the expense of the Company, subject to the budgetary constraints imposed by the Board;
- (f) review and approve the design of all option plans, stock plans and/or other equity based plans;
- (g) for each equity based plan, determine whether awards will be made under that plan;
- (h) review and approve each award as well as the total proposed awards under each plan in accordance with the rules governing each plan, including awards to directors and Senior Management Executives;

CORPORATE GOVERNANCE REPORT

- (i) review, approve and keep under review performance hurdles and/or fulfillment of performance hurdles for each equity based plan; and
- (j) approve the remuneration framework (including directors' fees) for non-executive directors of the Company.

The RC can seek expert advice, where necessary, inside and/or outside the Company on remuneration of all directors, at the Company's expense. No remuneration consultants were engaged by the Company for FY2025.

The RC considers all aspects of remuneration, including termination terms, to ensure they are fair.

Principle 7: Level and Mix of Remuneration

The level and structure of remuneration of the Board and key management personnel are appropriate and proportionate to the sustained performance and value creation of the company, taking into account the strategic objectives of the company.

The remuneration policy of the Group is designed to attract, retain and motivate executive directors to provide good stewardship of the Company and key management personnel to successfully manage the Company for long-term growth. A significant and appropriate proportion of executive directors' and key management personnel's remuneration is structured so as to link rewards to corporate and individual performance so as to align with the interests of shareholders and promote the long-term success of the Group.

The Company has entered into a service agreement (the "**Service Agreement**") dated 30 March 2023 with Mr Soong Chin Kum Jonathan Lloyd, Chairman and CEO, taking effect from the date of admission of the Company to the Catalist Board of the SGX-ST on 9 June 2023. The parties may terminate the respective Service Agreement by giving the other party not less than six months' notice in writing and does not contain onerous termination clauses.

There are no existing or proposed service agreements entered into or to be entered into by our directors with our Company or any of our subsidiaries which provide for benefits upon termination of employment.

Non-executive directors receive directors' fees, in accordance with their level of contribution, taking into account factors such as effort, time spent, and responsibilities of the directors. They are not overly remunerated to the extent that their independence may be compromised. Executive directors do not receive directors' fees. Directors' fees are recommended by the Board for approval by shareholders at the AGM.

The RC also oversees the administration of the Pasture Performance Share Plan ("**Pasture PSP**") (as well as other similar share plans as may be implemented by the Company from time to time) upon the terms of reference as set out in the Company's Offer Document dated 31 May 2023.

Principle 8: Disclosure on Remuneration

The company is transparent on its remuneration policies, level and mix of remuneration, the procedure for setting remuneration, and the relationships between remuneration, performance and value creation.

CORPORATE GOVERNANCE REPORT

The breakdown showing the level and mix of remuneration of the directors of the Company for FY2025 are as follows:

| Name of Directors | Fixed Salary ⁽¹⁾ (%) | Variable Bonus ⁽²⁾ (%) | Director's Fees (%) | Total (%) | Total (S\$'000) |
|---|------------------------------------|--------------------------------------|------------------------|--------------|--------------------|
| Soong Chin Kum Jonathan Lloyd | 100% | - | - | 100% | 310 |
| Claire Soong Jia Li (alternate Director to Lloyd Soong) | 96% | 4% | - | 100% | 108 |
| Prashanth Palepu | - | - | 100% | 100% | 36 |
| Lim Jit Soon | - | - | 100% | 100% | 36 |
| Teo Kwee Yee | - | - | 100% | 100% | 36 |
| Low Su-Shing | - | - | 100% | 100% | 36 |

(1) The salary percentage shown is inclusive of allowances, benefits in kind and CPF Contribution

(2) The bonus percentage shown is inclusive of CPF Contribution

The basic director's fees for Non-Executive Director and Independent Directors for FY2025 are S\$36,000 per director per annum. These fees are put to shareholders for approval annually at the Company's AGM.

The Code recommends that the Company should name and disclose the total remuneration paid to the top five (5) Key Management Personnel. However, the RC believes such disclosure would not be in the best interests of the Group, given the highly competitive environment where poaching of staff is prevalent.

The Company had three (3) Key Management Personnel in FY2025, a macro perspective of their remuneration patterns is provided below. To maintain confidentiality while ensuring transparency, the remuneration of these Key Management Personnel (who are not Directors or the CEO of the Company) is disclosed in bands of S\$250,000 for FY2025.

| Name of key management personnel | Fixed Salary ⁽¹⁾ (%) | Variable Bonus ⁽²⁾ (%) | Others (%) | Total (%) |
|----------------------------------|------------------------------------|--------------------------------------|---------------|--------------|
| Below S\$250,000 | | | | |
| Tan Xi Yi | 96% | 4% | - | 100% |
| Lee Quang Loong | 96% | 4% | - | 100% |
| Ho Huey-Yi | 96% | 4% | - | 100% |

(1) The salary percentage shown is inclusive of allowances, benefits in kind and CPF Contribution

(2) The bonus percentage shown is inclusive of CPF Contribution

The total remuneration paid to the above key management personnel (who are not directors or the CEO) for FY2025 was approximately S\$505,000.

The Board is of the view that the information disclosed in this report, including the above disclosure, is sufficient for shareholders to have adequate understanding of the Company's remuneration framework, policies and practice for Key Management Personnel, as well as the link between performance and remuneration.

CORPORATE GOVERNANCE REPORT

Ms Claire Soong Jia Li is the daughter of the CEO and her remuneration has been disclosed above.

Save as disclosed above, there are no other employees who are immediate family members of a Director, CEO or a substantial shareholder of the Company during this financial year.

Total remuneration package of executive directors and key management personnel comprises fixed cash component of salary and allowances, variable performance incentives and contributions to the Central Provident Fund. Variable performance incentives are tied to the performance of the Group or business unit and the individual's performance.

The Company also has in place long-term incentive schemes such as Pasture PSP as set out in the Company's Offer Document dated 31 May 2023. The scheme is administered by the Remuneration Committee. According to the Pasture PSP, total options and share awards shall not exceed 15% of the Company's total number of issued shares (excluding treasury shares and subsidiary holdings) on the date preceding the granting of the share awards or share options.

No share awards have been granted since the commencement of the Pasture PSP.

In view of the foregoing, the RC confirms that the level and structure of remuneration are aligned with the long-term interest and risk management policies of the Group.

ACCOUNTABILITY AND AUDIT

Principle 9: Risk Management and Internal Controls

The Board is responsible for the governance of risk and ensures that Management maintains a sound system of risk management and internal controls, to safeguard the interests of the company and its shareholders.

The Board currently does not have a separate Board Risk Committee. The Board is assisted by the Audit Committee ("AC") to oversee the Group's risk management framework and policies. The Board recognises the importance to maintain a good system of risk management and internal controls to safeguard shareholders' interests and the Group's assets. However, the Board is also mindful that internal controls can only provide reasonable and not absolute assurance to guard against human errors, poor judgement or fraud in a cost-effective manner.

The Group has developed an enterprise risk management ("ERM") framework based on the Committee of Sponsoring Organisations of the Treadway Commission (COSO ERM Framework) and the risk categories were derived from the insights by Gartner Risk Management Council, and the World Economic Forum Global Risk Report. This included the development of a Risk Management Policy, risk organization structure including clear roles and responsibilities, and a Risk Management Process to facilitate the Group to continuously assess, manage, report and monitor risks.

The Group has appointed HLS Risk Advisory Services Pte. Ltd. ("HLS") as internal auditors to evaluate and test the effectiveness of internal controls in selected areas that are in place in major operating companies of the Group and conduct the internal review of the Group's sustainability reporting processes. The internal audit review was conducted with a view to identify control gaps in the current business processes, ensure that operations were conducted within the policies and procedures laid down and identify areas for improvements, where controls can be strengthened. The internal auditors perform the internal audit functions in accordance with the International Standards for the Professional Practice of Internal Auditing issued by the Institute of Internal Auditors ("IIA").

CORPORATE GOVERNANCE REPORT

In addition, the external auditors, RSM SG Assurance LLP, will also highlight internal control weaknesses which have come to their attention in the course of their statutory audit. All external and internal audit findings and recommendations were reported to the AC. There were no high-risk weaknesses identified in the course of their audits for FY2025. Management will implement the recommendations from the auditors to further strengthen the Group's internal controls system.

The Board has received assurance from the CEO and the Chief Financial Officer ("CFO") that the financial records have been properly maintained and the financial statements give a true and fair view of the Group's operations and finances for FY2025. The CEO and key management personnel have also provided assurance that the Group's risk management and internal control systems are adequate and effective.

Based on the foregoing, the Board, with the concurrence of the Audit Committee, is of the opinion that the internal controls, including financial, operational, compliance and information technology controls, and risk management systems of the Group were adequate and effective for FY2025.

Principle 10: Audit Committee

The Board has an Audit Committee which discharges its duties objectively.

The AC comprises three independent directors, namely:

Lim Jit Soon – Chairman
Teo Kwee Yee
Low Su-Shing

The duties and responsibilities of the AC, under its terms of reference, are as follows:

- (a) assist the Board in the discharge of its responsibilities on financial and reporting matters;
- (b) review, with the Company's internal and external auditors, the audit plans, scope of work, their evaluation of the system of internal accounting controls, their management letter and the management's response, and results of the audits compiled by the internal and external auditors, and review at regular intervals with the management on the implementation by the Group of the internal control recommendations made by the internal and external auditors;
- (c) review the periodic financial statements and results announcements before submission to the Board for approval, focusing in particular, on changes in policies and practices, major risk areas, significant adjustments resulting from the audit, the going concern statement, compliance with financial reporting standards as well as compliance with the Catalist Rules and any other statutory/ regulatory requirements, concerns and issues arising from their audits, including any matters which the auditors may wish to discuss in the absence of the management, where necessary, before submission to the Board for approval;
- (d) review the assurance provided by the CEO and CFO that the financial records have been properly maintained and that the financial statements give a true and fair view of the Group's operation and finances;
- (e) review and report to the Board, at least annually, the effectiveness and adequacy of the Company's risk management and internal controls addressing financial, operational, information technology and compliance risks and discuss issues and concerns, if any, arising from the internal audits;
- (f) review the adequacy, effectiveness, independence, scope and results of the Company's internal and external functions as well as consider the appointment or re-appointment of internal and external auditors, including approving the remuneration and terms of engagement of the internal and external auditors;

CORPORATE GOVERNANCE REPORT

- (g) review and establish procedures for receipt, retention and treatment of complaints received by the Group, involving amongst others, criminal offences involving the Group or its employees, questionable accounting, auditing, business, safety or other matters that impact negatively on the Group and ensure that there are arrangements in place for independent investigation and follow-up action(s);
- (h) ensure the Company publicly discloses, and clearly communicates to employees, the existence of a whistleblowing policy and procedures for raising such concerns; and
- (i) generally undertake such other functions and duties as may be required by statute or the Catalist Rules, and by such amendments made thereto from time to time.

The AC has the authority to investigate any matters within its terms of reference, full access to and co-operation by management and full discretion to invite any director or executive officer to attend its meetings, and reasonable resources to enable it to discharge its functions properly. The AC can seek professional advice, where necessary, at the Company's expense.

The AC does not comprise of at least (2) two members who have recent and relevant accounting or related financial management expertise or experience.

Notwithstanding this, the Board is of the view that the AC is able to discharge its duties sufficiently. The AC Chairman has recent and relevant accounting and related financial management expertise and experience. The other AC members both have extensive management and operational experience, which as part of their managerial experience in their various capacities during their employment history, includes financial management experience. The AC is also supported by External Auditors and other relevant finance professionals.

None of the AC members is a partner or director of the Group's auditing firms or auditing corporations or was a former partner or former director of the Group's auditing firms or auditing corporations. None of them has any financial interest in the Group's auditing firms or auditing corporations.

The Company outsources the internal audit function to an external professional firm to perform the review and test of controls of the Group's processes. The Company has appointed HLS as the internal auditors to review the internal control processes of the Group and conduct the internal review of the Group's sustainability reporting processes. HLS possesses vast experience in providing internal audits, risk management services and advisory services in the region. The internal auditors report primarily to the AC, which also decides on its appointment, termination and remuneration. The internal auditors have unfettered access to all the Company's documents, records, properties and personnel, including the AC. The AC is satisfied that the internal audit function is independent, effective and adequately resourced.

The AC has met the external auditors and internal auditors, in each case without the presence of management, in FY2025 respectively.

WHISTLE-BLOWING POLICY

The Company has put in place a Whistle-Blowing Policy ("**Policy**") which sets out the procedures for a whistleblower to report misconduct or wrongdoing, or to raise concerns in good faith, with the reassurance of being protected from reprisals or victimisation, about possible improprieties in financial reporting or other matters, and to ensure that arrangements are in place for independent investigation of matters raised and for appropriate follow-up actions to be taken.

CORPORATE GOVERNANCE REPORT

The Company ensures that the identity of the whistleblower is kept confidential and is committed to ensure the whistleblower is protected against detrimental or unfair treatment. The identity of the whistle-blower will not be made known to anyone other than (i) the investigating team; (ii) the AC and Board; (iii) the Group CEO (provided the whistleblowing in question is not concerned with the integrity of staff directly reporting to the Group CEO or the Group CEO himself); and (iv) parties to whom the identity of the whistle-blower is required to be disclosed by law. The whistle-blower's consent will be obtained when his / her identity is to be revealed to anyone other than in the above circumstances.

The AC is responsible for oversight and monitoring of whistleblowing. The AC will review investigation reports on whistleblowing cases and decide/recommend follow-up or remedial actions to be taken, where appropriate, and report the same to the Board accordingly. The AC may in its absolute discretion designate an independent function/party as it deems fit to investigate whistleblowing reports made in good faith. This Policy will be reviewed by the AC, as and when deemed appropriate, with recommendations, if any, made to the Board for approval. The Company's Policy had been updated to be in line with the relevant amendments to the SGX-ST's Listing Manual.

The Policy has been disseminated and made available to all employees of the Group. A copy of the Policy is made available on the Company's corporate website at <https://pasturegroup.com/wp-content/uploads/2024/01/Whistleblowing-Policy-for-Pasture-Holdings-Ltd.pdf>

Material Associates And Joint Ventures

Material associates and joint ventures which the Company does not have control are not dealt with for the purposes of this report.

SHAREHOLDER RIGHTS AND ENGAGEMENT

Principle 11: Shareholder Rights and Conduct of General Meetings

The company treats all shareholders fairly and equitably in order to enable them to exercise shareholders' rights and have the opportunity to communicate their views on matters affecting the company. The company gives shareholders a balanced and understandable assessment of its performance, position and prospects.

Shareholders are encouraged to actively participate and vote at the Company's general meetings and the Company informs shareholders of the rules governing general meetings of shareholders. Notices of meetings are given to all shareholders together with explanatory notes or a circular on items of special business, at least fourteen clear days (for ordinary resolutions) or at least twenty-one clear days (for special resolutions) before the meeting. Reports or circulars of the general meetings are despatched or disseminated to all shareholders. If any shareholder is unable to attend, the Company's Constitution allows for absentia voting and the shareholder can appoint up to two proxies to attend, speak and vote on his/her behalf at the general meeting. The Company's Constitution allows corporations which are considered "relevant intermediary(ies)" to appoint more than two proxies to attend, speak and vote at the general meeting.

The Company ensures that there are separate resolutions at general meetings for substantially distinct matters unless the resolutions are interdependent and linked to form one significant proposal. Where the resolutions are "bundled", the Company explains the reasons and material implications in the notice of the meeting. For greater transparency, the Company puts all resolutions to vote by poll and detailed results of the number of votes cast for and against each resolution and the respective percentages are presented and announced on the same day. Independent scrutineers are appointed to conduct the voting process and verify votes after each resolution.

CORPORATE GOVERNANCE REPORT

Directors, external auditors and senior management are present and available to address shareholders' queries at general meetings. All directors attended the last AGM held on 29 October 2024. Minutes of meetings for the forthcoming AGM will be published on www.pasturegroup.com and the SGXNet within one month from the date of the AGM.

Dividend Policy

The Company does not have a formal dividend policy. The dividend that the Directors of the Company may recommend or declare in respect of any particular financial year or period will be subject to the factors outlined below as well as any other factors deemed relevant by the Directors of the Company:-

- (1) the level of the earnings of the Group;
- (2) the financial condition of the Group;
- (3) the projected levels of the Group's capital expenditure and other investment plans;
- (4) the restrictions on payment of dividends imposed on the Group by its financing arrangements (if any); and
- (5) other factors as the Directors of the Company may consider appropriate.

In line with the Groups' financial performance in FY2025, the Board has recommended a final tax exempt one-tier final ordinary dividend of 0.23 SGD cents (equivalent to 0.1776 USD cents) per share for shareholders' approval at the forthcoming AGM.

Principle 12: Engagement with Shareholders

The company communicates regularly with its shareholders and facilitates the participation of shareholders during general meetings and other dialogues to allow shareholders to communicate their views on various matters affecting the company.

The Board is accountable to the shareholders and is mindful of its obligation to provide timely and fair disclosure of material information to shareholders, investors and the public. The Board treats all shareholders fairly and equitably and seeks to protect and facilitate exercise of shareholder's rights.

The Company announces its Annual Report, half-yearly financial results, major developments and other price and/or trade sensitive information on SGXNET in a timely manner to ensure investors are kept abreast of the Group's developments. These documents are also made available on the Company's corporate website at www.pasturegroup.com.

Shareholders are given the opportunity to pose questions to the Board or the Management at the general meetings. The members of the AC, NC and RC will be present at the general meetings to answer questions relating to matters overseen by the respective committees. Shareholders are provided sufficient time to submit questions after the publication of notice of general meeting. The Company will address these questions timely to accord shareholders with reasonable time to consider matters tabled at the general meetings prior to the closing date and time for the lodgement of the proxy forms.

The Company has in place an investor relations policy and a corporate website which allows for an ongoing exchange of views so as to actively engage and promote regular, effective and fair communication with shareholders. Shareholders may contact the Company with questions on the corporate website and the Company's investor relations team will address them accordingly.

CORPORATE GOVERNANCE REPORT

MANAGING STAKEHOLDERS RELATIONSHIPS

Principle 13: Engagement with Stakeholders

The Board adopts an inclusive approach by considering and balancing the needs and interests of material stakeholders, as part of its overall responsibility to ensure that the best interests of the company are served.

The Company has identified stakeholders as those who have an interest in the Group and can either affect or be affected by the Group's business and operations. These stakeholders include employees, customers, suppliers, investors, government and regulators as well as the community.

The Company engages its stakeholders through various communication channels. The Group holds regular townhall meetings and events to engage with our employees; our sales and marketing teams interact frequently with our customers and suppliers to better align mutual business interests; investor relations activities to engage investors have been discussed above; we strive to be a good corporate citizen with regular consultations with various government agencies; and we participate in several social and community events to connect with the general public.

Stakeholders can learn more about the Group from the website of the Company.

OTHER CORPORATE GOVERNANCE MATTERS

Dealing In Securities

The Group has adopted internal policies that are consistent with Rule 1204(19) of the Catalist Rules of the SGX-ST's Listing Manual in relation to dealings in the Company's securities.

The Directors, officers and employees of the Company and its subsidiaries are notified that they are prohibited from trading in the Company's securities while in possession of unpublished material price-sensitive information.

The Company and Directors, officers and employees of the Company and its subsidiaries are prohibited from dealing in the Company's securities during the periods commencing one (1) month before the announcement of the Company's half year and full year unaudited financial statements and ending after the announcement of the relevant results.

The Directors, officers and employees of the Company and its subsidiaries are also expected to observe insider-trading laws at all times even when dealing in the Company's securities within the permitted trading period. They are also discouraged from dealing in the Company's securities on short-term considerations.

Directors are required to report to the Company Secretary whenever they deal in the Company's securities and the Company will make the necessary announcements in accordance with the disclosure requirements of the Listing Manual of the SGX-ST.

The Company confirms that it has complied with Rule 1204(19) of the SGX-ST Catalist Rules.

CORPORATE GOVERNANCE REPORT

Interested Person Transactions

A general mandate was obtained from our shareholders pursuant to Rule 920(2) during the listing of our Group on 9 June 2023 (the “**IPT General Mandate**”). The IPT General Mandate was renewed in the AGM held on 29 October 2024. Save as disclosed in the table below, there were no other interested person transactions entered into in FY2025.

| Name of interested person | Nature of relationship | Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than S\$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920 of the Catalist Rules) | Aggregate value of all interested person transactions conducted under the shareholders' mandate pursuant to Rule 920 of the Catalist Rules (excluding transactions less than S\$100,000) |
|---------------------------|---|--|--|
| Pleasant Exports | An associate of a director of the Company, Prashanth Palepu | None | Purchases – US\$ 1,000* |

* Although the amount is below S\$100k, this has been included for complete disclosure.

We anticipate that we would, in the ordinary course of business, continue to enter into certain transactions with our interested persons, including but not limited to those categories of transactions described below. In view of the time-sensitive and recurrent nature of such commercial transactions, it would be advantageous for us to obtain a general mandate from our Shareholders pursuant to Rule 920 of the Catalist Rules to enable any or all members of our Group, in the ordinary course of their business, to enter into the Mandated Transactions (as defined below) with the Mandated Interested Persons (as defined below) which are necessary for our day-to-day operations, provided that all such transactions are carried out on normal commercial terms and are not prejudicial to the interests of our Company and our minority Shareholders.

Rule 920 of the Catalist Rules allows a listed company to obtain a mandate from its shareholders for recurrent transactions of a revenue or trading nature or those necessary for its day-to-day operations such as the purchase and sale of supplies and materials (but not in respect of the purchase or sale of assets, undertakings or businesses) that may be carried out with the listed company's interested persons.

Pursuant to Rule 920(2) of the Catalist Rules, our Company may treat a general mandate as having been obtained from our Shareholders for us to enter into interested person transactions with our interested persons, if the information required under Rule 920(1)(b) of the Catalist Rules is included in the Company's Offer Document dated 31 May 2023.

In relation to our Company, the information required under Rule 920(1)(b) of the Catalist Rules is as follows:

- (a) the names of the interested persons with whom the Entity at Risk (as defined below) will be transacting;
- (b) the nature of the transactions contemplated under the mandate;

CORPORATE GOVERNANCE REPORT

- (c) the rationale for, and benefit to, the Entity at Risk;
- (d) the methods or procedures for determining transaction prices;
- (e) the independent financial adviser's opinion on whether the methods or procedures in above are sufficient to ensure that the transactions will be carried out on normal commercial terms and will not be prejudicial to the interests of our Company and our minority Shareholders;
- (f) an opinion from our Audit Committee if it takes a different view to the independent financial adviser;
- (g) a statement from us that we will obtain a fresh mandate from our Shareholders if the methods or procedures in (d) above become inappropriate; and
- (h) a statement that the interested person will abstain, and has undertaken to ensure that its Associates will abstain, from voting on the resolution approving the transaction.

For the avoidance of doubt, the IPT General Mandate will cover any and all Mandated Transactions, including transactions which have a value below S\$100,000, notwithstanding that the threshold and aggregation requirements under Chapter 9 of the Catalist Rules as at the date of the Company's Offer Document dated 31 May 2023 do not generally apply to such transactions.

Transactions which do not fall within the ambit of the IPT General Mandate shall be subject to the relevant provisions of Chapter 9 and/or other applicable provisions of the Catalist Rules and/or any applicable law. Transactions conducted under the IPT General Mandate are not separately subject to Rules 905 and 906 of the Catalist Rules pertaining to threshold and aggregation requirements.

There was no interested person transaction ("IPT") which was more than S\$100,000 entered into during FY2025.

The AC reviews all IPT transactions, if any, at its half yearly meetings to ensure that all transactions are carried out on arm's length basis and on normal commercial terms that will not be prejudicial to the interests of the Company or to its minority shareholders.

The AC reviews all IPT transactions, if any, at its half yearly meetings to ensure that all transactions are carried out on arm's length basis and on normal commercial terms that will not be prejudicial to the interests of the Company or to its minority shareholders.

Material Contracts

Save for the Service Agreements between the Company and the CEO, there were no material contracts of the Company or its subsidiaries involving the interest of the CEO, any director or controlling shareholder either still subsisting at the end of FY2025 or if not then subsisting, entered into since the end of the previous financial year.

Non-Sponsor Fees

With reference to Rule 1204(21) of the Catalist Rules, there were no non-sponsor fees incurred in FY2025 paid/payable to the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd.

CORPORATE GOVERNANCE REPORT

Auditors and Fees Paid to Auditors

The aggregate amount of fees paid to the Company's external auditors, RSM SG Assurance LLP and member firms of RSM SG Assurance LLP, in FY2025, were S\$92,500 and S\$26,200 respectively, comprising audit fees of S\$92,500 and non-audit fees of S\$26,200 for tax compliance and advisory services. The AC, having reviewed such non-audit services, is satisfied that the nature and extent of such services will not prejudice the independence and objectivity of the external auditors.

The AC considered and is satisfied with the adequacy of their resources, training and quality control, experience of the engagement team and the firm as a whole and quality of work carried out by the external auditor. The Group confirms that it has complied with Rule 712 and Rule 715 of the Catalyst Rules in relation to its appointment of the audit firm for the Group.

Having been satisfied as to the foregoing, the AC has recommended the re-appointment of RSM SG Assurance LLP as external auditors at the forthcoming AGM.

Use of IPO Proceeds

As of the time of this Annual Report, the IPO proceeds have been utilised as follows.

| Use of proceeds | Amount in aggregate US\$'000 | Balance At 1 July 2025 US\$'000 | Utilised in FY2025 US\$'000 | Amount Balance US\$'000 |
|--|------------------------------|---------------------------------|-----------------------------|-------------------------|
| Strengthening our existing business segments and diversification into new geographical market segments | 742 | 702 | (135) ^(b) | 567 |
| Exploring opportunities in mergers and acquisitions, joint ventures and strategic alliances | 1,187 | 1,187 | - | 1,187 |
| General working capital purposes | 342 | - | - | - |
| Total | 2,271 ^(a) | 1,889 | (135) | 1,754 |

(a) Based on exchange rate of S\$1.3479 = US\$1 (same manner as announcement) applied to the IPO net proceeds of S\$3,062,000 as stated in the Offer Document.

(b) Payments for plant and equipment relating to the new cold chain warehouse and expenses incurred for new geographical market segments.

The Company will continue to make periodic announcements via SGXNET on the utilization of the balance of the IPO net proceeds as and when such proceeds are materially disbursed.

Financial Statements

73 Statement by Directors

76 Independent Auditor's Report

**80 Consolidated Statement of Profit or Loss
and Other Comprehensive Income**

81 Statements of Financial Position

82 Statements of Changes in Equity

83 Consolidated Statement of Cash Flows

84 Notes to the Financial Statements



STATEMENT BY DIRECTORS

The directors of the company are pleased to present the accompanying financial statements of the company and of the group for the reporting year ended 30 June 2025.

1. Opinion of the directors

In the opinion of the directors,

- (a) the accompanying financial statements and the consolidated financial statements are drawn up so as to give a true and fair view of the financial position and performance of the company and, of the financial position and performance of the group for the reporting year covered by the financial statements or consolidated financial statements; and
- (b) at the date of the statement, there are reasonable grounds to believe that the company will be able to pay its debts as and when they fall due.

The board of directors approved and authorised these financial statements for issue.

2. Directors

The directors of the company in office at the date of this statement are:

Soong Chin Kum Jonathan Lloyd
 Prashanth Palepu
 Claire Soong Jia Li (alternate director to Soong Chin Kum Jonathan Lloyd)
 Lim Jit Soon
 Low Su-Shing
 Teo Kwee Yee

3. Directors' interests in shares and debentures

The directors of the company holding office at the end of the reporting year had no interests in shares in or debentures of the company or other related body corporate as recorded in the register of directors' interests in shares in or debentures kept by the company under section 164 of the Companies Act 1967 (the "Act") except as follows:

| Name of directors and companies in which interests are held | Direct interest | | Deemed interest | |
|---|--|------------------------------|------------------------------------|------------------------------|
| | At beginning of the reporting year | At end of the reporting year | At beginning of the reporting year | At end of the reporting year |
| Pasture Holdings Ltd. | <u>Number of ordinary shares of no-par value</u> | | | |
| (The company) | | | | |
| Soong Chin Kum Jonathan Lloyd ^(a) | – | – | 73,920,000 | 73,920,000 |
| Prashanth Palepu ^(b) | – | – | 38,080,000 | 38,080,000 |
| PMI Holdings Pte. Ltd. ^(a) | | | | |
| (Immediate and ultimate parent company) | | | | |
| Soong Chin Kum Jonathan Lloyd | 100 | 100 | – | – |

(a) Mr Lloyd Soong holds the entire issued and paid-up share capital of PMI Holdings Pte. Ltd.. Accordingly, Mr. Lloyd Soong is deemed to have an interest in all the shares held by PMI Holdings Pte. Ltd. by virtue of Section 4 of the Securities and Futures Act 2001 ("SFA").

STATEMENT BY DIRECTORS

3. Directors' interests in shares and debentures (cont'd)

- (b) Mr. Prashanth Palepu holds 25.0% of the issued and paid-up share capital of Plutus Star Holding Pte. Ltd. Accordingly, Mr. Prashanth Palepu is deemed to have an interest in all the Shares held by Plutus Star Holding Pte. Ltd. by virtue of Section 4 of the SFA.

By virtue of section 7 of the Act, the above directors with interests are deemed to have an interest in the company and all the related body corporates of the company.

The directors' interests as of 21 July 2025 were the same as those at the end of the reporting year.

4. Arrangements to enable directors to acquire benefits by means of the acquisition of shares and debentures

Neither at the end of the reporting year nor at any time during the reporting year did there subsist arrangements to which the company is a party, being arrangements whose objects are, or one of whose objects is, to enable directors of the company to acquire benefits by means of the acquisition of shares in or debentures of the company or any other body corporate.

5. Options

During the reporting year, no option to take up unissued shares of the company or other body corporate in the group was granted.

During the reporting year, there were no shares issued by virtue of the exercise of an option to take up unissued shares.

At the end of the reporting year, there were no unissued shares under option.

6. Independent auditor

RSM SG Assurance LLP has expressed willingness to accept re-appointment.

7. Report of audit committee

The members of the audit committee at the date of this report are as follows:

| | |
|--------------|--|
| Lim Jit Soon | (Chairman of audit committee) |
| Low Su-Shing | (Non-Executive and Independent Director) |
| Teo Kwee Yee | (Non-Executive and Independent Director) |

The audit committee performed the functions specified by section 201B (5) of the Act. Among other functions, it reviewed the following, where relevant, with management, the external auditors and the internal auditors:

- The audit plan of the independent external auditor.
- The independent external auditor's evaluation of the company's internal accounting controls relevant to the statutory audit, the audit report on the financial statements and the assistance given by management to the auditor.

STATEMENT BY DIRECTORS

7. Report of audit committee (cont'd)

- The scope and results of the internal audit procedures (including those relating to financial, operational and compliance controls and risk management) and the assistance given by the management to the internal auditor.
- The financial statements of the group and the company prior to their submission to the directors of the company for adoption.
- The interested person transactions (as defined in Chapter 9 of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited).

Other functions performed by the audit committee are described in the report on corporate governance included in the annual report of the company. It also includes an explanation of how the independent auditor objectivity and independence is safeguarded when the independent auditor provide non-audit services.

The audit committee has recommended to the board that the independent auditor, RSM SG Assurance LLP, be nominated for re-appointment as the independent auditor at the forthcoming annual general meeting of the company.

8. Directors' opinion on the adequacy of internal controls

Based on the internal controls established and maintained by the company, work performed by the internal and external auditors, and reviews performed by management, other committees of the board and the board, the board, with the concurrence of the audit committee, is of the opinion that the company's internal controls (including financial, operational, compliance and information technology controls), and risk management systems were adequate and effective as at 30 June 2025 to address the risks that the company considers relevant and material to its operations.

9. Subsequent developments

There are no significant developments subsequent to the release of the group's and the company's financial statements, as announced on 26 August 2025, which would materially affect the group's and the company's operating and financial performance as of the date of this report.

On behalf of the directors

Soong Chin Kum Jonathan Lloyd
Director

Prashanth Palepu
Director

1 October 2025

INDEPENDENT AUDITOR'S REPORT

To the Members of Pasture Holdings Ltd.

Report on the audit of the financial statements

Opinion

We have audited the accompanying financial statements of Pasture Holdings Ltd. (the "company") and its subsidiaries (the "group"), which comprise the consolidated statement of financial position of the group and the statement of financial position of the company as at 30 June 2025, and the consolidated statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows of the group, and statement of changes in equity of the company for the reporting year then ended, and notes to the financial statements, including the material accounting policy information.

In our opinion, the accompanying consolidated financial statements of the group and the statement of financial position and statement of changes in equity of the company are properly drawn up in accordance with the provisions of the Companies Act 1967 (the "Act") and Singapore Financial Reporting Standards (International) ("SFRS(I)") so as to give a true and fair view of the consolidated financial position of the group and the financial position of the company as at 30 June 2025 and of the consolidated financial performance, consolidated changes in equity and consolidated cash flows of the group and the changes in equity of the company for the reporting year ended on that date.

Basis for opinion

We conducted our audit in accordance with Singapore Standards on Auditing ("SSAs"). Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the Accounting and Corporate Regulatory Authority ("ACRA") Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities ("ACRA Code") together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matter

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current reporting year. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue recognition

Refer to Note 2A "Revenue and income recognition", Note 2B "Revenue recognition – agent versus principal considerations" for the relevant accounting policies and discussion of critical judgements respectively and Note 5 for the breakdown in revenue. Also refer to Note 21 for the amount of advance received from customers classified as contract liabilities at the end of the reporting year.

Key audit matter

The group generates revenue from the wholesale of mask and third-party pharmaceutical products to customers. The group typically bills these customers in advance prior to placing these orders with suppliers. Such advance payments received from customers are classified as contract liabilities.

INDEPENDENT AUDITOR'S REPORT

To the Members of Pasture Holdings Ltd.

Key audit matter (cont'd)

Key audit matter (cont'd)

For most sales arrangements, the group has control over the products before the products are transferred to customers even though the customers have prepaid for the products. Management has concluded that the group acts as a principal in these arrangements and the revenue from the sales of goods are only recognised when the group has satisfied the performance obligation to transfer the products by delivering the products to customers and when the customers have obtained control of the products.

The group has certain sales arrangements where the customer places orders directly with the group's suppliers and products are delivered directly from the suppliers to the customer concerned. For such arrangements, management has concluded that the group does not bear the credit risk and inventory risk of the products and thus, assessed that it acts as an agent for these sales arrangements and the related revenue has been recognised as net service income.

How we addressed the matter in our audit

We reviewed management's assessment and basis of recognition for revenue and factors that management considered in determining when control has passed to the customers and accordingly, the point at which revenue should be recognised. On a sample basis, we performed audit procedures to validate the point at which control of the products has been transferred to the customers and that revenue has been recognised accordingly.

We also obtained confirmations from customers with significant amounts of advance payments as at the end of the reporting year.

Other information

Management is responsible for the other information. The other information comprises the statement by directors but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of management and directors for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act and SFRS(I), and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

INDEPENDENT AUDITOR'S REPORT

To the Members of Pasture Holdings Ltd.

Responsibilities of management and directors for the financial statements (cont'd)

In preparing the financial statements, management is responsible for assessing the group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the group or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the group's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the group's internal control.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- f) Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

INDEPENDENT AUDITOR'S REPORT

To the Members of Pasture Holdings Ltd.

Auditor's responsibilities for the audit of the financial statements (cont'd)

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other legal and regulatory requirements

In our opinion, the accounting and other records required by the Act to be kept by the company and by the subsidiary corporations incorporated in Singapore of which we are the auditors have been properly kept in accordance with the provisions of the Act.

The engagement partner on the audit resulting in this independent auditor's report is Yeow Thuan Wee.

RSM SG Assurance LLP
Public Accountants and
Chartered Accountants
Singapore

1 October 2025

Engagement partner – effective from year ended 30 June 2025

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Year ended 30 June 2025

| | Notes | Group | |
|--|-------|------------------|------------------|
| | | 2025 US\$'000 | 2024 US\$'000 |
| Revenue | 5 | 12,165 | 14,063 |
| Cost of sales | | (8,770) | (10,597) |
| Gross profit | | 3,395 | 3,466 |
| Other income and gains | 6 | 221 | 342 |
| Marketing and distribution costs | | (80) | (134) |
| Administrative expenses | 7 | (2,811) | (2,848) |
| Other losses | 6 | (65) | (98) |
| Finance costs | 9 | (91) | (85) |
| Profit before tax | | 569 | 643 |
| Income tax expense | 10 | (28) | (84) |
| Profit, net of tax representing total comprehensive income, attributable to owners of the company | | 541 | 559 |
| Earnings per share | | | |
| - Basic and diluted (cents) | 11 | 0.41 | 0.42 |

The accompanying notes form an integral part of these financial statements.

STATEMENTS OF FINANCIAL POSITION

As at 30 June 2025

| | Notes | Group | | Company | |
|--|-------|------------------|------------------|------------------|------------------|
| | | 2025 US\$'000 | 2024 US\$'000 | 2025 US\$'000 | 2024 US\$'000 |
| ASSETS | | | | | |
| <u>Non-current assets</u> | | | | | |
| Property, plant and equipment | 12 | 1,369 | 1,639 | 1,098 | 1,380 |
| Other financial assets | 13 | 554 | 532 | - | - |
| Investment in subsidiaries | 14 | - | - | 137 | 137 |
| Total non-current assets | | 1,923 | 2,171 | 1,235 | 1,517 |
| <u>Current assets</u> | | | | | |
| Inventories | 15 | 2,362 | 3,870 | - | - |
| Other non-financial assets | 16 | 186 | 685 | 100 | 109 |
| Trade and other receivables | 17 | 504 | 1,050 | 1,249 | 1,591 |
| Cash and cash equivalents | 18 | 4,962 | 4,736 | 2,128 | 1,347 |
| Total current assets | | 8,014 | 10,341 | 3,477 | 3,047 |
| Total assets | | 9,937 | 12,512 | 4,712 | 4,564 |
| EQUITY AND LIABILITIES | | | | | |
| <u>Equity</u> | | | | | |
| Share capital | 19 | 3,671 | 3,671 | 3,671 | 3,671 |
| Retained earnings/(accumulated losses) | | 1,257 | 716 | (949) | (1,187) |
| Total equity | | 4,928 | 4,387 | 2,722 | 2,484 |
| <u>Non-current liabilities</u> | | | | | |
| Loans and borrowings | 20 | 368 | 520 | - | - |
| Lease liabilities | 22 | 951 | 1,144 | 951 | 1,144 |
| Total non-current liabilities | | 1,319 | 1,664 | 951 | 1,144 |
| <u>Current liabilities</u> | | | | | |
| Income tax payable | | 82 | 85 | 2 | 2 |
| Other non-financial liabilities | 21 | 2,693 | 5,265 | - | - |
| Loans and borrowings | 20 | 173 | 153 | - | - |
| Lease liabilities | 22 | 248 | 249 | 248 | 197 |
| Trade and other payables | 23 | 494 | 709 | 789 | 737 |
| Total current liabilities | | 3,690 | 6,461 | 1,039 | 936 |
| Total liabilities | | 5,009 | 8,125 | 1,990 | 2,080 |
| Total equity and liabilities | | 9,937 | 12,512 | 4,712 | 4,564 |

The accompanying notes form an integral part of these financial statements.

STATEMENTS OF CHANGES IN EQUITY

Year ended 30 June 2025

| | Share capital US\$'000 | Retained earnings US\$'000 | Total equity US\$'000 |
|---|------------------------------|----------------------------------|-----------------------------|
| Group: | | | |
| Opening balance at 1 July 2023 | 3,671 | 157 | 3,828 |
| Total comprehensive income for the year | - | 559 | 559 |
| Closing balance at 30 June 2024 | 3,671 | 716 | 4,387 |
| Total comprehensive income for the year | - | 541 | 541 |
| Closing balance at 30 June 2025 | 3,671 | 1,257 | 4,928 |

| | Share capital US\$'000 | Accumulated losses US\$'000 | Total equity US\$'000 |
|---|------------------------------|-----------------------------------|-----------------------------|
| Company: | | | |
| Opening balance at 1 July 2023 | 3,671 | (1,259) | 2,412 |
| Total comprehensive income for the year | - | 72 | 72 |
| Closing balance at 30 June 2024 | 3,671 | (1,187) | 2,484 |
| Total comprehensive income for the year | - | 238 | 238 |
| Closing balance at 30 June 2025 | 3,671 | (949) | 2,722 |

The accompanying notes form an integral part of these financial statements.

CONSOLIDATED STATEMENT OF CASH FLOWS

Year ended 30 June 2025

| | Group | |
|--|----------|----------|
| | 2025 | 2024 |
| | US\$'000 | US\$'000 |
| <u>Cash flows provided by operating activities</u> | | |
| Profit before tax | 569 | 643 |
| Adjustments for: | | |
| Interest income | (81) | (23) |
| Interest expense | 91 | 85 |
| Insurance premium for other financial assets | 1 | 1 |
| Loss from disposal of plant and equipment | 4 | 40 |
| Impairment of plant and equipment | 1 | - |
| Inventories written off | 4 | 24 |
| Reversal of provision for inventories obsolescence | - | (7) |
| Depreciation of property, plant and equipment | 355 | 296 |
| Unrealised exchange differences | 46 | (2) |
| Operating cash flows before changes in working capital | 990 | 1,057 |
| Inventories | 1,504 | (1,841) |
| Other non-financial assets | 499 | 24 |
| Trade and other receivables | 546 | (743) |
| Other non-financial liabilities | (2,572) | 2,031 |
| Trade and other payables | (215) | 274 |
| Net cash flows from operations | 752 | 802 |
| Income taxes (paid) recovered | (30) | 15 |
| Net cash provided by operating activities | 722 | 817 |
| <u>Cash flows used in investing activities</u> | | |
| Purchase of plant and equipment | (90) | (260) |
| Interest received | 81 | 23 |
| Net cash used in investing activities | (9) | (237) |
| <u>Cash flows used in financing activities</u> | | |
| Purchase of other financial assets | - | (539) |
| Increase in new loans and borrowings | - | 775 |
| Repayment of loans and borrowings | (195) | (136) |
| Cash pledged for bank facilities | - | (148) |
| Lease payments | (298) | (138) |
| Net cash used in financing activities | (493) | (186) |
| Net increase in cash and cash equivalents | 220 | 394 |
| Cash and cash equivalents, statement of cash flows, beginning balance | 4,588 | 4,194 |
| Cash and cash equivalents, statement of cash flows, ending balance (Note 18A) | 4,808 | 4,588 |

The accompanying notes form an integral part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

1. General information

Pasture Holdings Ltd. is incorporated in Singapore with limited liability and is listed on the Catalist Board (the "Catalist") of Singapore Exchange Securities Trading Limited.

The financial statements are presented in United States Dollar ("US\$") and they cover the company (referred to as "parent") and its subsidiaries. All financial information have been rounded to the nearest thousand ("000"), except when otherwise stated.

The board of directors approved and authorised these financial statements for issue on the date of the statement by directors. The directors have the power to amend and reissue the financial statements.

The principal activities of the company are those of investment holding and provision of management services. The principal activities of the subsidiaries are described in Note 14 below.

The registered office of the company is located at 2 Corporation Rd #03-04/05 Corporation Place, Singapore 618494. The company is situated in Singapore.

Statement of compliance with financial reporting standards

These financial statements have been prepared in accordance with the Singapore Financial Reporting Standards (International) ("SFRS (I)s") and the related Interpretations to SFRS (I) ("SFRS (I) INT") as issued by the Accounting Standards Committee under ACRA ("ASC"). They comply with the provisions of the Companies Act 1967 and with the IFRS Accounting Standards ("IFRSs") as issued by the International Accounting Standards Board ("IASB").

Basis of preparation of the financial statements

The financial statements are prepared on a going concern basis under the historical cost convention except where a financial reporting standard requires an alternative treatment (such as fair values) as disclosed where appropriate in these financial statements. The accounting policies in the financial reporting standards may not be applied when the effect of applying them is not material. The disclosures required by financial reporting standards may not be provided if the information resulting from that disclosure is not material.

Basis of presentation and principles of consolidation

The consolidated financial statements of the group include the financial statements made up to the end of the reporting year of the company and all of its subsidiaries, presented as those of a single economic entity and are prepared using uniform accounting policies for like transactions and other events in similar circumstances. All significant intragroup balances and transactions are eliminated on consolidation. Subsidiaries are consolidated from the date the reporting entity obtains control of the investee. They are de-consolidated from the date that control ceases.

Changes in the group's ownership interest in a subsidiary that do not result in the loss of control are accounted for within equity as transactions with owners in their capacity as owners. The carrying amounts of the group's and non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiary. When the group loses control of a subsidiary, it derecognises the assets and liabilities and related equity components of the former subsidiary. Any gain or loss is recognised in profit or loss. Any investment retained in the former subsidiary is measured at fair value at the date when control is lost and is subsequently accounted as equity investments financial assets in accordance with the financial reporting standard on financial instruments.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

1. General information (cont'd)

Basis of presentation and principles of consolidation (cont'd)

The company's separate financial statements have been prepared on the same basis, and as permitted by the Companies Act 1967, the company's separate statement of profit or loss and other comprehensive income is not presented.

2. Material accounting policy information and other explanatory information

2A. Material accounting policy information

Foreign currency transactions

The functional currency is the United States Dollar as it reflects the primary economic environment in which the entity operates. Transactions in foreign currencies are recorded in the functional currency at the rates ruling at the dates of the transactions. At each end of the reporting year, recorded monetary balances and balances measured at fair value that are denominated in non-functional currencies are reported at the rates ruling at the end of the reporting year and fair value measurement dates respectively. All realised and unrealised exchange adjustment gains and losses are dealt with in profit or loss except when a gain or loss on a non-monetary item is recognised in other comprehensive income, any exchange component of that gain or loss is recognised in other comprehensive income. The presentation is in the functional currency.

Fair value measurement

The fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When measuring the fair value of an asset or a liability, market observable data to the extent possible is used. If the fair value of an asset or a liability is not directly observable, an estimate is made using valuation techniques that maximise the use of relevant observable inputs and minimise the use of unobservable inputs (e.g. by use of the market comparable approach that reflects recent transaction prices for similar items, discounted cash flow analysis, or option pricing models refined to reflect the issuer's specific circumstances). Inputs used are consistent with the characteristics of the asset or liability that market participants would take into account. The entity's intention to hold an asset or to settle or otherwise fulfil a liability is not taken into account as relevant when measuring fair value.

Fair values are categorised into different levels in a fair value hierarchy based on the degree to which the inputs to the measurement are observable and the significance of the inputs to the fair value measurement in its entirety: Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (ie derived from prices). Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs). Transfers between levels of the fair value hierarchy are recognised at the end of the reporting period during which the change occurred.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

2. Material accounting policy information and other explanatory information (cont'd)

2A. Material accounting policy information (cont'd)

Fair value measurement (cont'd)

The carrying values of current financial instruments approximate their fair values due to the short-term maturity of these instruments and the disclosures of fair value are not made when the carrying amount of current financial instruments is a reasonable approximation of the fair value. The fair values of non-current financial instruments may not be disclosed separately unless there are material differences at the end of the reporting year and in the event the fair values are disclosed in the relevant notes to the financial statements. The recurring measurements are made at each reporting year end date.

Revenue and income recognition

General – Revenue is recognised at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to a customer (which excludes estimates of variable consideration that are subject to constraints, such as right of return exists, and modifications), net of any related taxes and excluding any amounts collected on behalf of third parties. An asset (goods or services) is transferred when or as the customer obtains control of that asset. As a practical expedient, the effects of any significant financing component is not adjusted if the payment for the good or service will be within one year.

Sale of goods – Revenue is recognised at a point in time when the performance obligation is satisfied by transferring a promised good to the customer. Control of the goods is transferred to the customer, generally on delivery of the goods (in this respect, incoterms are considered).

Services – Revenue from service orders is recognised when the entity satisfies the performance obligation at a point in time generally when the significant acts have been completed and when transfer of control occurs. For services that are not material transactions, revenue is recognised as the services are provided.

Interest income is recognised using the effective interest method.

Government grants are recognised at fair value when there is reasonable assurance that the conditions attaching to them will be complied with and that the grants will be received. Grants in recognition of specific expenses are recognised in profit or loss on a systematic basis over the periods necessary to match them with the related costs that they are intended to compensate.

Staff costs

Contributions to a defined contribution retirement benefit plan are recorded as an expense as they fall due. The entity's legal or constructive obligation is limited to the amount that it is obligated to contribute to an independently administered fund (such as the Central Provident Fund in Singapore, a government managed defined contribution retirement benefit plan). For employee leave entitlement, the expected cost of short-term employee benefits in the form of compensated absences is recognised in the case of accumulating compensated absences, when the employees render service that increases their entitlement to future compensated absences; and in the case of non-accumulating compensated absences, when the absences occur. A liability for bonuses is recognised where the entity is contractually obliged or where there is constructive obligation based on past practice.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

2. Material accounting policy information and other explanatory information (cont'd)

2A. Material accounting policy information (cont'd)

Borrowing costs

Borrowing costs are interest and other costs incurred in connection with the borrowings. Interest expense is calculated using the effective interest rate method. Borrowing costs are recognised as an expense in the period in which they are incurred.

Income tax

Tax expense (tax benefit) is the aggregate amount included in the determination of profit or loss for the reporting year in respect of current tax and deferred tax. Current income tax is the expected tax payable on the taxable income for the reporting year; calculated using rates enacted or substantively enacted at the statements of financial position date; and inclusive of any adjustment to income tax payable or recoverable in respect of previous reporting years. Deferred tax is recognised using the liability method; based on temporary differences between the carrying amounts of assets and liabilities in the financial statements and their respective income tax bases; and determined using tax rates that have been enacted or substantively enacted by the reporting year end date and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled. A deferred tax amount is recognised for all temporary differences, unless the deferred tax amount arises from the initial recognition of an asset or liability in a transaction which (i) is not a business combination; and (ii) at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

A deferred tax liability or asset is recognised for all taxable temporary differences associated with investments in subsidiaries, except where the reporting entity is able to control the timing of the reversal of the taxable temporary difference and it is probable that the taxable temporary difference will not reverse in the foreseeable future or for deductible temporary differences, they will not reverse in the foreseeable future and they cannot be utilised against taxable profits.

Plant and equipment

Plant and equipment are carried at cost on initial recognition and after initial recognition at cost less any accumulated depreciation and any accumulated impairment losses. Depreciation is provided on a straight-line method to allocate the gross carrying amounts of the assets less their residual values over their estimated useful lives of each part of an item of these assets (or, for certain leased assets, the shorter lease term). An asset is depreciated when it is available for use until it is derecognised even if during that period the item is idle.

Right-of-use assets

The right-of-use assets are accounted and presented as if they were owned such as property, plant and equipment, and depreciated over the lease terms.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

2. Material accounting policy information and other explanatory information (cont'd)

2A. Material accounting policy information (cont'd)

Leases of lessee

A lease conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration. Where a lease arrangement is identified, a liability to the lessor is recognised as a lease obligation calculated at the present value of minimum unavoidable lease payments. A corresponding right-of-use asset is recorded. Lease payments are apportioned between finance costs and reduction of the lease liability so as to reflect the interest on the remaining balance of the liability. Finance charges are recorded as a finance cost. Leases with a term of 12 months or less and leases for low value are not recorded as a liability and lease payments are recognised as an expense in profit or loss on a straight-line basis over the lease term.

Subsidiaries

A subsidiary is an entity including unincorporated and special purpose entity that is controlled by the reporting entity and the reporting entity is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. The existence and effect of substantive potential voting rights that the reporting entity has the practical ability to exercise (that is, substantive rights) are considered when assessing whether the reporting entity controls another entity. In the reporting entity's separate financial statements, an investment in a subsidiary is accounted for at cost less any allowance for impairment in value. Impairment loss recognised in profit or loss for a subsidiary is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. The carrying value and the net book value of the investment in a subsidiary are not necessarily indicative of the amount that would be realised in a current market exchange.

Carrying amounts of non-financial assets

The amounts of the non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated. An impairment loss is recognised in the statement of profit or loss whenever the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount.

Inventories

Inventories are stated at the lower of cost and selling price less costs to complete and sell. Cost is calculated using the first in first out method.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

2. Material accounting policy information and other explanatory information (cont'd)

2A. Material accounting policy information (cont'd)

Financial instruments

Recognition and derecognition of financial instruments:

A financial asset or a financial liability is recognised when, and only when, the entity becomes a party of the contractual provisions of the instrument. All other financial instruments (including regular-way purchases and sales of financial assets) are recognised and derecognised, as applicable, using trade date accounting or settlement date accounting. A financial asset is derecognised when the contractual rights to the cash flows from the financial asset expire or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the entity neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. A financial liability is removed from the statement of financial position when, and only when, it is extinguished, that is, when the obligation specified in the contract is discharged or cancelled or expires. At initial recognition, the financial asset or financial liability is measured at its fair value plus or minus, in the case of a financial asset or financial liability not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition or issue of the financial asset or financial liability.

Classification of financial assets and financial liabilities and subsequent measurement:

The financial reporting standard on financial instruments requires the certain classification of financial assets and financial liabilities. At the end of the reporting year, the reporting entity had the following classes:

- Financial asset classified as measured at amortised cost: A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at fair value through profit or loss ("FVTPL"), that is (a) the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Typically trade and other receivables, bank and cash balances are in this class.
- Financial liabilities are classified as at FVTPL in either of the following circumstances: (1) the liabilities are managed, evaluated and reported internally on a fair value basis; or (2) the designation eliminates or significantly reduces an accounting mismatch that would otherwise arise. All other financial liabilities are carried at amortised cost using the effective interest method. Reclassification of any financial liability is not permitted.

Cash and cash equivalents

For the statement of cash flows, cash and cash equivalents includes cash and cash equivalents less cash subject to restriction and bank overdrafts payable on demand that form an integral part of cash management. Cash equivalents are short-term (three months or less), highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Cash flows are reported using the indirect method, whereby profit or loss is adjusted for the effects of transactions of a non-cash nature, and items of income or expense associated with investing or financing cash flows.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

2. Material accounting policy information and other explanatory information (cont'd)

2A. Material accounting policy information (cont'd)

Other specific material accounting policy information and other explanatory information

These are included in the relevant notes to the financial statements.

2B. Judgements and sources of estimation uncertainties

Disclosures on material information about the assumptions management made about the future, and other major sources of estimation uncertainty at the end of the reporting year, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below or in the corresponding notes to these financial statements. These estimates and assumptions are periodically monitored to ensure they incorporate all relevant information available at the date when financial statements are prepared. However, this does not prevent actual figures differing from estimates.

Revenue recognition - agent versus principal considerations:

Management follows the guidance provided in SFRS(I) 15 *Revenue from Contracts with Customers* in determining whether the group is the principal or an agent in arrangements with customers that involve another party that contributes to providing the goods and/or services to the customer. In these instances, management determines whether the group has promised to provide the goods and/or services itself (as principal) or to arrange for the specified goods and/or service to be provided by another party (as an agent). Where the group is not primarily responsible for the fulfilment of goods and/or service, does not have control of the promised goods and/or service, and does not have full discretion in establishing prices, management has assessed that it is the agent in such transactions and recognises the revenue on a net basis as service income. For all other arrangements, management has determined that the group acts as a principal and the revenue is recognised on a gross basis. The revenue recognised for the year is disclosed in the note on revenue.

Allowance for impairment on inventories:

The assessment of the allowance for impairment loss on inventories requires a degree of estimation and judgement. The level of the loss allowance is assessed by taking into account the recent sales experience, the expiry dates of inventories, committed purchase orders from customers for the inventories on hand and other factors that affect inventory obsolescence and subsequent events. Possible changes in these estimates could result in revisions to the stated value of the inventories. The carrying amounts of inventories at the end of the reporting year is disclosed in the note on inventories.

Expected credit loss allowance on trade receivables:

The assessment of the expected credit losses ("ECL") requires a degree of estimation and judgement. In measuring the ECL, management considers all reasonable and supportable information such as the group's past experience at collecting receipts, any increase in the number of delayed receipts in the portfolio past the average credit period, and forward looking information such as forecasts of future economic conditions. The carrying amounts might change materially within the next reporting year but these changes may not arise from assumptions or other sources of estimation uncertainty at the end of the reporting year. The carrying amount is disclosed in the note on trade and other receivables.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

2. Material accounting policy information and other explanatory information (cont'd)

2B. Judgements and sources of estimation uncertainties (cont'd)

Determination of functional currency:

Judgement is required to determine the functional currency of the group and of the company. Management considers economic environment in which the reporting entity operates and factors such as the currency that mainly influences the prices for its revenue items; the currency of the country whose competitive forces and regulations mainly determine the prices for its revenue items; and the currency that mainly influences labour, material and other costs of providing goods or services. It also considers other relevant factors that may also provide evidence of an entity's functional currency. Based on this assessment, management has determined United States Dollar as the functional currency of the group and of the company.

Assessing the impairment loss on subsidiary:

Where an investee is in net equity deficit and or has suffered losses, a test is made whether the investment in the investee has suffered any impairment loss. This measurement requires significant judgement. An estimate is made of the future profitability of the investee, and the financial health of and near-term business outlook for the investee, including factors such as industry and sector performance, and operational and financing cash flows. It is impracticable to disclose the extent of the possible effects. It is reasonably possible, based on existing knowledge, that outcomes within the next reporting year that are different from assumptions could require a material adjustment to the carrying amount of the investee affected. The carrying amount is disclosed in the note on investment in subsidiaries.

Estimating of useful lives of plant and equipment:

The estimates for the useful lives and related depreciation charges for plant and equipment are based on commercial and other factors that could change materially because of innovations and in response to market conditions. The depreciation charge is increased where useful lives are less than previously estimated lives, or the carrying amounts written off or written down for technically obsolete items or assets that have been abandoned. It is impracticable to disclose the extent of the possible effects. It is reasonably possible, based on existing knowledge, that outcomes within the next reporting year that are different from assumptions could require a material adjustment to the carrying amount of the balances affected. The carrying amount of the specific asset or class of assets at the end of the reporting year is disclosed in the note on plant and equipment.

3. Related party relationships and transactions

The financial reporting standard on related party disclosures requires the reporting entity to disclose: (a) related party relationships, transactions and outstanding balances, including commitments, including (b) relationships between parents and subsidiaries irrespective of whether there have been transactions between those related parties. A party is related to a party if the party controls, or is controlled by, or can significantly influence or is significantly influenced by the other party.

The ultimate controlling party is Soong Chin Kum Jonathan Lloyd.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

3. Related party relationships and transactions (cont'd)

3A. Member of a group:

| Name | Relationship | Country of incorporation |
|------------------------|---------------------------------------|--------------------------|
| PMI Holdings Pte. Ltd. | Immediate and ultimate parent company | Singapore |

Related companies in these financial statements include the member of the above group of companies.

3B. Related party transactions:

There are transactions and arrangements between the reporting entity and related parties and the effects of these on the basis determined between the parties are reflected in these financial statements. The related party balances and transfer of resources, services or obligations, if any, are unsecured, without fixed repayment terms and interest or charge unless stated otherwise.

Intragroup transactions and balances that have been eliminated in these consolidated financial statements are not disclosed as related party transactions and balances below.

In addition to the information disclosed elsewhere in the notes to the financial statements, other related party transactions include the following material related party transactions:

| | Group | |
|--------------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| <u>Related parties:</u> | | |
| Purchases ^(a) | 1 | 23 |

(a) Transactions are with Pleasant Exports, an entity where the entire issued share capital is held by Prashanth Palepu, a director of the company, together with his immediate family, Srinivasa Gopal Palepu and Pranay Palepu.

3C. Key management compensation:

| | Group | |
|---|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Salaries and other short-term employee benefits | 816 | 893 |

The above amounts are included under staff costs. Included in the above amounts are the following items:

| | Group | |
|--|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Fees to directors of the company | 106 | 81 |
| Remuneration of directors of the company | 330 | 416 |

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

3. Related party relationships and transactions (cont'd)

3C. Key management compensation (cont'd):

Key management personnel include the directors and those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly. Further information about the remuneration of individual directors is provided in the report on corporate governance.

3D. Other receivables from and other payables to related parties:

The trade transactions and the related receivables and payables balances arising from sales and purchases of goods and services are disclosed elsewhere in the notes to the financial statements. The movements in other receivables from and other payables to related parties are as follows:

| <u>Company</u> | <u>Subsidiaries</u> | |
|--|--------------------------------|--------------------------------|
| | <u>2025</u> <u>US\$'000</u> | <u>2024</u> <u>US\$'000</u> |
| <u>Other receivables / (other payables):</u> | | |
| At beginning of the year | 1,192 | (459) |
| Amounts paid in and settlement of liabilities on behalf of the company | (528) | - |
| Amounts paid out and settlement of liabilities on behalf of the subsidiaries | - | 1,651 |
| At end of the year – net debit | <u>664</u> | <u>1,192</u> |
| Presented in the statement of financial position as follows: | | |
| Other receivables (Note 17) | 1,249 | 1,591 |
| Other payables (Note 23) | (585) | (399) |
| At end of the year – net debit | <u>664</u> | <u>1,192</u> |

4. Financial information by operating segments

The reporting entity discloses financial and descriptive information about its consolidated reportable segments. Reportable segments are operating segments or aggregations of operating segments that meet specified criteria. Operating segments are components about which separate financial information is available that is evaluated regularly by the chief operating decision maker to allocate resources and in assessing performance. Generally, financial information on segments is reported on the same basis as is used internally for evaluating operating segment performance and deciding how to allocate resources to operating segments. Disclosure of information about operating segments, products and services, the geographical areas, and the major customers are made as required by the financial reporting standard on operating segments. This disclosure standard has no impact on the reported financial performance or financial position of the reporting entity.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

4. Financial information by operating segments (cont'd)

4A. Information about reportable segment profit or loss, assets and liabilities

For management purposes, the group is organised into three (3) major strategic operating segments: pharmaceutical wholesale and drop-shipment, masks and medical supplies and other services. Such a structural organisation is determined by the nature of risks and returns associated with each business segment and it defines the management structure as well as the internal reporting system. It represents the basis on which the management reports the primary segment information that is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing the performance. They are managed separately because each business requires different strategies.

The group distributes and sells its products via the following market segments:

- 1) Pharmaceutical wholesale and drop-shipment ("Pharma WDS") refer to sales generated from the wholesale procurement and transshipment of pharmaceutical and nutraceutical products and backend support of pharmaceutical supplies to international clients' online pharmacy businesses.
- 2) Masks and medical supplies refer to sales generated from surgical masks, N95 respirators, surgical N95 respirators, N95 respirators for general public use and wholesale procurement of medical supplies and devices.
- 3) Other services refer mainly to sales of new lines of products and services in new markets, such as oral disintegrating strips and the pet pharmaceutical and nutraceutical products and services.

This is determined by the nature or risks and returns associated with each business segment and defines the management structure as well as the internal reporting system. It also represents the basis on which management reports the primary segment information.

Inter-segment sales are measured on the basis that the group actually uses to price the transfers. Internal transfer pricing policies of the group are as far as practicable based on market prices. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies.

The management reporting system evaluates performances based on a number of factors. However, the primary profitability measurement to evaluate segment's operating results comprises two major financial indicators: (1) earnings before interest, tax, depreciation and amortisation ("EBITDA"); (2) profit before tax.

The following tables illustrate the information about the reportable segment profit or loss, assets and liabilities.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

4. Financial information by operating segments (cont'd)

4B. Profit or loss from continuing operations and reconciliations

| | Pharma WDS US\$'000 | Mask and medical supplies US\$'000 | Other services US\$'000 | Unallocated US\$'000 | Total US\$'000 |
|----------------------------------|---------------------------|---|-------------------------------|-------------------------|-------------------|
| 2025 | | | | | |
| Revenue by segment | | | | | |
| Total revenue by segment | 11,798 | 214 | 153 | - | 12,165 |
| Total revenue | 11,798 | 214 | 153 | - | 12,165 |
| EBITDA | | | | | |
| Finance costs | - | (39) | - | (52) | (91) |
| Depreciation and amortisation | - | - | - | (355) | (355) |
| Profit / (loss) before tax | 2,165 | 85 | 49 | (1,730) | 569 |
| Income tax expense | | | | | (28) |
| Profit, net of tax | | | | | 541 |
| 2024 | | | | | |
| Revenue by segment | | | | | |
| Total revenue by segment | 13,860 | 154 | 49 | - | 14,063 |
| Total revenue | 13,860 | 154 | 49 | - | 14,063 |
| EBITDA | | | | | |
| Finance costs | (39) | - | - | (46) | (85) |
| Depreciation and amortisation | - | - | - | (296) | (296) |
| Profit / (loss) before tax | 2,101 | 69 | 54 | (1,581) | 643 |
| Income tax expense | | | | | (84) |
| Profit, net of tax | | | | | 559 |

The unallocated expenses mainly included the group's corporate expenses such as staff costs and professional fees.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

4. Financial information by operating segments (cont'd)

4C. Assets and reconciliations

| | Pharma WDS US\$'000 | Mask and medical supplies US\$'000 | Other services US\$'000 | Unallocated US\$'000 | Total US\$'000 |
|---|---------------------------|---|-------------------------------|-------------------------|-------------------|
| 2025 | | | | | |
| Total assets for reportable segments ^(a) | 2,705 | 199 | 14 | - | 2,918 |
| Unallocated: Property, plant and equipment | - | - | - | 1,369 | 1,369 |
| Other financial assets | - | - | - | 554 | 554 |
| Cash and cash equivalents | - | - | - | 4,962 | 4,962 |
| Other non-financial assets | - | - | - | 134 | 134 |
| Total group assets | 2,705 | 199 | 14 | 7,019 | 9,937 |
| 2024 | | | | | |
| Total assets for reportable segments ^(a) | 4,903 | 242 | 300 | - | 5,445 |
| Unallocated: Property, plant and equipment | - | - | - | 1,639 | 1,639 |
| Cash and cash equivalents | - | - | - | 532 | 532 |
| Income tax recoverable | - | - | - | 4,736 | 4,736 |
| Other non-financial assets | - | - | - | 160 | 160 |
| Total group assets | 4,903 | 242 | 300 | 7,067 | 12,512 |

(a) The segment assets consist principally of trade receivables, inventories and advances to suppliers. The other assets are not allocated to operating segments because they are not directly attributable to the segments or cannot be allocated to the segments on a reasonable basis.

4D. Liabilities and reconciliations

| | Pharma WDS US\$'000 | Mask and medical supplies US\$'000 | Unallocated US\$'000 | Total US\$'000 |
|---|---------------------------|---|-------------------------|-------------------|
| 2025 | | | | |
| Total liabilities for reportable segments | 2,844 | 32 | 2,133 | 5,009 |
| Total group liabilities | 2,844 | 32 | 2,133 | 5,009 |
| 2024 | | | | |
| Total liabilities for reportable segments | 5,424 | 6 | 2,695 | 8,125 |
| Total group liabilities | 5,424 | 6 | 2,695 | 8,125 |

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

4. Financial information by operating segments (cont'd)

4E. Other material items and reconciliations

| | Unallocated US\$'000 | Total US\$'000 |
|-----------------------------------|-------------------------|-------------------|
| <u>Depreciation</u> | | |
| 2025 | 355 | 355 |
| 2024 | 296 | 296 |
| <u>Capital expenditure</u> | | |
| 2025 | 90 | 90 |
| 2024 | 260 | 260 |

4F. Geographical information

| | 2025 US\$'000 | 2024 US\$'000 |
|---------------|------------------|------------------|
| Canada | 5,653 | 4,971 |
| Japan | 3,977 | 5,590 |
| Hong Kong | 1,830 | 3,076 |
| Singapore | 199 | 140 |
| Others | 506 | 286 |
| Total revenue | 12,165 | 14,063 |

Revenues are attributed to country on the basis of the customer's location, irrespective of the origin of the goods and services.

The group's non-current assets were all located in Singapore.

4G. Information on major customers

Except for the major customers disclosed below, there is no other single customer that accounted for 10% or more of the group's total revenue in 2025 and 2024.

| | 2025 US\$'000 | 2024 US\$'000 |
|---|------------------|------------------|
| Customer 1 - Pharmaceutical wholesale and drop-shipment | 3,944 | 3,400 |
| Customer 2 - Pharmaceutical wholesale and drop-shipment | 3,239 | 4,705 |

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

5. Revenue

| | Group | |
|-----------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Rendering of services | 342 | 254 |
| Sale of goods | 11,823 | 13,809 |
| Total revenue | <u>12,165</u> | <u>14,063</u> |

All the contracts are less than 12 months. The revenue from sale of goods and rendering of services are recognised based on point in time. The customers are mainly those in the pharmaceutical industry. A large portion of the goods is exported.

6. Other income and gains and (other losses)

| | Group | |
|---|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Interest income | 81 | 23 |
| Impairment of plant and equipment (Note 12) | (1) | - |
| Foreign exchange translation losses | (56) | (34) |
| Government grant income | 21 | 312 |
| Loss from disposal of plant and equipment | (4) | (40) |
| Reversal of provision for inventories obsolescence (Note 15) | - | 7 |
| Inventories written off (Note 15) | (4) | (24) |
| Reversal of allowance of impairment for trade receivables (Note 17) | 119 | - |
| Net | <u>156</u> | <u>244</u> |
| Presented in profit or loss as: | | |
| Other income and gains | 221 | 342 |
| Other losses | (65) | (98) |
| Net | <u>156</u> | <u>244</u> |

7. Administrative expenses

The major components and other selected components include the following:

| | Group | |
|---|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Depreciation of property, plant and equipment (Note 12) | 355 | 296 |
| Staff costs (Note 8) | <u>1,562</u> | <u>1,577</u> |

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

8. Staff costs

| | Group | |
|--|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Salaries and bonuses | 1,354 | 1,377 |
| Contributions to defined contribution plan | 139 | 115 |
| Other benefits | 69 | 85 |
| Total staff costs | 1,562 | 1,577 |

9. Finance costs

| | Group | |
|-------------------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Interest expense | 39 | 40 |
| Interest on lease liabilities | 52 | 45 |
| Total finance costs | 91 | 85 |

10. Income tax

10A. Components of tax expense recognised in profit or loss

| | Group | |
|--|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| <u>Current tax expense:</u> | | |
| Current tax expense | 81 | 84 |
| Over adjustments in respect of prior periods | (53) | - |
| | 28 | 84 |

The income tax in profit or loss varied from the amount of income tax amount determined by applying the Singapore income tax rate of 17% (2024: 17%) to profit before income tax as a result of the following differences:

| | Group | |
|--|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Profit before tax | 569 | 643 |
| Income tax expense at the above rate | 97 | 109 |
| Expenses not deductible for tax purposes | 3 | 51 |
| Income not subject to tax | (5) | (50) |
| Stepped income exemption | (14) | (26) |
| Over adjustments in respect of prior periods | (53) | - |
| Total income tax expense | 28 | 84 |

There are no income tax consequences of dividends to owners of the company.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

11. Earnings per share

| | Group | |
|---|-------------|-------------|
| | 2025 | 2024 |
| Earnings per share, attributable to owners of the company (in US\$ cent) | 0.41 | 0.42 |
| Number of ordinary shares | 132,000,000 | 132,000,000 |

Diluted earnings per share are the same as basic earnings per share as there were no potential dilutive ordinary shares existing during the respective financial years.

12. Property, plant and equipment

| <u>Group:</u> | Plant and equipment US\$'000 | Right-of-use assets ^(a) US\$'000 | Total US\$'000 |
|---|------------------------------------|---|-------------------|
| <u>Cost:</u> | | | |
| At 1 July 2023 | 198 | 399 | 597 |
| Additions | 260 | 1,363 | 1,623 |
| Disposal/written off | (114) | (56) | (170) |
| At 30 June 2024 | 344 | 1,706 | 2,050 |
| Additions | 90 | - | 90 |
| Disposal/written off | (12) | - | (12) |
| At 30 June 2025 | 422 | 1,706 | 2,128 |
| <u>Accumulated depreciation and impairment:</u> | | | |
| At 1 July 2023 | 119 | 102 | 221 |
| Depreciation for the year | 53 | 243 | 296 |
| Disposal/written off | (74) | (32) | (106) |
| At 30 June 2024 | 98 | 313 | 411 |
| Depreciation for the year | 123 | 232 | 355 |
| Disposal/written off | (8) | - | (8) |
| Impairment for the year | 1 | - | 1 |
| At 30 June 2025 | 214 | 545 | 759 |
| <u>Carrying value:</u> | | | |
| At 1 July 2023 | 79 | 297 | 376 |
| At 30 June 2024 | 246 | 1,393 | 1,639 |
| At 30 June 2025 | 208 | 1,161 | 1,369 |

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

12. Property, plant and equipment (cont'd)

| <u>Company:</u> | Plant and equipment US\$'000 | Right-of-use assets ^(b) US\$'000 | Total US\$'000 |
|----------------------------------|------------------------------------|---|-------------------|
| <u>Cost:</u> | | | |
| At 1 July 2023 | - | - | - |
| Additions | 223 | 1,363 | 1,586 |
| At 30 June 2024 | 223 | 1,363 | 1,586 |
| Additions | 14 | - | 14 |
| At 30 June 2025 | 237 | 1,363 | 1,600 |
| <u>Accumulated depreciation:</u> | | | |
| At 1 July 2023 | - | - | - |
| Additions | 24 | 182 | 206 |
| At 30 June 2024 | 24 | 182 | 206 |
| Depreciation for the year | 78 | 218 | 296 |
| At 30 June 2025 | 102 | 400 | 502 |
| <u>Carrying value:</u> | | | |
| At 1 July 2023 | - | - | - |
| At 30 June 2024 | 199 | 1,181 | 1,380 |
| At 30 June 2025 | 135 | 963 | 1,098 |

Depreciation expenses are charged to profit or loss and included in administrative expenses.

The right-of-use assets included in property, plant and equipment are as follows:

| (a) <u>Group:</u> | Motor vehicle US\$'000 | Office and warehouse premises US\$'000 | Total US\$'000 |
|----------------------------------|------------------------------|---|-------------------|
| <u>Cost:</u> | | | |
| At 1 July 2023 | 343 | 56 | 399 |
| Additions | - | 1,363 | 1,363 |
| Written off | - | (56) | (56) |
| At 30 June 2024 and 30 June 2025 | 343 | 1,363 | 1,706 |
| <u>Accumulated depreciation:</u> | | | |
| At 1 July 2023 | 77 | 25 | 102 |
| Depreciation for the year | 54 | 189 | 243 |
| Written off | - | (32) | (32) |
| At 30 June 2024 | 131 | 182 | 313 |
| Depreciation for the year | 14 | 218 | 232 |
| At 30 June 2025 | 145 | 400 | 545 |
| <u>Carrying value:</u> | | | |
| At 1 July 2023 | 266 | 31 | 297 |
| At 30 June 2024 | 212 | 1,181 | 1,393 |
| At 30 June 2025 | 198 | 963 | 1,161 |

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

12. Property, plant and equipment (cont'd)

| (b) <u>Company:</u> | Office and warehouse premises US\$'000 |
|--|---|
| <u>Cost:</u> | |
| At 1 July 2023 | - |
| Additions | 1,363 |
| At 30 June 2024 and 30 June 2025 | <u>1,363</u> |
| <u>Accumulated depreciation:</u> | |
| At 1 July 2023 | - |
| Depreciation for the year At 30 June 2024 | <u>182</u> |
| Depreciation for the year At 30 June 2025 | <u>218</u> |
| | <u>400</u> |
| <u>Carrying value:</u> | |
| At 1 July 2023 | - |
| At 30 June 2024 | <u>1,181</u> |
| At 30 June 2025 | <u>963</u> |

The useful lives are as follows:

| | | |
|-------------------------------|---|----------------------------------|
| Leasehold property | - | over the lease terms of 60 years |
| Plant and equipment | - | 3 to 5 years |
| Motor vehicle | - | 10 years (2024: 3 years) |
| Office and warehouse premises | - | 6.25 years |

As a result of the annual review, the useful life of motor vehicles was revised from 3 to 10 years. The change in estimates has no material impact on the results for the reporting year. The effect of the change in the accounting estimate is recognised in the current and future periods affected by the change.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

13. Other financial assets

| | Group | |
|---|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| At beginning of the year | 532 | - |
| Acquisition of keyman insurance | - | 539 |
| Insurance premium recognised in profit and loss | (1) | (1) |
| Foreign exchange difference | 23 | (6) |
| At end of the year | 554 | 532 |

Keyman insurance asset (life insurance settlement contract, which is a financial instrument) is accounted under the amortised cost method. The initial investment at the transaction price plus all the direct external costs, the policy premiums and direct external costs to keep the policy in force are capitalised. The reporting entity does not recognise a gain until the policy is terminated, at which time the reporting entity recognises in profit or loss the difference between the carrying amount of a life settlement contract and the life insurance proceeds of the underlying life insurance policy. A test for impairment is made if there is new or updated information that indicates that the expected proceeds (based on current interest rates) from the insurance policy will not be sufficient to recover the carrying amount of the investment plus anticipated undiscounted future premiums and capitalisable direct external costs, when the policy matures. The impairment allowance is charged to profit or loss. The surrender value of the policy as at the end of the reporting year is S\$580,699 (approximately US\$456,817).

14. Investments in subsidiaries

| | Company | |
|--|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| At cost: | | |
| Balance at beginning and end of the year | 137 | 137 |
| Total cost comprising: | | |
| Unquoted equity shares at cost | 137 | 137 |
| Net book value of subsidiaries | 2,343 | 2,029 |

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

14. Investments in subsidiaries (cont'd)

The listing of and information on the subsidiaries are given below:

| Name of subsidiary, country of incorporation, place of operations and principal activities | Cost in books of company | | Effective percentage of equity held | |
|--|-----------------------------|----------|---|------|
| | 2025 | 2024 | 2025 | 2024 |
| | US\$'000 | US\$'000 | % | % |
| Pasture Pharma Pte Ltd ^(a) Singapore Wholesale of medicinal and pharmaceutical products (western) and wholesale of medical, professional, scientific and precision equipment | 137 | 137 | 100 | 100 |
| Pasture PharmaHub Pte. Ltd. ^(a) Singapore Wholesale of medicinal and pharmaceutical products (western) and wholesale of medical, professional, scientific and precision equipment | (*) | (*) | 100 | 100 |
| Pacific Biosciences Pte Ltd ^{(a), (b)} Singapore Wholesale of medicinal and pharmaceutical products (western) and veterinary activities | (*) | (*) | 100 | 100 |
| | 137 | 137 | | |

(a) Audited by RSM SG Assurance LLP.

(b) The company has provided an undertaking to provide financial support to this entity.

(*) Amount less than US\$1,000.

15. Inventories

| | Group | |
|---|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Finished goods and goods for resale | 2,362 | 3,870 |
| Inventories are stated after allowance. | | |
| Movements in allowance: | | |
| At beginning of the year | - | 7 |
| Reversed to profit or loss and included in other income and gains (Note 6) | - | (7) |
| At end of the year | - | - |
| Write-off of inventories charged to profit or loss and included in other losses (Note 6) | (4) | (24) |
| The amount of inventories included in cost of sales | 7,899 | 9,807 |

There are no inventories pledged as securities for liabilities.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

16. Other non-financial assets

| | Group | | Company | |
|-----------------------------|------------------|------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 | 2025 US\$'000 | 2024 US\$'000 |
| Advance to suppliers | 52 | 524 | - | - |
| Deposits to secure services | 99 | 114 | 90 | 90 |
| Prepayments | 22 | 47 | 10 | 19 |
| Others | 13 | - | - | - |
| | 186 | 685 | 100 | 109 |

17. Trade and other receivables

| | Group | | Company | |
|--|------------------|------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 | 2025 US\$'000 | 2024 US\$'000 |
| <u>Trade receivables:</u> | | | | |
| Outside parties | 238 | 340 | - | - |
| Less allowance for impairment | - | (149) | - | - |
| Goods and services tax receivable | 266 | 859 | - | - |
| Net trade receivables – subtotal | 504 | 1,050 | - | - |
| <u>Other receivables:</u> | | | | |
| Subsidiaries (Note 3) | - | - | 1,249 | 1,591 |
| Net other receivables – subtotal | - | - | 1,249 | 1,591 |
| Total trade and other receivables | 504 | 1,050 | 1,249 | 1,591 |
| <u>Movements in above allowance on trade receivables:</u> | | | | |
| At beginning of the year | 149 | 149 | - | - |
| Reversal of allowance of impairment for trade receivable included in other income and gains (Note 6) | (119) | - | - | - |
| Used | (30) | - | - | - |
| At end of the year | - | 149 | - | - |

There are no collaterals held as security and other credit enhancements for the trade receivables.

The ECL on the above trade receivables are based on the simplified approach to measuring ECL which uses a lifetime ECL allowance approach for all trade receivables recognised from initial recognition of these assets. These assets are grouped based on shared credit risk characteristics and the days past due for measuring the ECL including the impact of the current economic conditions. The allowance model is based on the historical observed default rates (over a period of certain months) over the expected life of the trade receivables and is adjusted for forward-looking estimates.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

17. Trade and other receivables (cont'd)

The aging of the trade receivables balances are as follows:

| | Group | | | |
|---|--------------|----------|----------------|----------|
| | Gross amount | | Loss allowance | |
| | 2025 | 2024 | 2025 | 2024 |
| | US\$'000 | US\$'000 | US\$'000 | US\$'000 |
| <u>Aging analysis of trade receivables:</u> | | | | |
| Current | 220 | 142 | - | - |
| 1 to 30 days past due | 18 | 49 | - | - |
| 31 to 60 days past due | - | - | - | - |
| 61 to 90 days past due | - | - | - | - |
| Over 90 days past due | - | 149 | - | (149) |
| Total | 238 | 340 | - | (149) |

The amounts are written off when there are indications that there is no reasonable expectation of recovery or the failure of a debtor to make contractual payments over an extended period.

As part of the process of setting customer credit limits, different credit terms are used. The average credit period generally granted to trade customers is about 23 days (2024: 18 days) as the group typically collects monies in advance. However, some customers take a longer period to settle the amounts. The customers' balances are subject to the ECL assessment under the financial reporting standard on financial instruments.

Concentration of trade receivable customers as at the end of reporting year:

| | Group | |
|-----------------|----------|----------|
| | 2025 | 2024 |
| | US\$'000 | US\$'000 |
| Top 1 customer | 174 | 125 |
| Top 2 customers | 209 | 173 |
| Top 3 customers | 223 | 182 |

Other receivables:

The other receivables shown above are subject to the ECL allowance assessment under the financial reporting standard on financial instruments. The other receivables can be graded for credit risk individually. At inception, they are recorded net of any expected 12 month expected credit losses. At the end of the reporting year, a loss allowance is recognised if there has been a material increase in credit risk since initial recognition. For any material increase or decrease in credit risk, an adjustment is made to the loss allowance. The credit risk grade assessed is based on predictive nature of the risk of loss (such as the use of internal and external ratings, management accounts and cash flow projections and available published information about debtors that is available without undue cost or effort) and applying experienced credit judgement.

Other receivables are normally with no fixed terms and therefore there is no fixed maturity date.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

18. Cash and cash equivalents

| | Group | | Company | |
|---|------------------|------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 | 2025 US\$'000 | 2024 US\$'000 |
| Not restricted in use | 4,808 | 4,588 | 2,128 | 1,347 |
| Cash pledged for bank facilities ^(a) | 154 | 148 | - | - |
| | <u>4,962</u> | <u>4,736</u> | <u>2,128</u> | <u>1,347</u> |

(a) This is for the placement of fixed deposit with the bank for the bank facilities.

The rate of interest for cash on interest earning balances is 4.19% (2024: NIL).

18A. Cash and cash equivalents in the statement of cash flows

| | Group | |
|---|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Amount as shown above | 4,962 | 4,736 |
| Cash pledged for bank facilities | (154) | (148) |
| Cash and cash equivalents for statement of cash flows purposes at end of the year | <u>4,808</u> | <u>4,588</u> |

18B. Non-cash transactions

| | Group | |
|---|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Acquisitions of certain right-of-use assets under lease contracts | - | 1,363 |

18C. Reconciliation of liabilities arising from financing activities

| | Group | |
|--|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| <u>Lease liabilities</u> | | |
| At beginning of the year | 1,393 | 149 |
| Cash flow changes: | | |
| Lease payments | (298) | (138) |
| | <u>1,095</u> | <u>11</u> |
| Non-cash changes: | | |
| Acquisition of right-of-use assets | - | 1,363 |
| Write-off of right-of-use assets (Note 12) | - | (24) |
| Interest expense (Note 9) | 52 | 45 |
| Unrealised exchange loss / (gain) | 52 | (2) |
| Net non-cash changes | <u>104</u> | <u>1,382</u> |
| At end of the year (Note 22) | <u>1,199</u> | <u>1,393</u> |

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

18. Cash and cash equivalents (cont'd)

18C. Reconciliation of liabilities arising from financing activities (cont'd)

| | Group | |
|--------------------------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| <u>Loans and borrowings</u> | | |
| At beginning of the year | 673 | - |
| Cash flow changes: | | |
| Increase in new loans and borrowings | - | 775 |
| Repayment of loans and borrowings | (195) | (136) |
| Net cash flow changes | 478 | 639 |
| Non-cash changes: | | |
| Interest expense (Note 9) | 39 | 40 |
| Unrealised exchange loss / (gain) | 24 | (6) |
| Net non-cash changes | 63 | 34 |
| At end of the year (Note 20) | 541 | 673 |

19. Share capital

| | Group and Company | |
|---|------------------------------------|------------------------------|
| | Number of shares issued '000 | Share capital US\$'000 |
| Ordinary shares: | | |
| Balance at 1 July 2023, 30 June 2024 and 30 June 2025 | 132,000 | 3,671 |

The ordinary shares of no par value are fully paid, carry one vote each and have no right to fixed income. The company is not subject to any externally imposed capital requirements.

Capital management

The objectives when managing capital are: to safeguard the reporting entity's ability to continue as a going concern, so that it can continue to provide returns for owners and benefits for other stakeholders, and to provide an adequate return to owners by pricing the sales commensurately with the level of risk. The management sets the amount of capital to meet its requirements and the risk taken. There were no changes in the approach to capital management during the year. The management manages the capital structure and makes adjustments to it where necessary or possible in the light of changes in conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the management may adjust the amount of dividends paid to owners, return capital to owners, issue new shares, or sell assets to reduce debt. Adjusted capital comprises all components of equity (that is, share capital and reserves) less other amounts recognised in the statement of equity relating to cash flow hedges, and some forms of subordinated debt, if any.

There are material borrowings, but these are secured by guarantees and specific assets as disclosed in Note 20. The debt-to-adjusted capital ratio may not provide a meaningful indicator of risk from borrowings.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

19. Share capital (cont'd)

Capital management (cont'd)

In order to maintain its listing on the Singapore Stock Exchange, it has to have share capital with a free float of at least 10% of the shares. The company met the capital requirement on its initial listing and the rules limiting treasury share purchases mean it will continue to satisfy that requirement, as it did throughout the reporting year.

Management receives a report from the share registrars frequently on substantial share interests showing the non-free float to ensure continuing compliance with the 10% limit throughout the reporting year.

20. Loans and borrowings

| | Group | |
|--|----------|----------|
| | 2025 | 2024 |
| | US\$'000 | US\$'000 |
| <u>Non-current:</u> | | |
| <u>Financial instruments with floating interest rates:</u> | | |
| Bank loan A (secured) | 321 | 345 |
| <u>Financial instruments with fixed interest rates:</u> | | |
| Bank loan B | 47 | 175 |
| Total non-current portion | 368 | 520 |
| <u>Current:</u> | | |
| <u>Financial instruments with floating interest rates:</u> | | |
| Bank loan A (secured) | 38 | 33 |
| <u>Financial instruments with fixed interest rates:</u> | | |
| Bank loan B | 135 | 120 |
| Total current portion | 173 | 153 |
| Total non-current and current | 541 | 673 |
| The non-current portion is repayable as follows: | | |
| Due within 2 to 5 years | 216 | 324 |
| After 5 years | 152 | 196 |
| Total non-current portion | 368 | 520 |

The range of floating interest rates paid was as follows:

| | Group | |
|--------------------------------------|---------------|---------------|
| | 2025 | 2024 |
| Bank loan A ^(a) (secured) | 3.75% - 5.48% | 5.48% - 5.60% |

(a) Calculated at 1.5% per annum over bank's cost of fund.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

20. Loans and borrowings (cont'd)

20A. Bank loan

Both bank loan agreements provide among other matters for the following:

- a) The group shall maintain an average credit balance of US\$1,000,000 with the bank.
- b) Restrictions on dividend payment.
- c) No direct or indirect change of control in the shareholding is allowed.

Bank loan A which is repayable over a period of 10 years from September 2023, is secured and covered by the following:

- a) Legal assignment of life policy in respect of a director for a day one cash surrender value of not less than S\$545,264 (approximately US\$408,153).
- b) Letter of charge and set off by a director in respect of fixed deposits of not less than S\$200,000 (approximately US\$154,406) to be placed with the bank (Note 18).
- c) A corporate guarantee by the company.

Bank loan B which is repayable over a period of 3 years from November 2023, is covered by a corporate guarantee by the company and bears a fixed interest rate of 7.5% per annum.

21. Other non-financial liabilities

| | Group | |
|--|----------|----------|
| | 2025 | 2024 |
| | US\$'000 | US\$'000 |
| Contract liabilities on advances received from customers | 2,693 | 5,265 |

The movements in contract liabilities are as follows:

| | Group | |
|---|----------|----------|
| | 2025 | 2024 |
| | US\$'000 | US\$'000 |
| At beginning of the year | 5,265 | 3,234 |
| Consideration received or receivable | 6,177 | 8,255 |
| Performance obligation satisfied - revenue recognised in the reporting year | (8,749) | (6,224) |
| At end of the year | 2,693 | 5,265 |

The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting year:

| | | |
|---|-------|-------|
| Expected to be recognised within 1 year | 2,693 | 5,265 |
|---|-------|-------|

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

21. Other non-financial liabilities (cont'd)

The contract liabilities primarily relate to the advance consideration received from customers for which no transfer of control occurs, and therefore no revenue is recognised. The entity recognises revenue for each respective performance obligation when control of the product or service transfers to the customer.

The decrease was due to receipt of less advances from customers as the demand for certain pharmaceutical products decreases.

22. Lease liabilities

| | Group | | Company | |
|--------------------------------|------------------|------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 | 2025 US\$'000 | 2024 US\$'000 |
| Lease liabilities, current | 248 | 249 | 248 | 197 |
| Lease liabilities, non-current | 951 | 1,144 | 951 | 1,144 |
| | <u>1,199</u> | <u>1,393</u> | <u>1,199</u> | <u>1,341</u> |

Lease for right-of-use assets – The group has leases relating to the office and warehouse premises and motor vehicle. The lease for motor vehicle has matured during the year. Other information about the leasing activities is summarised as follows – The leases prohibit the lessee from selling or pledging the underlying leased assets as security unless permitted by the owners. There are no variable payments linked to an index. The leases are for terms between 3 to 6.25 years. The office lease provides options to extend for a further term.

The lease liabilities above do not include the short-term leases of less than 12 months and leases of low-value underlying assets. Variable lease payments which do not depend on an index or a rate or based on a percentage of revenue are not included from the initial measurement of the lease liability and the right-of-use assets.

The incremental borrowing rates applied to lease liabilities recognised for office and warehouse premises are 4% per year (2024: 4%).

A summary of the maturity analysis of lease liabilities is disclosed in Note 24E. Total cash outflows from leases are shown in the statement of cash flows. The related right-of-use assets are disclosed in Note 12.

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

There were no future cash outflows to which the lessee is potentially exposed that are not reflected in the measurement of lease liabilities above.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

23. Trade and other payables

| | Group | | Company | |
|--------------------------------|------------------|------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 | 2025 US\$'000 | 2024 US\$'000 |
| <u>Trade payables:</u> | | | | |
| Outside parties | 179 | 288 | 17 | 28 |
| Goods and services tax payable | 38 | 89 | 17 | 89 |
| Trade payables – subtotal | 217 | 377 | 34 | 117 |
| <u>Other payables:</u> | | | | |
| Accrued liabilities | 277 | 332 | 170 | 221 |
| Subsidiaries (Note 3) | - | - | 585 | 399 |
| Other payables – subtotal | 277 | 332 | 755 | 620 |
| Total trade and other payables | 494 | 709 | 789 | 737 |

24. Financial instruments: information on financial risks and other explanatory information

24A. Categories of financial assets and financial liabilities

The following table categorises the carrying amount of financial assets and liabilities recorded at the end of the reporting year:

| | Group | | Company | |
|---|------------------|------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 | 2025 US\$'000 | 2024 US\$'000 |
| <u>Financial assets:</u> | | | | |
| Financial assets at amortised cost | 6,020 | 6,318 | 3,377 | 2,938 |
| <u>Financial liabilities:</u> | | | | |
| Financial liabilities at amortised cost | 2,234 | 2,775 | 1,988 | 2,078 |

Further quantitative disclosures are included throughout these financial statements.

24B. Financial risk management

The main purpose for holding or issuing financial instruments is to raise and manage the finances for the entity's operating, investing and financing activities. There are exposures to the financial risks on the financial instruments such as credit risk, liquidity risk and market risk comprising interest rate, currency risk and price risk exposures. Management has certain practices for the management of financial risks and closely monitors the short and long-term objectives and action to be taken in order to manage the financial risks.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

24. Financial instruments: information on financial risks and other explanatory information (cont'd)

24B. Financial risk management (cont'd)

The process includes the following:

1. Minimise interest rate, currency, credit and market risk for all kinds of transactions.
2. Maximise the use of "natural hedge": favouring as much as possible the natural off-setting of sales and costs and payables and receivables denominated in the same currency and therefore put in place hedging strategies only for the excess balance (if necessary). The same strategy is pursued with regard to interest rate risk.
3. All financial risk management activities are carried out and monitored by senior management staff.
4. All financial risk management activities are carried out following acceptable market practices.
5. Whether appropriate consideration is given to entering into derivatives or any other similar instruments for hedging purposes.

There have been no changes to the exposures to risk; the objectives, policies and processes for managing the risk and the methods used to measure the risk.

24C. Fair value of financial instruments

The analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 are disclosed in the relevant notes to the financial statements. These include the material financial instruments stated at amortised cost and at fair value in the statement of financial position. The carrying values of current financial instruments approximate their fair values due to the short-term maturity of these instruments. The disclosures of fair value are not made when the carrying amount of current financial instruments is a reasonable approximation of the fair value.

24D. Credit risk on financial assets

Financial assets subject to concentrations of credit risk and failures by counterparties to discharge their obligations in full or in a timely manner arise principally from cash balances with banks, receivables and other financial assets. The general approach in the financial reporting standard on financial instruments is applied to measure ECL allowance on financial assets measured at amortised cost. On initial recognition, a loss allowance is recorded equal to the 12 month ECL unless the assets are considered credit impaired. The ECL allowance for debt assets is recognised at an amount equal to the lifetime ECL if the credit risk on that financial instrument has increased significantly since initial recognition. However, for trade receivables that do not contain a material financing component or when the reporting entity applies the practical expedient of not adjusting the effect of a material financing component, the simplified approach in calculating ECL is applied. Under the simplified approach, the loss allowance is recognised at an amount equal to lifetime ECL at each reporting date using historical loss rates for the respective risk categories and incorporating forward-looking estimates. Lifetime ECL may be estimated individually or collectively. For the credit risk on the financial assets, an ongoing credit evaluation is performed on the financial condition of the debtors and any loss is recognised in profit or loss. Reviews and assessments of credit exposures in excess of designated limits are made. Renewals and reviews of credits limits are subject to the same review process.

Note 18 discloses the cash balances. There was no identified impairment loss.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

24. Financial instruments: information on financial risks and other explanatory information (cont'd)

24E. Liquidity risk – financial liabilities maturity analysis

Liquidity risk refers to the difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. It is expected that all the liabilities will be settled at their contractual maturity. The average credit period taken to settle trade payables is about 23 days (2024: 18 days). The classification of the financial assets is shown in the statement of financial position as they may be available to meet liquidity needs, and no further analysis is deemed necessary.

The following table analyses the non-derivative financial liabilities by remaining contractual maturity (contractual and undiscounted cash flows):

| <u>Group</u> | Less than 1 year US\$'000 | 2 – 5 years US\$'000 | Over 5 years US\$'000 | Total US\$'000 |
|---------------------------------------|--|---------------------------------|--------------------------------------|---------------------------|
| Non-derivative financial liabilities: | | | | |
| <u>2025:</u> | | | | |
| Gross loans and borrowings | 195 | 253 | 162 | 610 |
| Gross lease liabilities | 291 | 1,021 | - | 1,312 |
| Trade and other payables | 494 | - | - | 494 |
| At end of the year | 980 | 1,274 | 162 | 2,416 |
| Non-derivative financial liabilities: | | | | |
| <u>2024:</u> | | | | |
| Gross loans and borrowings | 191 | 394 | 219 | 804 |
| Gross lease liabilities | 303 | 1,112 | 140 | 1,555 |
| Trade and other payables | 709 | - | - | 709 |
| At end of the year | 1,203 | 1,506 | 359 | 3,068 |
| | | | | |
| <u>Company</u> | Less than 1 year US\$'000 | 2 – 5 years US\$'000 | Over 5 years US\$'000 | Total US\$'000 |
| Non-derivative financial liabilities: | | | | |
| <u>2025:</u> | | | | |
| Gross lease liabilities | 291 | 1,021 | - | 1,312 |
| Trade and other payables | 789 | - | - | 789 |
| At end of the year | 1,080 | 1,021 | - | 2,101 |
| Non-derivative financial liabilities: | | | | |
| <u>2024:</u> | | | | |
| Gross lease liabilities | 248 | 1,112 | 140 | 1,500 |
| Trade and other payables | 737 | - | - | 737 |
| At end of the year | 985 | 1,112 | 140 | 2,237 |

The undiscounted amounts on borrowings with fixed and floating interest rates are determined by reference to the conditions existing at the reporting date.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

24. Financial instruments: information on financial risks and other explanatory information (cont'd)

24E. Liquidity risk – financial liabilities maturity analysis (cont'd)

The above amounts disclosed in the maturity analysis are the contractual undiscounted cash flows and such undiscounted cash flows differ from the amount included in the statement of financial position. When the counterparty has a choice of when an amount is paid, the liability is included on the basis of the earliest date on which it can be required to pay.

Bank facilities:

| | Group | |
|------------------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Undrawn borrowing facilities | 1,200 | 2,675 |

The undrawn borrowing facilities are available for operating activities and to settle other commitments. Borrowing facilities are maintained to ensure funds are available for the operations. A schedule showing the maturity of financial liabilities and unused bank facilities is provided regularly to management to assist in monitoring the liquidity risk.

24F. Interest rate risk

Interest rate risk arises on interest-bearing financial instruments. The interest from financial assets is not material. The following table analyses the breakdown of the material financial instruments by type of interest rate:

| | Group | | Company | |
|---|------------------|------------------|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 | 2025 US\$'000 | 2024 US\$'000 |
| <u>Financial liabilities with interest:</u> | | | | |
| Fixed rates | 1,381 | 1,688 | 1,199 | 1,341 |
| Floating rates | 359 | 378 | - | - |
| | 1,740 | 2,066 | 1,199 | 1,341 |

For the floating rate debt instruments are with interest rates that are re-set at regular intervals, the material interest rates are disclosed in the respective notes.

Sensitivity analysis: The effect on pre-tax profit is not material.

24G. Foreign currency risks

Foreign exchange risk arises on financial instruments that are denominated in a foreign currency that is a currency other than the functional currency in which they are measured. Currency risk does not arise from financial instruments that are non-monetary items or from financial instruments denominated in the functional currency as defined in the financial reporting standard on financial instruments.

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

24. Financial instruments: information on financial risks and other explanatory information (cont'd)

24G. Foreign currency risks (cont'd)

Analysis of amounts denominated in non-functional currency:

Singapore Dollar

2025:

Financial assets:

| | Group US\$'000 | Company US\$'000 |
|-----------------------------|-------------------|---------------------|
| Cash and cash equivalents | 318 | 17 |
| Trade and other receivables | 278 | - |
| Total financial assets | <u>596</u> | <u>17</u> |

Financial liabilities:

| | | |
|--|----------------|----------------|
| Trade and other payables | (394) | (204) |
| Loans and borrowings | (541) | - |
| Lease liabilities | (1,199) | (1,199) |
| Total financial liabilities | <u>(2,134)</u> | <u>(1,403)</u> |
| Net financial liabilities at end of the year | <u>(1,538)</u> | <u>(1,386)</u> |

2024:

Financial assets:

| | | |
|-----------------------------|--------------|------------|
| Cash and cash equivalents | 1,156 | 792 |
| Trade and other receivables | 867 | - |
| Total financial assets | <u>2,023</u> | <u>792</u> |

Financial liabilities:

| | | |
|--|----------------|----------------|
| Trade and other payables | (519) | (337) |
| Loans and borrowings | (673) | - |
| Lease liabilities | (1,393) | (1,342) |
| Total financial liabilities | <u>(2,585)</u> | <u>(1,679)</u> |
| Net financial liabilities at end of the year | <u>(562)</u> | <u>(887)</u> |

Sensitivity analysis: The effect on pre-tax profit is not material.

25. Items in profit or loss

In addition to the profit and loss line items disclosed elsewhere in the notes to the financial statements, this item includes the following expenses:

| | Group | |
|--|------------------|------------------|
| | 2025 US\$'000 | 2024 US\$'000 |
| Audit fees to the independent auditor of the company | 68 | 75 |
| Non-ARS fees to the independent auditor of the company | <u>20</u> | <u>10</u> |

NOTES TO THE FINANCIAL STATEMENTS

30 June 2025

26. Events after the end of the reporting year

On 16 July 2025, the group entered into a shareholders' agreement cum share subscription agreement to subscribe for a strategic stake in AP Bioresources Sdn Bhd for a total consideration of RM 175,000 (approximately US\$ 40,000). The investment would be funded by the proceeds from the company's Initial Public Offering. The acquisition of the Strategic Stake in APB was completed on 30 September 2025. Management is of the view that the investment is not expected to have a material impact on the group's financial position or performance for the financial year ending 30 June 2026.

The United States of America ("United States") announced on 2 April 2025 that it will impose tariffs on countries with which the United States conducts international trade. These are proposed to be differentiated based on specific goods and dependent on which country the goods originate from. This has created uncertainty in the global economy and could potentially result in an economic downturn. Management has assessed that such tariffs would have a limited initial impact on the group's revenue, given the subsidiaries' base charters are in place until end 2026. However, a prolonged global economic downturn could have longer-term negative consequences in terms of earnings and asset values.

27. Changes and adoption of financial reporting standards

For the current reporting year, the ASC issued certain new or revised financial reporting standards. None had material impact on the reporting entity.

28. New or amended standards in issue but not yet effective

The ASC issued certain new or revised financial reporting standards for the future reporting years. The transfer to the applicable new or revised standards from the effective dates is not expected to result in material modification of the measurement methods or the presentation in the financial statements for the following reporting year from the known or reasonably estimable information relevant to assessing the possible impact that application of the new or revised standards may have on the entity's financial statements in the period of initial application.

Those applicable to the reporting entity for future reporting years are listed below.

| SFRS (I) No. | Title | Effective date for periods beginning on or after |
|-----------------|--|--|
| SFRS(I) 1-21 | The Effects of Changes in Foreign Exchange Rates (amendment) Lack of Exchangeability | 1 January 2025 |
| SFRS(I) 9 and 7 | Classification and Measurement of Financial Instruments – Amendments | 1 January 2026 |
| SFRS(I) 18 | Presentation and disclosures in financial statements | 1 January 2027 |
| SFRS(I) 19 | Subsidiaries without Public Accountability: Disclosures | 1 January 2027 |

STATISTICS OF SHAREHOLDINGS

As at 12 September 2025

| | | |
|-------------------------------|---|--------------------|
| Number of issued shares | : | 132,000,000 |
| Class of shares | : | Ordinary Shares |
| Number of treasury shares | : | Nil |
| Number of subsidiary holdings | : | Nil |
| Voting rights | : | One vote per share |

DISTRIBUTION OF SHAREHOLDERS BY SIZE OF SHAREHOLDINGS

| SIZE OF SHAREHOLDINGS | NO. OF SHAREHOLDERS | % | NO. OF SHARES | % |
|-----------------------|---------------------|---------------|--------------------|---------------|
| 1 - 99 | - | 0.00 | - | 0.00 |
| 100 - 1,000 | 11 | 15.49 | 5,100 | 0.01 |
| 1,001 - 10,000 | 18 | 25.35 | 110,400 | 0.08 |
| 10,001 - 1,000,000 | 35 | 49.30 | 3,958,900 | 3.00 |
| 1,000,001 AND ABOVE | 7 | 9.86 | 127,925,600 | 96.91 |
| TOTAL | 71 | 100.00 | 132,000,000 | 100.00 |

TWENTY-TWO LARGEST SHAREHOLDERS

| | NAME OF SHAREHOLDER | NO. OF SHARES | % OF SHARES |
|----|--|--------------------|--------------|
| 1 | PMI HOLDINGS PTE. LTD. | 73,920,000 | 56.00 |
| 2 | PLUTUS STAR HOLDING PTE. LTD. | 38,080,000 | 28.85 |
| 3 | MAYBANK SECURITIES PTE. LTD. | 5,205,700 | 3.94 |
| 4 | CHNG NAI WEE | 4,000,000 | 3.03 |
| 5 | TAY ENG HSEON | 3,760,000 | 2.85 |
| 6 | UOB KAY HIAN PTE LTD | 1,759,900 | 1.33 |
| 7 | ANG MENG HAI MARKUS DAVID | 1,200,000 | 0.91 |
| 8 | WONG HENG YIEW | 400,000 | 0.30 |
| 9 | MOOMOO FINANCIAL SINGAPORE PTE. LTD. | 362,900 | 0.27 |
| 10 | ABN AMRO CLEARING BANK N.V. | 283,800 | 0.22 |
| 11 | LONG JEE JONG | 205,800 | 0.16 |
| 12 | CGS INTERNATIONAL SECURITIES (SINGAPORE) PTE LTD | 183,000 | 0.14 |
| 13 | BERNARDO WANGSA | 160,000 | 0.12 |
| 14 | CAROLINA ROSALINDA LAU | 160,000 | 0.12 |
| 15 | CHRISTIE KERK LAY TIN | 160,000 | 0.12 |
| 16 | HENG TUNG LAN | 160,000 | 0.12 |
| 17 | HO PEI JIA ANNA | 160,000 | 0.12 |
| 18 | KOH KEE LIAN LILIAN | 160,000 | 0.12 |
| 19 | LEE KIAM LENG DESMOND (LI JIANLONG DESMOND) | 160,000 | 0.12 |
| 20 | LUCA SELDON@LUCA MORETTI SELDON | 160,000 | 0.12 |
| 21 | TAN SOCK HUA (CHEN SHU HUA) | 160,000 | 0.12 |
| 22 | YAP BOH WEI | 160,000 | 0.12 |
| | TOTAL: | 130,961,100 | 99.20 |

STATISTICS OF SHAREHOLDINGS

As at 12 September 2025

LIST OF SUBSTANTIAL SHAREHOLDERS

| Name of Substantial Shareholders | Direct Interest | % | Deemed Interest | % |
|--|-----------------|-------|-----------------|-------|
| Plutus Star Holding Pte. Ltd. | 38,080,000 | 28.85 | 0 | 0.00 |
| PMI Holdings Pte. Ltd. | 73,920,000 | 56.00 | 0 | 0.00 |
| Srinivasa Gopal Palepu ⁽¹⁾ | 0 | 0.00 | 38,080,000 | 28.85 |
| Pranay Palepu ⁽²⁾ | 0 | 0.00 | 38,080,000 | 28.85 |
| Prashanth Palepu ⁽³⁾ | 0 | 0.00 | 38,080,000 | 28.85 |
| Soong Chin Kum Jonathan Lloyd ⁽⁴⁾ | 0 | 0.00 | 73,920,000 | 56.00 |

Footnote:

- (1) Mr. Srinivasa Gopal Palepu holds 50.0% of the issued and paid-up share capital of Plutus Star Holding Pte. Ltd.. Accordingly, Mr. Srinivasa Gopal Palepu is deemed to have an interest in the 38,080,000 shares held by Plutus Star Holding Pte. Ltd. by virtue of Section 4 of the Securities and Futures Act 2001 ("SFA") and Section 7 of the Companies Act 1967 ("CA").
- (2) Mr. Pranay Palepu holds 25.0% of the issued and paid-up share capital of Plutus Star Holding Pte. Ltd.. Accordingly, Mr. Pranay Palepu is deemed to have an interest in the 38,080,000 shares held by Plutus Star Holding Pte. Ltd. by virtue of Section 4 of the SFA and Section 7 of the CA.
- (3) Mr. Prashanth Palepu holds 25.0% of the issued and paid-up share capital of Plutus Star Holding Pte. Ltd.. Accordingly, Mr. Prashanth Palepu is deemed to have an interest in the 38,080,000 shares held by Plutus Star Holding Pte. Ltd. by virtue of Section 4 of the SFA and Section 7 of the CA.
- (4) Mr. Soong Chin Kum Jonathan Lloyd holds the entire issued and paid-up share capital of PMI Holdings Pte. Ltd.. Accordingly, Mr. Soong Chin Kum Jonathan Lloyd is deemed to have an interest in the 73,920,000 shares held by PMI Holdings Pte. Ltd. by virtue of Section 4 of the SFA and Section 7 of the CA.

SHAREHOLDINGS HELD IN THE HANDS OF PUBLIC

Based on the information provided and to the best knowledge of the Directors, approximately 15.15% of the issued ordinary shares of the Company are held in the hands of the public as at 12 September 2025. Therefore, Rule 723 of the SGX-ST Listing Manual Section B: Rules of Catalyst is complied with.

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the Annual General Meeting of the Company will be held at Huone Singapore, 3D River Valley Road, #03-01, Singapore 179023 on Thursday, 23 October 2025 at 10.30 a.m. to transact the following business: -

AS ORDINARY BUSINESS

1. To receive and adopt the Audited Financial Statements of the Company for the financial year ended 30 June 2025 together with the Directors' Statement and Independent Auditors' Report thereon. **(Resolution 1)**
2. To declare a tax exempt (one-tier) final dividend of S\$0.0023 per ordinary share in respect of the financial year ended 30 June 2025. **(Resolution 2)**
3. To approve the payment of Directors' fees of S\$149,500.00 for the financial year ending 30 June 2026, to be paid half-yearly in arrears. **(Resolution 3)**
4. To re-elect Ms Teo Kwee Yee who is retiring pursuant to Regulation 111 of the Company's Constitution. **(Resolution 4)**

Ms Teo Kwee Yee, will upon re-election as a Director of the Company, continue to serve as the Non-Executive and Independent Director, the Chairman of the Nominating Committee and a member of the Audit Committee. Ms Teo Kwee Yee shall be considered independent for the purposes of Rule 704(7) of the Catalist Rules.

[See Explanatory Note (i)]

5. To re-elect Ms Low Su-Shing who is retiring pursuant to Regulation 111 of the Company's Constitution. **(Resolution 5)**

Ms Low Su-Shing, will upon re-election as a Director of the Company, continue to serve as the Non-Executive and Independent Director, the Chairman of the Remuneration Committee and a member of the Audit Committee. Ms Low Su-Shing shall be considered independent for the purposes of Rule 704(7) of the Catalist Rules.

[See Explanatory Note (i)]

6. To re-appoint Messrs RSM SG Assurance LLP as auditors of the Company and to authorise the Directors to fix their remuneration. **(Resolution 6)**
7. To transact any other ordinary business which may be properly transacted at an Annual General Meeting.

NOTICE OF ANNUAL GENERAL MEETING

AS SPECIAL BUSINESS

To consider and, if thought fit, to pass the following Ordinary Resolutions with or without any modifications:-

8. Authority to allot and issue shares and convertible securities (Resolution 7)

- (a) That pursuant to Section 161 of the Companies Act 1967, and Rule 806 of the Catalist Rules, authority be and is hereby given to the Directors of the Company at any time to such persons and upon such terms and for such purposes as the Directors may in their absolute discretion deem fit, to:
- (i) issue and allot shares in the capital of the Company ("**Shares**") whether by way of rights, bonus or otherwise;
 - (ii) make or grant offers, agreements or options (collectively, "**Instruments**") that might or would require Shares to be issued or other transferable rights to subscribe for or purchase Shares including but not limited to the creation and issue of warrants, debentures or other instruments convertible into Shares;
 - (iii) issue additional Instruments arising from adjustments made to the number of Instruments previously issued in the event of rights, bonus or capitalisation issues; and
- (b) (notwithstanding the authority conferred by the shareholders may have ceased to be in force) issue Shares in pursuance of any Instrument made or granted by the Directors while the authority was in force,

provided always that

- (i) the aggregate number of Shares to be issued pursuant to this resolution (including Shares to be issued in pursuance of Instruments made or granted pursuant to this resolution) does not exceed 100% of the total number of issued Shares excluding treasury shares and subsidiary holdings of the Company, of which the aggregate number of Shares (including Shares to be issued in pursuance of Instruments made or granted pursuant to this resolution) to be issued other than on a pro rata basis to shareholders of the Company does not exceed 50% of the total number of issued Shares excluding treasury shares of the Company.

For the purpose of this resolution, the total number of issued Shares excluding treasury shares and subsidiary holdings is based on the Company's total number of issued shares excluding treasury shares and subsidiary holdings at the time this resolution is passed, after adjusting for;

- (a) new Shares arising from the conversion or exercise of convertible securities, or
- (b) new Shares arising from exercising share options or vesting of share awards outstanding or subsisting at the time this resolution is passed provided the options or awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules, and

NOTICE OF ANNUAL GENERAL MEETING

- (c) any subsequent bonus issue, consolidation or subdivision of the Shares, and

any adjustments in accordance with (a) and (b) are only to be made in respect of new Shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this resolution;

- (ii) in exercising the authority conferred by this resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance is waived by the SGX-ST) and the Constitution of the Company; and
- (iii) such authority shall, unless revoked or varied by the Company at a general meeting, continue in force until the conclusion of the next Annual General Meeting or the date by which the next Annual General Meeting of the Company is required by law to be held, whichever is the earlier.

[See Explanatory Note (ii)]

9. Authority to issue shares under Pasture Performance Share Plan (Resolution 8)

That the Directors of the Company be authorised and empowered to offer and grant awards under the Pasture Performance Share Plan (the “Plan”) and to issue from time to time such number of shares in the capital of the Company as may be required to be issued pursuant to the vesting of awards under the Plan, whether granted during the subsistence of this authority or otherwise, provided always that the aggregate number of additional ordinary shares to be issued pursuant to the Plan and such other share-based incentive schemes shall not exceed 15% of the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company from time to time and that such authority shall, unless revoked or varied by the Company in a general meeting, continue in force until the conclusion of the next Annual General Meeting of the Company or the date by which the next Annual General Meeting of the Company is required by law to be held, whichever is earlier.

[See Explanatory Note (iii)]

10. Renewal of the Shareholders’ General Mandate for Interested Person Transactions (Resolution 9)

That for the purposes of Chapter 9 of the Catalist Rules:

- (a) approval be given for the renewal of the mandate for the Company, its subsidiaries and associated companies that are considered to be “entities at risk” within the meaning of Chapter 9 of the Catalist Rules, or any of them to enter into any of the transactions falling within the categories of Mandated Transactions described in the Appendix to the Annual Report dated 8 October 2025 (the “Appendix”) with any Mandated Interested Person described in the Appendix, provided that such transactions are carried out on normal commercial terms and in accordance with the review procedures of the Company for such interested person transactions as set out in the Appendix (the “IPT General Mandate”);

NOTICE OF ANNUAL GENERAL MEETING

- (b) the IPT General Mandate shall, unless revoked or varied by the Company in a general meeting, continue in force until the conclusion of the next annual general meeting of the Company (unless revoked or varied by the Company in general meeting) or the date by which the next annual general meeting is required by law to be held, whichever is the earlier; and
- (c) the Directors of the Company and/or any of them be and are hereby authorised to do all such acts and things (including, without limitation, executing all such documents as may be required) as they or he/she may consider necessary, desirable or expedient or in the interests of the Company to give effect to the IPT General Mandate and/or this resolution.

[See Explanatory Note (iv)]

BY ORDER OF THE BOARD

Peck Jen Jen
Company Secretary
8 October 2025

Explanatory Note:-

- (i) Detailed information on Ms Teo Kwee Yee and Ms Low Su-Shing who are proposed to be re-elected as Directors of the Company can be found under sections “Board of Directors” and “Additional Information on Directors seeking re-election” in the Company’s Annual Report for the financial year ended 30 June 2025.
- (ii) The ordinary resolution 7 proposed in item 8 above, if passed, will empower the Directors of the Company from the date of this Meeting until the next Annual General Meeting to issue shares and convertible securities in the Company up to an amount not exceeding in aggregate 100% of the issued share capital of the Company of which the total number of shares and convertible securities issued other than on a pro-rata basis to existing shareholders shall not exceed 50% of the issued share capital of the Company, excluding treasury shares and subsidiary holdings, at the time the resolution is passed, for such purposes as they consider would be in the interests of the Company. This authority will, unless revoked or varied at a general meeting, expire at the next Annual General Meeting of the Company.
- (iii) The Ordinary Resolution 8 proposed in item 9 above, if passed, will empower the Directors of the Company, from the date of this Annual General Meeting until the next Annual General Meeting of the Company, or the date by which the next Annual General Meeting of the Company is required by law to be held or such authority is varied or revoked by the Company in a general meeting, whichever is the earlier, to issue shares in the Company pursuant to the exercise of options granted or to be granted under the Plan and such other share-based incentive scheme up to a number not exceeding in total (for the entire duration of the Plan) 15% of the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company from time to time.
- (iv) The Ordinary Resolution 9 proposed in item 10 above, if passed, will renew the IPT General Mandate for the Company, its subsidiaries and associated companies that are considered to be “entities at risk” within the meaning of Chapter 9 of the Catalist Rules, or any of them to enter into certain types of transactions with specified classes of the Interested Persons set out in the Appendix. This authority will, unless revoked or varied by the Company in a general meeting, continue to be in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting is required by law to be held, whichever is the earlier. More details to the renewal of the IPT General Mandate can be found in the Appendix.

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. The AGM is being convened and will be held physically at Huone Singapore, 3D River Valley Road, #03-01, Singapore 179023. **There will be no option for members to participate virtually.**
2. Printed copies of the Annual Report which include its Appendix to members, Notice of AGM, Proxy Form and Request Form are available to members via publication on the Company's website at <https://pasturegroup.com/investors/> and the SGX website at <https://www.sgx.com/securities/company-announcements>.

Printed copies of the Annual Report will not be sent to members. For members who prefer to receive a printed copy of the Annual Report, please refer to the Request Form on how to make a request.

3. Members (including CPFIS and SRS investors) may participate in the AGM by:
 - (a) attending the AGM in person;
 - (b) submitting questions to the Chairman of the Meeting in advance of, or at, the AGM; and/or
 - (c) voting at the AGM
 - (i) themselves personally; or
 - (ii) through their duly appointed proxy(ies).

CPFIS and SRS investors who wish to appoint the Chairman of the Meeting (and not third party prox(ies)) as proxy to approach their respective CPF Agent Banks or SRS Operators to submit their votes. Please see item 7 below for details.

4.
 - (a) A member who is not a relevant intermediary is entitled to appoint not more than two (2) proxies to attend, speak and vote in his/her stead at the AGM.
 - (b) A member who is a relevant intermediary is entitled to appoint more than two (2) proxies to attend, speak and vote at the AGM, but each proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where such member appoints more than two (2) proxies, the number and class of shares held by such member in relation to which each proxy has been appointed shall be specified in the proxy form.

"**Relevant intermediary**" has the meaning ascribed to it in Section 181(6) of the Companies Act 1967.

5. A proxy need not be a member of the Company.
6. A member can appoint the Chairman of the Meeting as his/her/its proxy **but** this is **not mandatory**.

If a member wishes to appoint the Chairman of the Meeting as proxy, such member (whether individual or corporate) must give specific instructions as to voting for, voting against, or abstentions from voting on, each resolution in the instrument appointing the Chairman of the Meeting as proxy. If no specific direction as to voting is given or in the event of any other matter arising at the Meeting and at any adjournment thereof, the Chairman of the Meeting will vote at his discretion.

7. CPFIS/SRS investors who hold shares through CPF Agent Banks/SRS Operators:
 - (a) may vote at the Meeting if they are appointed as proxies by their respective CPF Agent Banks/SRS Operators, and should contact their respective CPF Agent Banks/SRS Operators if they have any queries regarding their appointment as proxies; or
 - (b) may appoint the Chairman of the Meeting as proxy to vote on their behalf at the Meeting, in which case they should approach their CPF Agent Banks/SRS Operators to submit their votes at least (7) working days prior to the date of AGM i.e. **by 10.30 a.m. on 10 October 2025**.
8. Submission of instrument of proxy or proxies ("**Proxy Form**") – **By 10.30 a.m. on 20 October 2025**

The Proxy Form must be submitted through any one of the following means:

- (a) if submitted by post, be lodged with the Company's Share Registrar, Tricor Barbinder Share Registration Services at 9 Raffles Place #26-01 Republic Plaza, Singapore 048619; or
- (b) if submitted electronically, be submitted via contact@pasturegroup.com.

in either case, **by 10.30 a.m. on 20 October 2025**, being not less than seventy-two (72) hours before the time appointed for holding the Meeting (or any adjournment thereof) and in default the instrument of proxy shall not be treated as valid.

NOTICE OF ANNUAL GENERAL MEETING

9. The Company shall be entitled to, and will, treat any valid Proxy Form which was delivered by a member to the Company **before 10.30 a.m. on 20 October 2025** as a valid instrument as the member's proxy to attend, speak and vote at the Meeting if: (a) the member had indicated how he/she/it wished to vote for or vote against or abstain from voting on each resolution; and (b) the member has not withdrawn the appointment by 10.30 a.m. on 20 October 2025.
10. If the member is a corporation, the instrument appointing the proxy must be under seal or the hand of an officer or attorney duly authorised.
11. Completion and return of the Proxy Form by a member will not prevent him/her from attending, speaking and voting at the Meeting if he/she so wishes. The appointment of the proxy(ies) for the Meeting will be deemed to be revoked if the member attends the Meeting in person and in such event, the Company reserves the right to refuse to admit any person or persons appointed under the relevant instrument appointing a proxy(ies) to the Meeting.
12. Submission of questions by members in advance of the Meeting – **By 15 October 2025**
 - (a) Members may also submit questions related to the resolutions to be tabled for approval at the Meeting. All questions, together with the members' full names, identification numbers, contact numbers and email addresses and manner in which they hold shares in the Company ("**Shares**"), must be submitted no later than **15 October 2025** via contact@pasturegroup.com or by post to the registered office of the Company at 2 Corporation Road, #03-04/05 Corporation Place, Singapore 618494.
 - (b) The Company will publish the responses to substantial and relevant questions on the SGX website at <https://www.sgx.com/securities/company-announcements> and the Company's website <https://pasturegroup.com/investors/> not later than **10.30 a.m. on 17 October 2025**, being 48 hours before the closing date and time for the lodgement of proxy forms.
 - (c) The Company endeavours to address (i) subsequent clarifications sought (ii) follow-up questions or (iii) subsequent substantial and relevant questions which are received after its Responses to Q&A at the Meeting itself. Where substantially similar questions are received, we will consolidate such questions and consequently not all questions may be individually addressed.
 - (d) Minutes of AGM - The Company will, within one month after the date of the AGM, publish the minutes of the AGM on SGXNET, and the minutes will include the responses to the questions which are addressed during the AGM, if any.
13. Members are reminded to check the Company's website at <https://pasturegroup.com/investors/> and on the SGX website at <https://www.sgx.com/securities/company-announcements> for the latest updates on the status of the AGM.

Personal data privacy:

By submitting an instrument appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the AGM and/or any adjournment thereof, a member of the Company (i) consents to the collection, use and disclosure of the member's personal data by the Company (or its agents or service providers) for the purpose of the processing, administration and analysis by the Company (or its agents or service providers) of proxies and representatives appointed for the AGM (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the AGM (including any adjournment thereof), and in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, take-over rules, regulations and/or guidelines (collectively, the "**Purposes**"); (ii) warrants that where the member discloses the personal data of the member's proxy(ies) and/or representative(s) to the Company (or its agents or service providers), the member has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/or representative(s) for the Purposes, and (iii) agrees that the member will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the member's breach of warranty.

DISCLOSURE OF INFORMATION ON DIRECTORS SEEKING RE-ELECTION

Ms Teo Kwee Yee and Ms Low Su Shing are the Directors seeking re-election at the forthcoming Annual General Meeting of the Company to be convened on 23 October 2025 (“AGM”) (collectively, the “Retiring Directors” and each a “Retiring Director”).

Pursuant to Rule 720(5) of the Catalist Rules of the SGX-ST, the following is the information relating to the Retiring Director as set out in Appendix 7F of the Catalist Rules:

| | Teo Kwee Yee | Low Su-Shing |
|---|--|--|
| Date of Appointment | 29 March 2023 | 29 March 2023 |
| Date of last re-appointment | N/A | N/A |
| Age | 59 | 50 |
| Country of principal residence | Singapore | Singapore |
| The Board’s comments on this appointment (including rationale, selection criteria, and the search and nomination process) | <p>The Board of Directors of the Company has considered, among others, the recommendation of the Nominating Committee (“NC”) and has reviewed and considered the contribution and performance, attendance, preparedness, participation, candour and suitability of Ms Teo Kwee Yee for re-appointment as Non-Executive and Independent Director of the Company.</p> <p>The Board has reviewed and concluded that Ms Teo Kwee Yee possesses the experience, expertise, knowledge and skills to contribute towards the core competencies of the Board.</p> | <p>The Board of Directors of the Company has considered, among others, the recommendation of the Nominating Committee (“NC”) and has reviewed and considered the contribution and performance, attendance, preparedness, participation, candour and suitability of Ms Low Su-Shing for re-appointment as Non-Executive and Independent Director of the Company.</p> <p>The Board has reviewed and concluded that Ms Low Su-Shing possesses the experience, expertise, knowledge and skills to contribute towards the core competencies of the Board.</p> |
| Whether appointment is executive, and if so, the area of responsibility | Non-Executive | Non-Executive |
| Job Title (e.g. Lead ID, AC Chairman, AC Member etc.) | Non-Executive and Independent Director, Chairman of Nominating Committee and a member of the Audit Committee. | Non-Executive and Independent Director, Chairman of Remuneration Committee and a member of the Audit Committee. |
| Professional qualifications | Ms Teo completed her Bachelor of Laws (Hons) at the University of Manchester. She is dually qualified as a barrister and a solicitor of England and Wales and is admitted to the Rolls of Solicitors of Hong Kong and the Singapore Bar. | Ms Low obtained a Bachelor of Science (Hons) in Biochemistry, Molecular Biology & Biotechnology from the University of Bristol. |

DISCLOSURE OF INFORMATION ON DIRECTORS SEEKING RE-ELECTION

| | Teo Kwee Yee | Low Su-Shing |
|--|---|--|
| Working experience and occupation(s) during the past 10 years | <p>Ms Teo is currently the head of the corporate and financial services practice group in Harry Elias Partnership LLP. She has over 20 years of experience in advising on landmark transactions in corporate finance, including initial public offerings on the SGX-ST, placements and rights issues, privatisations, compliance and corporate governance issues.</p> <p>Between June 2015 to October 2021, Ms Teo served as an independent non-executive director of iX Biopharma Ltd. (a company listed on the SGX-ST), where she served as the chairperson of the nominating committee and the risk management committee and was also a member of the audit committee and remuneration committee.</p> <p>Ms Teo is also a non-executive director and a member of the investment committee and the governance and risk committee of Ren Ci Hospital, a Singapore charity healthcare institution. She is also a member of the investment committee of Singapore Hokkien Huay Kuan and an independent director of The Hokkien Foundation.</p> | <p>Ms. Low currently serves as a non-executive director of KRZ Limited, a company in Hong Kong which provides consulting and investment services.</p> <p>Prior to the foregoing, Ms. Low was the founder and managing director of StemLife Berhad from December 2002 to August 2012, a cord blood and peripheral stem cell collection, testing, processing and storage facility, where she was responsible for the overall growth and development of the company and its business.</p> |
| Shareholding interest in the listed issuer and its subsidiaries | No | No |
| Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries | No | No |
| Conflict of Interest (including any competing business) | No | No |
| Undertaking (in the format set out in Appendix 7H) under Rule 720(1) has been submitted to the listed issuer | Yes | Yes |

DISCLOSURE OF INFORMATION ON DIRECTORS SEEKING RE-ELECTION

| | Teo Kwee Yee | Low Su-Shing |
|--|---|--------------|
| Other Principal Commitments Including Directorships | | |
| Past (for the last 5 years) | iX Biopharma Ltd. T5@Singapore Pte. Ltd. | N/A |
| Present | Harry Elias Partnership LLP The Hokkien Foundation Ren Ci Hospital Singapore Hokkien Huay Kuan | KRZ Limited |
| Disclose the following matters concerning an appointment of director, chief executive officer, chief financial officer, chief operating officer, general manager or other officer of equivalent rank. If the answer to any question is "yes", full details must be given. | | |
| a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner? | No | No |
| b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency? | No | No |
| c) Whether there is any unsatisfied judgment against him? | No | No |

DISCLOSURE OF INFORMATION ON DIRECTORS SEEKING RE-ELECTION

| | Teo Kwee Yee | Low Su-Shing |
|---|--------------|--------------|
| d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose? | No | No |
| e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach? | No | No |
| f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part? | No | No |
| g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust? | No | No |

DISCLOSURE OF INFORMATION ON DIRECTORS SEEKING RE-ELECTION

| | Teo Kwee Yee | Low Su-Shing |
|---|--------------|--------------|
| h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust? | <i>No</i> | <i>No</i> |
| i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity? | <i>No</i> | <i>No</i> |
| j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of: - | | |
| i. any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or | <i>No</i> | <i>No</i> |
| ii. any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or | <i>No</i> | <i>No</i> |
| iii. any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or | <i>No</i> | <i>No</i> |

DISCLOSURE OF INFORMATION ON DIRECTORS SEEKING RE-ELECTION

| | Teo Kwee Yee | Low Su-Shing |
|---|--|--|
| <p>iv. any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere</p> <p>in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?</p> | No | No |
| <p>k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?</p> | No | No |
| Disclosure applicable to the appointment of Director only | | |
| <p>Any prior experience as a director of a listed company?</p> <p>If yes, please provide details of prior experience.</p> <p>If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange.</p> <p>Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable).</p> | <p>Not applicable, as this relates to the re-election of a director.</p> | <p>Not applicable, as this relates to the re-election of a director.</p> |

APPENDIX

APPENDIX DATED 8 OCTOBER 2025

THIS APPENDIX IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. PLEASE READ IT CAREFULLY.

IF YOU ARE IN DOUBT AS TO ANY ACTION YOU SHOULD TAKE, YOU SHOULD CONSULT YOUR STOCKBROKER, BANK MANAGER, SOLICITOR, ACCOUNTANT, FINANCIAL, TAX OR OTHER PROFESSIONAL ADVISER IMMEDIATELY.

This Appendix is circulated to the Shareholders of Pasture Holdings Ltd. (the “**Company**”) together with the Company’s annual report for the financial year ended 30 June 2025 (“**Annual Report**”), and its purpose is to explain to the Shareholders the rationale and provide information to the Shareholders for the proposed renewal of the IPT General Mandate (as defined in this Appendix) to be tabled at the Annual General Meeting (“**AGM**”) of the Company to be held at Huone Singapore, 3D River Valley Road, #03-01, Singapore 179023 on 23 October 2025 at 10.30 a.m..

A printed copy of this Appendix and the Annual Report will NOT be despatched to Shareholders. Printed copies of the Notice of AGM and the accompanying Proxy Form and Request Form will be despatched to members via post. Members who wish to obtain a printed copy of the Annual Report and the Appendix should complete the Request Form and return it by post to the registered office address of the Company at 2 Corporation Road, #03-04/05 Corporation Place, Singapore 618494 no later than 15 October 2025.

If you have sold or transferred all your shares in the capital of the Company, you should immediately inform the purchaser or transferee or bank, stockbroker or agent through whom the sale or transfer was effected for onward notification to the purchaser or transferee, that this Appendix (together with the Annual Report, Notice of AGM and the accompanying Proxy Form and Request Form) may be accessed on SGXNET at <https://www.sgx.com/securities/company-announcements> and the Company’s website at <https://pasturegroup.com/>.

This Appendix has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”). This Appendix has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.



PASTURE HOLDINGS LTD.

(Company Registration Number 201731601W)
(Incorporated in the Republic of Singapore on 3 November 2017)

APPENDIX TO SHAREHOLDERS

IN RELATION TO

**THE PROPOSED RENEWAL OF THE SHAREHOLDERS’ GENERAL MANDATE FOR
INTERESTED PERSON TRANSACTIONS**

CONTENTS

| | Page |
|--|-------------|
| DEFINITIONS | 134 |
| LETTER TO SHAREHOLDERS | 137 |
| 1. INTRODUCTION | 137 |
| 2. THE PROPOSED RENEWAL OF THE SHAREHOLDERS' GENERAL MANDATE FOR INTERESTED PERSON TRANSACTIONS..... | 137 |
| 3. DIRECTORS' RECOMMENDATIONS..... | 150 |
| 4. ANNUAL GENERAL MEETING..... | 150 |
| 5. ABSTENTION FROM VOTING..... | 150 |
| 6. DIRECTORS' RESPONSIBILITY STATEMENT | 151 |
| 7. DOCUMENTS AVAILABLE FOR INSPECTION | 151 |

APPENDIX

DEFINITIONS

In this Appendix, the following definitions apply throughout unless otherwise stated.

| | | |
|--|---|--|
| “AGM” | : | The annual general meeting of the Company to be held at Huone Singapore, 3D River Valley Road, #03-01, Singapore 179023 on 23 October 2025 at 10.30 a.m., notice of which is attached to the Annual Report |
| “Annual Report” | : | The annual report of the Company for FY2025 dated 8 October 2025 |
| “Appendix” | : | This appendix to the Annual Report dated 8 October 2025 issued by the Company to the Shareholders in relation to the proposed renewal of the IPT General Mandate |
| “Audit Committee” | : | The audit committee of the Company as at the date of this Appendix, comprising Mr. Lim Jit Soon, Ms. Low Su-Shing and Ms. Teo Kwee Yee |
| “Board” or “Board of Directors” | : | The board of Directors of the Company as at the date of this Appendix |
| “Catalist” | : | The Catalist of the SGX-ST, being the sponsor-supervised listing platform of the SGX-ST |
| “Catalist Rules” | : | The SGX-ST Listing Manual Section B: Rules of Catalist, as amended, modified or supplemented from time to time |
| “CDP” | : | The Central Depository (Pte) Limited |
| “Chief Executive Officer” | : | The chief executive officer of the Company, Mr. Soong Chin Kum Jonathan Lloyd |
| “Chief Financial Officer” | : | The chief financial officer of the Company, Mr. Lee Quang Loong |
| “Company” | : | Pasture Holdings Ltd. |
| “Companies Act” | : | The Companies Act 1967 of Singapore, as amended, modified or supplemented from time to time |
| “Comparable Quotes” | : | Has the meaning ascribed to it in Section 2.5.6(a)(i) of this Appendix |
| “Comparable Sales” | : | Has the meaning ascribed to it in Section 2.5.6(b)(i) of this Appendix |
| “Constitution” | : | The constitution of the Company, as may be amended or modified from time to time |
| “Directors” | : | The directors of the Company for the time being |

APPENDIX

| | | |
|-------------------------------------|---|---|
| “EAR Group” | : | The Company, its subsidiaries and associated companies that are considered to be “entities at risk” within the meaning of Chapter 9 of the Catalist Rules |
| “FY” | : | The financial year ended or, as the case may be, ending 30 June |
| “FY2024 AGM” | : | The annual general meeting of the Company held on 29 October 2024 |
| “FY2024 Annual Report” | : | The annual report of the Company for FY2024 dated 14 October 2024 |
| “Group” | : | The Company and its subsidiaries |
| “IPT General Mandate” | : | The general mandate from the Shareholders pursuant to Chapter 9 of the Catalist Rules to enable any or all members of the EAR Group, in the ordinary course of their business, to enter into Mandated Transactions with the Mandated Interested Persons which are necessary for its day-to-day operations, provided that all such transactions are carried out on normal commercial terms and are not prejudicial to the interests of the Company and its minority Shareholders |
| “IPT Register” | : | Has the meaning ascribed to it in Section 2.5.7(b) of this Appendix |
| “Mandated Interested Person” | : | Pleasant Exports |
| “Mandated Transactions” | : | The categories of interested person transactions that fall within the scope of the IPT General Mandate and which are defined in Section 2.5.4 of this Appendix |
| “Non-Interested Directors” | : | The Directors who are considered to be independent for the purposes of the proposed renewal of the IPT General Mandate, being Mr. Soong Chin Kum Jonathan Lloyd, Ms. Claire Soong Jia Li, Mr. Lim Jit Soon, Ms. Teo Kwee Yee and Ms. Low Su-Shing |
| “NTA” | : | Net tangible assets |
| “Palepu Pharma” | : | Palepu Pharma Private Limited |
| “Proposed Resolution” | : | Has the meaning ascribed to it in Section 1.1 of this Appendix |
| “Register of Members” | : | The Register of Members of the Company |
| “Securities Account” | : | A securities account maintained by a Depositor with CDP, but not including a securities sub-account maintained with a Depository Agent |
| “SFA” | : | Securities and Futures Act 2001 of Singapore, as amended, modified or supplemented from time to time |
| “SGX-ST” | : | Singapore Exchange Securities Trading Limited |

APPENDIX

| | |
|--------------------------------|--|
| “Shareholders” | : Registered holders of Shares in the Register of Members, except that where the registered holder is CDP, the term “Shareholders” shall, in relation to such Shares and where the context admits, mean the persons named as Depositors in the Depository Register maintained by the CDP and whose Securities Accounts maintained with CDP are credited with those Shares |
| “Shares” | : Ordinary shares in the capital of the Company |
| “Sponsor” | : PrimePartners Corporate Finance Pte. Ltd. |
| “S\$”, “\$” and “cents” | : Singapore dollars and cents, respectively |
| “%” or “per cent” | : Per centum or percentage |

The terms **“Depositor”**, **“Depository Agent”** and **“Depository Register”** shall have the meanings ascribed to them respectively in Section 81SF of the SFA.

The expressions **“associate”**, **“associated company”**, **“subsidiary”**, **“controlling shareholder”** and **“substantial shareholder”** shall have the meaning ascribed to them respectively in the Companies Act and the Catalist Rules.

Words importing the singular shall, where applicable, include the plural and *vice versa*. Words importing the masculine gender shall, where applicable, include the feminine and neuter genders and *vice versa*. References to persons, where applicable, shall include corporations.

Any reference in this Appendix to any enactment is a reference to that enactment as for the time being amended or re-enacted. Any term defined under the Companies Act, SFA or Catalist Rules or any statutory or regulatory modification thereof and used in this Appendix shall, where applicable, have the meaning assigned to it under the Companies Act, SFA or Catalist Rules or such statutory or regulatory modification thereof, as the case may be, unless otherwise provided.

The headings in this Appendix are inserted for convenience only and shall be ignored in construing this Appendix.

Any reference to a time of day in this Appendix shall be a reference to Singapore time unless otherwise stated.

All discrepancies in the figures included herein between the listed amounts and totals thereof are due to rounding. Accordingly, figures shown as totals in this Appendix may not be an arithmetic aggregation of the figures that precede them.

LETTER TO SHAREHOLDERS

PASTURE HOLDINGS LTD.

(Company Registration Number 201731601W)
(Incorporated in the Republic of Singapore on 3 November 2017)

Board of Directors

Mr. Soong Chin Kum Jonathan Lloyd (Executive Chairman and Chief Executive Officer)
Ms. Claire Soong Jia Li (Alternate Director to Soong Chin Kum Jonathan Lloyd)
Mr. Prashanth Palepu (Non-Executive and Non-Independent Director)
Mr. Lim Jit Soon (Non-Executive Director and Lead Independent Director)
Ms. Teo Kwee Yee (Non-Executive and Independent Director)
Ms. Low Su-Shing (Non-Executive and Independent Director)

Registered Office

2 Corporation Road
#03-04/05
Corporation Place
Singapore 618494

8 October 2025

To: The Shareholders of Pasture Holdings Ltd.

Dear Sir / Madam

1. INTRODUCTION**1.1 AGM**

The Board of Directors has on 8 October 2025 issued the Notice of AGM convening the AGM to be held on 23 October 2025 at 10.30 a.m. at Huone Singapore, 3D River Valley Road, #03-01, Singapore 179023 to seek Shareholders' approval for, *inter alia*, the proposed renewal of the IPT General Mandate (the "**Proposed Resolution**").

1.2 Appendix

The purpose of this Appendix is to provide Shareholders with information relating to the Proposed Resolution.

2. THE PROPOSED RENEWAL OF THE SHAREHOLDERS' GENERAL MANDATE FOR INTERESTED PERSON TRANSACTIONS**2.1 Background and Renewal of the IPT General Mandate**

The IPT General Mandate was first adopted from the date of the Company's admission of the Shares to the Official List of Catalist on 9 June 2023. Shareholders had at the FY2024 AGM on 29 October 2024, approved the renewal of the IPT General Mandate which will continue to remain in effect until the conclusion of the upcoming AGM of the Company to be held on 23 October 2025. Accordingly, the Directors propose that the IPT General Mandate be renewed at the forthcoming AGM.

The IPT General Mandate enables the EAR Group, in the ordinary course of business, to enter into the Mandated Transactions with the Mandated Interested Persons which are necessary for the day-to-day operations, provided that all such transactions are carried out on normal commercial terms and are not prejudicial to the interests of the Company and its minority Shareholders.

APPENDIX

2.2 Particulars of the IPT General Mandate to be Renewed

Save for the removal of Palepu Pharma from the list of Mandated Interested Persons as it is no longer considered as an interested person (as defined under Chapter 9 of the Catalist Rules), as described further in Section 2.5 of this Appendix, the nature of the Mandated Transactions in respect of which the IPT General Mandate is sought to be renewed, remain unchanged since the FY2024 AGM. Particulars of the IPT General Mandate, including the rationale for the IPT General Mandate, the benefits to be derived by the Company, as well as the review procedures for determining transaction prices with the Mandated Interested Person, are set out in Section 2.5 of this Appendix.

2.3 Audit Committee's Confirmation

Pursuant to Rule 920(1)(c) of the Catalist Rules, the Audit Committee confirms that:

- (a) the methods or procedures for determining the transaction prices have not changed since the renewal of the IPT General Mandate which was last approved by the Shareholders at the Company's previous AGM; and
- (b) the methods or procedures referred to in sub-paragraph (a) above are sufficient to ensure that the Mandated Transactions carried out thereunder will be on normal commercial terms and will not be prejudicial to the interests of the Company and its minority shareholders.

2.4 Chapter 9 of the Catalist Rules

Chapter 9 of the Catalist Rules governs transactions in which an "entity at risk" (as defined under Chapter 9 of the Catalist Rules) enters into or proposes to enter into with a party who is an "interested person" (as defined under Chapter 9 of the Catalist Rules). The purpose is to guard against the risk that an interested person could influence the listed company, its subsidiaries or associated companies to enter into transactions with it that may adversely affect the interests of the listed company or its shareholders.

Pursuant to Rule 905 of the Catalist Rules, an issuer must make an immediate announcement of any interested person transaction of a value, equal to, or more than, 3.0% of the group's latest audited NTA. If the aggregate value of all transactions entered into with the same interested person during the same financial year amounts to 3.0% or more of the group's latest audited NTA, the issuer must make an immediate announcement of the latest transaction and all future transactions entered into with that same interested person during the financial year.

Pursuant to Rule 906 of the Catalist Rules, an issuer must obtain shareholders' approval for any interested person transaction of a value equal to, or more than:

- (a) 5.0% of the group's latest audited consolidated NTA; or
- (b) 5.0% of the group's latest audited consolidated NTA, when aggregated with other transactions entered into with the same interested person (as such term is construed under Chapter 9 of the Catalist Rules) during the same financial year. However, a transaction which has been approved by shareholders, or is the subject of aggregation with another transaction that has been approved by shareholders, need not be included in any subsequent aggregation.

The above requirements for immediate announcement and/or for shareholders' approval do not apply to any transaction below S\$100,000. Under Rules 905(5) and 906(4) of the Catalist Rules, while transactions below S\$100,000 are not normally aggregated, the SGX-ST may aggregate any such transaction entered into during the same financial year and treat them as if they were one (1) transaction in accordance with Rule 902 of the Catalist Rules.

Pursuant to Rule 909 of the Catalist Rules, the value of a transaction is the amount at risk to the listed company. This is illustrated by the following examples:

- (a) in the case of a partly-owned subsidiary or associated company, the value of the transaction is the listed company's effective interest in that transaction;
- (b) in the case of a joint venture, the value of the transaction includes the equity participation, shareholders' loans and guarantees given by the entity at risk;
- (c) in the case of borrowing of funds from an interested person, the value of the transaction is the interest payable on the borrowing. In the case of lending of funds to an interested person, the value of the transaction is the interest payable on the loan and the value of the loan; and
- (d) in the case that the market value or book value of the asset to be disposed of is higher than the consideration from an interested person, the value of the transaction is the higher of the market value or book value of the asset.

Based on the audited consolidated financial statements of the Group for FY2025, the consolidated NTA of the Group was US\$4,928,000. Accordingly, in relation to the Group, for the purposes of Chapter 9 of the Catalist Rules, in the current financial year and until the audited consolidated financial statements of the Group for FY2025 are published, 5.0% of the Group's latest audited consolidated NTA would be US\$246,400.

For the purposes of Chapter 9 of the Catalist Rules:

- (a) an **"approved exchange"** means a stock exchange that has rules which safeguard the interests of shareholders against interested person transactions according to similar principles as Chapter 9;
- (b) an **"associate"** means:
 - (i) in relation to an interested person who is a director, chief executive officer or controlling shareholder (being an individual), an immediate family member (that is, the spouse, child, adopted child, step-child, sibling or parent) of such director, chief executive officer or controlling shareholder, the trustees of any trust of which the interested person or his immediate family is a beneficiary, or in the case of a discretionary trust, is a discretionary object, and any company in which the interested person and his immediate family has or have an aggregate interest (directly or indirectly) of 30.0% or more; and
 - (ii) in relation to an interested person who is a controlling shareholder (being a corporation), any other company which is its subsidiary or holding company or fellow subsidiary or a company in which it and/or such other company or companies taken together have (directly or indirectly) an interest of 30.0% or more;
- (c) an **"associated company"** means a company in which at least 20.0% but not more than 50.0% of its shares are held by the listed company or group;
- (d) an **"entity at risk"** means:
 - (i) the listed company;
 - (ii) a subsidiary of the listed company that is not listed on the SGX-ST or an approved exchange; or

APPENDIX

- (iii) an associated company of the listed company that is not listed on the SGX-ST or an approved exchange, provided that the listed company and/or its subsidiaries (the “listed group”), or the listed group and its interested person(s), has control over the associated company;
- (e) an “**interested person**” means a director, chief executive officer or controlling shareholder of the listed company or an associate of such director, chief executive officer or controlling shareholder.

The SGX-ST may deem any person or entity to be an interested person if the person or entity has entered into or proposes to enter into (i) a transaction with an entity at risk; and (ii) an agreement or arrangement with an interested person in connection with that transaction;

- (f) a “**primary interested person**” means a director, chief executive officer or controlling shareholder of the listed company;
- (g) an “**interested person transaction**” means a transaction between an entity at risk and an interested person;
- (h) a “**transaction**” includes the provision or receipt of financial assistance; the acquisition, disposal or leasing of assets; the provision or receipt of goods or services; the issuance or subscription of securities; the granting of or being granted options; and the establishment of joint ventures or joint investments, whether or not entered into in the ordinary course of business, and whether or not entered into directly or indirectly; and
- (i) in interpreting the term “**same interested person**” for the purpose of aggregation of the values of all transactions entered into with the same interested person during the same financial year under Rules 905 and 906 of Chapter 9 of the Catalist Rules, the following applies:
 - (i) transactions between (A) an entity at risk and a primary interested person; and (B) an entity at risk and an associate of that primary interested person, are deemed to be transactions between an entity at risk with the same interested person.

Transactions between (1) an entity at risk and a primary interested person; and (2) an entity at risk and another primary interested person, are deemed to be transactions between an entity at risk with the same interested person if the primary interested person is also an associate of the other primary interested person; and

- (ii) transactions between an entity at risk and interested persons who are members of the same group are deemed to be transactions between the entity at risk with the same interested person.

If an interested person (which is a member of a group) is listed, its transactions with the entity at risk need not be aggregated with transactions between the entity at risk and other interested persons of the same group, provided that the listed interested person and other listed interested persons have boards the majority of whose directors are different and are not accustomed to act on the instructions of the other interested persons and have audit committees whose members are completely different.

2.5 Renewal of the IPT General Mandate

2.5.1 *Introduction*

The Company anticipates that the EAR Group would, in the ordinary course of business, continue to enter into certain transactions with its interested persons (as such term is defined in the Catalist Rules), including but not limited to those categories of transactions described below. In view of the time-sensitive and recurrent nature of commercial transactions, it would be advantageous for the Company to obtain a renewal of the IPT General Mandate from its Shareholders to enter into the Mandated Transactions with the Mandated Interested Persons in the EAR Group's ordinary course of business, which are necessary for the day-to-day operations of the EAR Group, provided that all such transactions are carried out on normal commercial terms and are not prejudicial to the interests of the Company and its minority Shareholders.

Rule 920 of the Catalist Rules allows a listed company to obtain a mandate from its shareholders for recurrent interested person transactions which are of a revenue or trading nature or for those necessary for its day-to-day operations. These transactions may not include the purchase or sale of assets, undertakings or businesses which are not part of its day-to-day operations.

The renewal of the IPT General Mandate, if approved, will take effect from the passing of the ordinary resolution relating thereto, and will continue in force until the conclusion of the next annual general meeting of the Company (unless revoked or varied by the Company in general meeting). Approval from Shareholders will be sought for the renewal of the IPT General Mandate at the next annual general meeting (or extraordinary general meeting following such annual general meeting) and each subsequent annual general meeting (or extraordinary general meeting following such annual general meeting) of the Company, subject to satisfactory review by the Audit Committee of its continued application to the Mandated Transactions.

2.5.2 *Entities at Risk*

For the purposes of the IPT General Mandate, an “**Entity at Risk**” means:

- (a) the Company;
- (b) a subsidiary of the Company (excluding subsidiaries listed on the SGX-ST or an approved exchange); and
- (c) an associated company of the Company (other than an associated company that is listed on the SGX-ST or an approved exchange) over which the Group, or the Group and its interested person(s), has or have control.

(collectively, the “**EAR Group**”).

2.5.3 *Classes of Mandated Interested Persons*

The IPT General Mandate will apply to the transactions that are carried out between any Entity at Risk and Pleasant Exports (“**Mandated Interested Person**”, being “interested persons” as defined in the Catalist Rules).

Mr. Prashanth Palepu, a Non-Executive and Non-Independent Director of the Company, together with his immediate family, namely Mr. Srinivasa Gopal Palepu and Mr. Pranay Palepu, hold the entire issued share capital of Pleasant Exports. Accordingly, Pleasant Exports is an associate of Mr. Prashanth Palepu and an interested person.

APPENDIX

Transactions between the Mandated Interested Person and the Group which do not fall within the ambit of the IPT General Mandate shall be subject to the relevant provisions of Chapter 9 of the Catalist Rules and/or other applicable provisions of the Catalist Rules. In particular, if such a transaction, when aggregate with other transactions entered into with the same interested person during the same financial year, is equal to or more than 5.0% of the Group's latest audited NTA, such transaction will be subject to Shareholders' approval before they can be entered into.

On 7 October 2025, the Company was informed by Mr. Srinivasa Gopal Palepu, a controlling shareholder of the Company, that the aggregate interest in the share capital of Palepu Pharma held by him together with his immediate family, had decreased from 40.0% to below 5.0%. Accordingly, Palepu Pharma has ceased to be an associate of Mr. Srinivasa Gopal Palepu and an interested person of the Group for the purposes of Chapter 9 of the Catalist Rules. In this regard, Palepu Pharma which was previously a Mandated Interested Person covered under the IPT General Mandate (which was last renewed at the FY2024 AGM), is no longer an interested person of the Group and any transaction between the EAR Group and Palepu Pharma will no longer be interested person transactions for the purposes of Chapter 9 of the Catalist Rules. For the avoidance of doubt, there had been no transactions between the EAR Group and Palepu Pharma during FY2025.

Save for the above, the terms and conditions of the IPT General Mandate relating to transactions between any of the entity within the EAR Group with the Mandated Interested Person remain the same.

2.5.4 *Categories of Mandated Interested Person Transactions*

The types of transactions with the Mandated Interested Person to which the IPT General Mandate will apply are:

- (a) the purchase of pharmaceutical products by the Group from the Mandated Interested Person; and
- (b) the sale of masks and medical supplies by the Group to the Mandated Interested Person,

(the "Mandated Transactions").

The IPT General Mandate covers only such recurrent Mandated Transactions of a revenue or trading nature or those necessary for the Group's day-to-day operations, which are entered into in the ordinary course of business. For the avoidance of doubt, any purchase or sale of any assets, undertakings or businesses are not covered under the IPT General Mandate.

The IPT General Mandate does not cover any transaction by any member of the Group with the Mandated Interested Person where such transaction is below S\$100,000 in value, as the threshold and aggregation requirements contained in Chapter 9 of the Catalist Rules would not apply to such transactions. Under Rules 905(5) and 906(4) of the Catalist Rules, while transactions below S\$100,000 are not normally aggregated, the SGX-ST may aggregate any such transaction entered into during the same financial year and treat them as if they were one (1) transaction in accordance with Rule 902 of the Catalist Rules.

2.5.5 *Rationale for and Benefits of the IPT General Mandate*

Pleasant Exports has been one of the Group's suppliers for quality pharmaceutical products since the establishment of the Group in 1996, even prior to the shareholders of Pleasant Exports becoming controlling shareholders of the Company. Pleasant Exports has a strong track record of supplying a wide variety of pharmaceutical products as it has established an extensive network to procure from reputable and reliable drugs manufacturers and pharmaceutical companies based in India, which is a key pharmaceutical manufacturing hub in the world. Accordingly, the IPT General Mandate would enable the EAR Group to tap on the extensive network of Pleasant Exports and obtain quality pharmaceutical products on normal commercial terms from a reliable source, being Pleasant Exports, in the normal course of business of the EAR Group.

Although the Group did not sell any masks and medical supplies to Pleasant Exports during FY2025, given that Pleasant Exports has a strong presence and extensive outreach in India, the EAR Group intends to also tap on Pleasant Exports' extensive network to expand the Group's clientele base for the distribution of its masks and medical supplies, in the normal course of business of the EAR Group.

The IPT General Mandate is intended to facilitate transactions which are transacted from time to time between the EAR Group and the Mandated Interested Person, provided that they are carried out at arm's length and on normal commercial terms, and are not prejudicial to the interests of the Company and its minority Shareholders. The EAR Group will benefit from having access to competitive quotes from the Mandated Interested Person in addition to obtaining quotes from, or transacting with, non-Mandated Interested Person for the purchase of pharmaceutical products as well as having more sales channels for the sale of the Group's masks and medical supplies. Given the nature of the Group's business, it is envisaged that the Mandated Transactions are likely to occur from time to time, in the ordinary course of business.

The IPT General Mandate and its subsequent renewal on an annual basis would eliminate the need to announce, or to announce and convene separate general meetings from time to time to seek Shareholders' prior approval as and when potential Mandated Transactions with the Mandated Interested Person arise, thereby saving substantial administrative time and costs expended in convening such meetings, without compromising the corporate objectives of the EAR Group and adversely affecting the business opportunities available to the EAR Group.

In accordance with the requirements of Chapter 9 of the Catalist Rules, the Company will (a) disclose in its annual report the aggregate value of transactions conducted with the Mandated Interested Person pursuant to the IPT General Mandate during the financial year (as well as in the annual reports for subsequent financial years that the IPT General Mandate continues to be in force); and (b) announce the aggregate value of transactions conducted with the Mandated Interested Person pursuant to the IPT General Mandate for the financial periods that the Company is required to report on pursuant to Rule 705 of the Catalist Rules within the time required for the announcement of such report.

APPENDIX

2.5.6 *Review Procedures for Mandated Transactions with Mandated Interested Person*

To ensure that Mandated Transactions with the Mandated Interested Person are undertaken (a) at arm's length basis and on normal commercial terms consistent with the Group's usual business practices and on terms which are generally not more favourable to the Mandated Interested Person than those extended by the Group to unrelated third-parties or not less favourable to the Group than those extended by unrelated third-parties to the Group; or (b) in any event on terms no less favourable to the Group than prevailing open market rates, and will not be prejudicial to the interests of the Company and its minority Shareholders, the Group will adopt the following procedures for the review and approval of Mandated Transactions under the IPT General Mandate:

- (a) The following procedures will be adopted for the purchase of pharmaceutical products by the EAR Group from the Mandated Interested Person:
 - (i) Before any purchase of pharmaceutical products from the Mandated Interested Person, quotations from at least two (2) unrelated third-party suppliers for the same or similar types of pharmaceutical products will be obtained for comparison wherever appropriate and practicable ("**Comparable Quotes**"). In general, the Group will only purchase pharmaceutical products from the Mandated Interested Person if the Group is satisfied that the purchase price of such pharmaceutical products to be paid by the EAR Group to the Mandated Interested Person is not higher than the most competitive quote of the Comparable Quotes, after taking into account relevant factors such as the track record of the suppliers, the availability and delivery schedule, the relevant certification (if applicable, in particular for new pharmaceutical products), expiry dates and any other relevant factors.
 - (ii) In the event that two (2) Comparable Quotes are not available (for instance, there are no unrelated third-party suppliers of similar products, or only one (1) Comparable Quote was obtained, or if the product is a proprietary item distributed only by the Mandated Interested Person), the Group will request for two (2) recent transaction documents from the Mandated Interested Person for the sale of the same or substantially similar products by the Mandated Interested Person to its unrelated third-party customers, as the basis for comparison to determine whether the prices and terms offered by the Mandated Interested Person are on normal commercial terms and not less favourable to the EAR Group as compared to those offered by the Mandated Interested Person to its unrelated third-party customers.
 - (iii) In the event that the Mandated Interested Person is unable to share the relevant transaction documents with the Group for the above comparison purposes, the Chief Executive Officer or the Chief Financial Officer or, in the event the Chief Executive Officer and the Chief Financial Officer have an interest in the Mandated Transaction(s) or are nominees of the Mandated Interested Person, an officer of similar or equivalent rank (who must have no interest, direct or indirect, in the transaction) will determine whether the prices and terms offered by the Mandated Interested Person are in accordance with the Group's usual business practices and pricing policies or industry norms, on normal commercial terms and not prejudicial to the interests of the Company and its minority Shareholders after taking into account factors such as the historical rates or prices paid by the Group for the same or substantially similar products, credit terms, strategic purposes of the transaction and any other relevant factors. The Chief Executive Officer, the Chief Financial Officer and/or other officer of similar or equivalent rank

may, if they deem fit, request for any additional information pertaining to the transaction under review from independent sources, advisers or valuers, or require additional review by the Group's internal auditors in respect of the Mandated Transactions.

- (b) The following procedures will be adopted for the sale of masks and medical supplies by the EAR Group to the Mandated Interested Person:
 - (i) Before any sale of masks and/or medical supplies by the EAR Group to the Mandated Interested Person, the Group will compare the quotation to be given to the Mandated Interested Person with at least two (2) recent successful sales of the same masks and/or medical supplies by the EAR Group to its unrelated third-party customers ("**Comparable Sales**"). In general, the Group will only transact with the Mandated Interested Person if the Group is satisfied that the selling price of such masks and/or medical supplies by the EAR Group to the Mandated Interested Person is not lower than the most competitive selling price of the Comparable Sales after taking into account relevant factors such as the credit terms granted for the sale, freight charges, the volume of sale and any other relevant factors.
 - (ii) In the event that Comparable Sales are not available (for instance, when the Mandated Interested Person requests for customised packaging for sale in their territories), the Chief Executive Officer or the Chief Financial Officer or, in the event the Chief Executive Officer and the Chief Financial Officer have an interest in the Mandated Transaction(s) or are nominees of the Mandated Interested Person, an officer of similar or equivalent rank (who must have no interest, direct or indirect, in the transaction) will determine whether the prices and terms offered to the Mandated Interested Person are in accordance with the Group's usual business practices and pricing policies or industry norms, on normal commercial terms and not prejudicial to the interests of the Company and its minority Shareholders after taking into account factors such as the gross profit as well as the gross profit margin to be generated by the Group from the sale such that the Group's gross profit margin will not be adversely affected by the sale. The Chief Executive Officer, the Chief Financial Officer and/or other officer of similar or equivalent rank may, if they deem fit, request for any additional information pertaining to the transaction under review from independent sources, advisers or valuers, or require additional review by the Group's internal auditors in respect of the Mandated Transactions.
- (c) The following approval thresholds will apply to the Mandated Transactions generally:
 - (i) All Mandated Transactions will be subject to review and prior approval by the Chief Executive Officer or the Chief Financial Officer or, in the event the Chief Executive Officer and the Chief Financial Officer have an interest in the Mandated Transaction(s) or are nominees of the Mandated Interested Person, an officer of similar or equivalent rank (who must have no interest, direct or indirect, in the transaction).
 - (ii) In respect of the purchase of pharmaceutical products by the EAR Group from the Mandated Interested Person, where the value of such Mandated Transactions (either individually or cumulative during the same financial year) is equal to or exceeding 3.0% of the value of the Group's latest audited NTA, such Mandated Transaction(s) will be subject to the review and prior approval of the Audit Committee.

APPENDIX

- (iii) In respect of sale of masks and/or medical supplies by the EAR Group to the Mandated Interested Person, where the value of such Mandated Transactions (either individually or cumulatively during the same financial year) is equal to or exceeding 3.0% of the value of the Group's latest audited NTA, such Mandated Transaction(s) will be subject to the review and prior approval of the Audit Committee.
- (iv) For the avoidance of doubt, Mandated Transactions which have already been reviewed and approved by the Audit Committee will not be included in such calculations.
- (v) In the event that a member of the Audit Committee has an interest in the Mandated Transaction(s), or is a nominee for the time being of any of the Mandated Interested Person (or its associates), or if he/she also serves as a director on the board of directors of any of the Mandated Interested Person, he/she shall abstain from participating in the review and approval process of the Audit Committee in relation to such Mandated Transaction(s).

Any transaction to be entered into under the IPT General Mandate shall only be approved by the above approving authority if the transaction is carried out at arm's length and on normal commercial terms, in accordance with the methods and procedures outlined in Section 2.5.6(a) and Section 2.5.6(b) of this Appendix, and the basis on which the transactions are entered into are properly documented in the IPT Register (as defined Section 2.5.7(b) below), accompanied with supporting documents. For the purposes of Section 2.5.6(a)(i) and Section 2.5.6(a)(ii) above, the value of a transaction shall be determined based on the full contract value at the time of entry into the transaction.

2.5.7 *Additional Guidelines and Review Procedures*

In addition to the guidelines and review procedures set out above, the Group will implement the following additional guidelines to ensure that the Mandated Transactions carried out under the IPT General Mandate are undertaken at arms' length basis and on normal commercial terms:

- (a) The Company will maintain a register of interested persons and their associates (which is to be updated immediately if there are any changes) to enable identification of interested persons. The list of interested persons shall be reviewed on a semi-annual basis by the Chief Financial Officer and subject to such verifications or declarations as required by the Audit Committee for such period as determined by them. This list of interested persons shall be disseminated to any staff of the Group that the Group's finance team considers relevant for the purposes of entering into transactions that fall under the IPT General Mandate.
- (b) The Company will maintain a register of all interested person transactions (including the Mandated Transactions) carried out with interested persons (including with the Mandated Interested Person) (including the bases on which the interested person transactions are entered into, amount, nature, material terms and conditions and supporting evidence and quotations obtained to support such bases) (the "**IPT Register**") by the Group's finance team, which shall be reviewed by the Chief Financial Officer on a monthly basis. The IPT Register will also record any interested person transactions that are below S\$100,000 in value, although such transactions are not required to be aggregated under Chapter 9 of the Catalist Rules.

- (c) The Audit Committee will review all Mandated Transactions (except where Mandated Transactions are required under the methods and procedures of the IPT General Mandate to be approved by the Audit Committee prior to the entry thereof) at least on a semi-annual basis, or such other frequency as deemed necessary, to ensure that they are carried out on normal commercial terms and in accordance with the procedures outlined above. All relevant non-quantitative factors will also be taken into account. Such review includes the examination of the transaction and its supporting documents or such other data deemed necessary by the Audit Committee. The Audit Committee shall, when it deems fit, request for any additional information pertaining to the transaction under review from independent sources, advisers or valuers, or require additional review by the Group's internal auditors in respect of the Mandated Transactions.
- (d) The annual internal audit plan will incorporate a review of the Mandated Transactions entered into, pursuant to the IPT General Mandate to ensure that the methods and procedures in respect of the Mandated Transactions have been adhered to. The Group's internal auditors will report to the Audit Committee annually and highlight any discrepancies or significant variances from the established methods and procedures for the Mandated Transactions to the Audit Committee.
- (e) The Audit Committee will also review, at least on a semi-annual basis, or such other frequency as deemed necessary, such methods and procedures to determine if they are adequate and/or commercially practicable in ensuring that transactions between the EAR Group and the Mandated Interested Person are conducted at arm's length and on normal commercial terms. If, during any of the reviews by the Audit Committee, the Audit Committee is of the view that the methods and procedures for Mandated Transactions have become inappropriate or insufficient in the event of changes to the nature of, or manner in which, the business activities of the Group or the Mandated Interested Person are conducted, it will, in consultation with the Board, take such actions as it deems proper in respect of such methods and procedures and/or modify or implement such methods and procedures as may be necessary to ensure that the Mandated Transactions will be conducted on normal commercial terms and will not be prejudicial to the interests of the Company and its minority Shareholders, and the Company will revert to Shareholders for a fresh general mandate based on new methods and procedures so that the Mandated Transactions will be carried out on an arm's length basis, on normal commercial terms and will not be prejudicial to the interests of the Company and its minority Shareholders. In the interim, the Audit Committee will review every Mandated Transaction pending the grant of the fresh mandate, which will be in accordance with the requirements of the relevant provisions of Chapter 9 and/or other applicable provisions of the Catalist Rules (as may be amended, modified or supplemented from time to time).
- (f) The Board will also ensure that all disclosure, approval and other requirements on interested person transactions, including those required by prevailing legislation, the Catalist Rules (in particular, Chapter 9 thereof) and relevant accounting standards, are complied with. The Company will also endeavour to comply with the recommendations set out in the Code of Corporate Governance.

The additional guidelines and review procedures for the Mandated Transactions above remain the same as those disclosed in the appendix of the FY2024 Annual Report.

APPENDIX

2.5.8 *Review of Non-Mandated Interested Person Transactions and Review by the Audit Committee*

All other existing and future interested person transactions not subject to the IPT General Mandate will be reviewed and approved in accordance with the threshold limits as set out under Chapter 9 of the Catalyst Rules, to ensure that they are carried out on normal commercial terms and on an arm's length basis, and are not prejudicial to the interests of the Company and its minority Shareholders. In the event that such interested person transactions require the approval of the Board and the Audit Committee, the relevant information will be submitted to the Board and the Audit Committee for review. In the event that such interested person transactions require the approval of the Shareholders, additional information may be required to be presented to Shareholders and an independent financial adviser may be appointed for an opinion.

In the review of all future interested person transactions not subject to the IPT General Mandate, the following procedures will be applied:

- (a) In relation to any purchase of products or procurement of services by the Group from any interested persons, the Group will obtain or procure additional quotations from at least two (2) unrelated third-party suppliers in respect of the same or substantially the same type of product or service to be used as comparison wherever possible. The purchase price or procurement fee shall not be less favourable than the most competitive price of the two (2) comparative prices from unrelated third-party suppliers.
- (b) In relation to any sale of products or provision of services by the Group to interested persons, the Group will compare the price or fee quoted to the interested person with at least two (2) recent completed transactions of the same or substantially the same nature entered by the Group with unrelated third-party customers wherever possible. The price or fee for the sale of products or the provision of services shall not be more favourable to the interested persons than those charged by the Group for the recently completed transactions with unrelated third-party customers.
- (c) When renting properties from or to an interested person, the Audit Committee shall take appropriate steps to ensure that such rent is commensurate with the prevailing market rates, including obtaining an independent valuation report by a property valuer and/or making relevant enquiries with landlords of similar properties (where available). The rent payable shall be based on the most competitive market rental rate of similar properties in terms of size and location, based on the results of the relevant enquiries.
- (d) In the event that it is not possible for appropriate information (for comparative purposes) to be obtained and given that the products or services may be purchased only from an interested person, the Audit Committee will determine whether the price, fees and/or the other terms offered by or to the interested persons are in accordance with usual business practices and pricing policies and consistent with the usual margins and/or terms to be obtained for the same or substantially similar types of transactions to determine whether the relevant transaction is undertaken on an arm's length basis and on normal commercial terms.

- (e) The following thresholds also apply:
- (i) transactions (either individually or as part of a series or if aggregated with other transactions involving the same interested person during the same financial year) equal to or exceeding S\$100,000 in value but below 3.0% of the value of the Group's latest audited NTA will be subject to review by the Audit Committee at least on a semi-annual basis, or such other frequency as deemed necessary;
 - (ii) transactions (either individually or as part of a series or if aggregated with other transactions involving the same interested person during the same financial year) equal to or exceeding 3.0% but below 5.0% of the value of the Group's latest audited NTA will be subject to the review and prior approval of the Audit Committee. Such approval shall only be given if the transactions are on an arm's length basis and on normal commercial terms and are consistent with similar types of transactions made with non-interested parties; transactions (either individually or as part of a series or if aggregated with other transactions involving the same interested person during the same financial year) equal to or exceeding 5.0% of the value of the Group's latest audited NTA will be reviewed and approved by the Audit Committee and the independent Shareholders, prior to the carrying out of such transactions; and
 - (iii) in the review of such interested person transactions, the Audit Committee may, as it deems fit, request advice on the transaction from independent sources or advisers, including the obtaining of valuations from independent professional valuers.

The IPT Register will be maintained to record all interested person transactions (including the bases on which they are entered into, amount, nature, material terms and conditions and supporting evidence and quotations obtained to support such bases). The Audit Committee will review all interested person transactions (other than those already pre-approved by the Audit Committee or the independent Shareholders) at least on a semi-annual basis, or such other frequency as deemed necessary, to ensure that they are carried out on normal commercial terms and in accordance with the procedures outlined above. All relevant non-quantitative factors will also be taken into account. Such review includes the examination of the transaction and its supporting documents or such other data deemed necessary by the Audit Committee. The Audit Committee may request for any additional information pertaining to the transaction under review from independent sources, advisers or valuers as it deems fit.

In addition, the Board will also ensure that all disclosure, approval and other requirements on interested person transactions, including those required by prevailing legislation, the Catalist Rules (in particular, Chapter 9 thereof) and relevant accounting standards, are complied with. The Company will also endeavour to comply with the recommendations set out in the Code of Corporate Governance.

The annual internal audit plan will incorporate a review of all interested person transactions entered into. The Audit Committee will review internal audit reports to ascertain that the guidelines and procedures established to monitor interested person transactions have been complied with. In addition, the Audit Committee will also review at least on a semi-annual basis, or such other frequency as deemed necessary, such guidelines and procedures to determine if they are adequate and/or commercially practicable in ensuring that transactions between the Group and its interested persons are conducted on arm's length commercial terms. In the event that a member of the Audit Committee is interested in any interested person transaction, he/she will abstain from reviewing that particular transaction.

APPENDIX

The Company will also disclose the aggregate value of interested person transactions conducted during the current financial year in the annual report, including the name of the interested person, nature of relationship and the corresponding aggregate value of the interested person transactions entered into with the same interested person.

The review procedures for all other existing and future interested person transactions not subject to the IPT General Mandate remain the same as those disclosed in the appendix of the FY2024 Annual Report.

3. DIRECTORS' RECOMMENDATIONS

Mr. Prashanth Palepu, a Non-Executive and Non-Independent Director of the Company, together with his immediate family, namely Mr. Srinivasa Gopal Palepu and Mr. Pranay Palepu, hold the entire issued share capital of Pleasant Exports. Accordingly, Mr. Prashanth Palepu will abstain from making any recommendation to Shareholders on the proposed renewal of the IPT General Mandate in his capacity as a Director.

The Non-Interested Directors, having considered, *inter alia*, the scope, procedures, rationale and benefits of the IPT General Mandate, are of the opinion that the proposed renewal of the IPT General Mandate is in the best interests of the Company and its Shareholders. Accordingly, the Non-Interested Directors recommend that the Shareholders **VOTE IN FAVOUR** of Ordinary Resolution 9 in relation to the proposed renewal of the IPT General Mandate, to be proposed at the AGM.

The Chairman of the AGM will accept appointment as proxy for any Shareholder to vote in respect of Ordinary Resolution 9 relating to the proposed renewal of the IPT General Mandate where such Shareholder has given specific instructions in a validly completed and submitted Proxy Form as to voting, or abstentions from voting, in respect of such ordinary resolution.

4. ANNUAL GENERAL MEETING

4.1 Date and Time of the AGM

The AGM will be held at Huone Singapore, 3D River Valley Road, #03-01, Singapore 179023 on 23 October 2025 at 10.30 a.m. for the purpose of considering and, if thought fit, passing with or without modifications the ordinary resolutions set out in the Notice of AGM dated 8 October 2025 which is attached to the Annual Report.

4.2 When Depositor Regarded as Shareholder

A Depositor shall not be regarded as a Shareholder of the Company entitled to attend the AGM and to speak and vote thereat unless his name appears on the Depository Register at least 72 hours before the time fixed for the AGM.

5. ABSTENTION FROM VOTING

Mr. Prashanth Palepu, Mr. Pranay Palepu and Mr. Srinivasa Gopal Palepu hold 25.0%, 25.0% and 50.0% of the issued and paid-up share capital of Plutus Star Holding Pte. Ltd., respectively. Accordingly, in accordance with Rule 920(1)(b)(viii) of the Catalist Rules, Plutus Star Holding Pte. Ltd. will abstain, and has undertaken to ensure that it and its associates will abstain, from voting at the AGM in respect of Ordinary Resolution 9 approving to the proposed renewal of the IPT General Mandate, and that Plutus Star Holding Pte. Ltd. and its associates will not accept appointments as proxies in relation to the proposed Ordinary Resolution 9 unless specific instructions as to voting are given. The Company will disregard any votes cast on a resolution by the persons required to abstain from voting.

6. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this Appendix and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, this Appendix constitutes full and true disclosure of all material facts about the proposed renewal of the IPT General Mandate, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this Appendix misleading. Where information in this Appendix has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this Appendix in its proper form and context.

7. DOCUMENTS AVAILABLE FOR INSPECTION

The following documents or copies thereof may be inspected at the registered office of the Company at 2 Corporation Road, #03-04/05 Corporation Place, Singapore 618494 during normal business hours from the date of this Appendix up to and including the date of the AGM:

- (a) the Annual Report; and
- (b) the Constitution.

The Annual Report may also be accessed on SGXNET at the following URL: <https://www.sgx.com/securities/company-announcements> and is also available on the Company's website at the following URL: <https://pasturegroup.com/>.

Yours faithfully

By order of the Board of Directors of
PASTURE HOLDINGS LTD.

Peck Jen Jen
Company Secretary
8 October 2025

PASTURE HOLDINGS LTD.

(Company Registration No.: 201731601W)
(Incorporated in the Republic of Singapore)

PROXY FORM

ANNUAL GENERAL MEETING

Important

1. For CPFIS/SRS investors who have used their CPFIS/SRS monies to buy shares in Pasture Holdings Ltd. (the "**Company**"), this proxy form is not valid for use and shall be ineffective for all intents and purposes if used or purported to be used by them. CPFIS/SRS investors should contact their respective agent banks if they have any queries regarding their appointment as proxies.
2. By submitting an instrument appointing a proxy(ies) and/or representative(s), the member accepts and agrees to the personal data privacy terms set out in the Notice of Annual General Meeting dated 8 October 2025.
3. Please read the notes overleaf which contain instructions on, inter alia, the appointment of proxy(ies).

I/We _____ (Name) NRIC/Passport No _____

of _____ (Address)

being a member(s) of Pasture Holdings Ltd. (the "Company"), hereby appoint: -

| Name | NRIC/Passport No. | Email Address | Proportion of Shareholdings | |
|---------|-------------------|---------------|-----------------------------|---|
| | | | Number of Shares | % |
| Address | | | | |

and/or (delete as appropriate)

| Name | NRIC/Passport No. | Email Address | Proportion of Shareholdings | |
|---------|-------------------|---------------|-----------------------------|---|
| | | | Number of Shares | % |
| Address | | | | |

or failing whom, the Chairman of the Annual General Meeting of the Company as *my/our *proxy/proxies to vote for *me/us on *my/our behalf at the Annual General Meeting of the Company to be held at **Huone Singapore, 3D River Valley Road, #03-01, Singapore 179023 on Thursday, 23 October 2025 at 10.30 a.m.** and at any adjournment thereof.

*I/We direct *my/our *proxy/proxies to vote for, against or abstain the Resolutions proposed at the Annual General Meeting as indicated hereunder.

If no specific direction as to voting is given or in the event of any other matter arising at the Annual General Meeting and at any adjournment thereof, the proxy/proxies will vote or abstain from voting at his/her discretion. All resolutions put to the vote at the Annual General Meeting shall be decided by way of poll.

(If you wish to exercise all your votes "For", "Against" or "Abstain", please tick [✓] within the box provided. Alternatively, please indicate the number of votes as appropriate.)

| No. | Ordinary Resolutions | For | Against | Abstain |
|--------------------------|--|-----|---------|---------|
| Ordinary Business | | | | |
| 1. | Adoption of the Audited Financial Statements of the Company for the financial year ended 30 June 2025 together with the Directors' Statement and Independent Auditors' Report thereon. | | | |
| 2. | Declaration of a tax exempt (one-tier) final dividend of S\$0.0023 per ordinary share in respect of the financial year ended 30 June 2025. | | | |
| 3. | Approval of the payment of Directors' fees of S\$149,500.00 for the financial year ending 30 June 2026, to be paid half-yearly in arrears. | | | |
| 4. | Re-election of Ms Teo Kwee Yee pursuant to Regulation 111 of the Company's Constitution. | | | |
| 5. | Re-election of Ms Low Su-Shing pursuant to Regulation 111 of the Company's Constitution. | | | |
| 6. | Re-appointment of Messrs RSM SG Assurance LLP as auditors of the Company. | | | |
| Special Business | | | | |
| 7. | Authority to allot and issue shares and convertible securities. | | | |
| 8. | Authority to issue shares under Pasture Share Performance Plan. | | | |
| 9. | Renewal of the Shareholders' General Mandate for Interested Person Transactions | | | |

Dated this _____ day _____ 2025

| |
|------------------------------------|
| Total Number of Shares Held |
| |

Signature(s) of Member(s) or Common Seal of Corporate Member

* Delete accordingly

IMPORTANT: PLEASE READ NOTES OVERLEAF BEFORE COMPLETING THIS PROXY FORM



Notes:-

1. A member who is unable to attend the AGM and wishes to appoint proxy(ies) to attend, speak and vote at the AGM on his/her/its behalf should complete, sign and return the instrument of proxy in accordance with the instructions printed thereon.
2. A proxy need not to be a member of the Company.
3. Please insert the total number of shares of the Company (“Shares”) held by you. If you have Shares entered against your name in the Depository Register (as defined in Section 81SF of the Securities and Futures Act 2001), you should insert that number of Shares. If you have Shares registered in your name in the Register of Members, you should insert that number of Shares. If you have Shares entered against your name in the Depository Register and Shares registered in your name in the Register of Members, you should insert the aggregate number of Shares entered against your name in the Depository Register and registered in your name in the Register of Members. If no number is inserted, the instrument appointing a proxy or proxies shall be deemed to relate to all the Shares held by you.
4. In relation to the appointment of proxy(ies) to attend, speak and vote on his/her/its behalf at the AGM, a member (whether individual or corporate) appointing his/her/its proxy(ies) should give specific instructions as to his/her/its manner of voting, or abstentions from voting, in respect of a resolution in the instrument of proxy. If no specific instructions as to voting are given, or in the event of any other matter arising at the AGM and at any adjournment thereof, the proxy(ies) will vote at his discretion.
5. The instrument appointing a proxy or proxies must be under the hand of the appointor or of his attorney duly authorised in writing. Where the instrument appointing a proxy or proxies is executed by a corporation, it must be executed either under its seal, executed as a deed in accordance with the Companies Act 1967 or under the hand of an attorney or an officer duly authorised, or in some other manner approved by the Directors. Where the instrument appointing a proxy or proxies is executed by an attorney on behalf of the appointor, the letter or power of attorney or a duly certified copy thereof must be lodged with the instrument of proxy.
6. The instrument appointing the proxy, together with the letter or power of attorney or other authority under which it is signed or a duly certified copy thereof (if applicable), must be submitted either: -
 - (a) if submitted by post, be lodged with the Company’s Share Registrar, Tricor Barbinder Share Registration Services at 9 Raffles Place #26-01 Republic Plaza, Singapore 048619; or
 - (b) if submitted electronically, be submitted via contact@pasturegroup.com.in either case, by **10.30 a.m. on 20 October 2025**, being not less than seventy-two (72) hours before the time appointed for holding the Meeting (or any adjournment thereof) and in default the instrument of proxy shall not be treated as valid.
7. A member can appoint the Chairman of the Meeting as his/her/its proxy, but this is not mandatory.
8. A member who is not a relevant intermediary is entitled to appoint not more than two proxies to attend, speak and vote in his/her stead. Where a member appoints two proxies, the appointments shall be invalid unless he/she specifies the proportion of his/her shareholding (expressed as a percentage of the whole) to be represented by each proxy.
9. A member who is a relevant intermediary entitled to attend the meeting and vote is entitled to appoint more than two proxies to attend and vote instead of the member, but each proxy must be appointed to exercise the rights attached to a different Share or Shares held by such member. Where such member appoints more than two proxies, the appointments shall be invalid unless the member specifies the number of Shares in relation to which each proxy has been appointed.
10. “Relevant intermediary” has the meaning ascribed to it in section 181(6) of the Companies Act and refers to:
 - (a) a banking corporation licensed under the Banking Act 1970 or a wholly-owned subsidiary of such a banking corporation, whose business includes the provision of nominee services and who holds shares in that capacity;
 - (b) a person holding a capital markets services licence to provide custodial services for securities under the Securities and Futures Act 2001 and who holds shares in that capacity; or
 - (c) the Central Provident Fund Board established by the Central Provident Fund Act 1953, in respect of shares purchased under the subsidiary legislation made under that Act providing for the making of investments from the contributions and interest standing to the credit of members of the Central Provident Fund, if the Board holds those shares in the capacity of an intermediary pursuant to or in accordance with that subsidiary legislation.
11. For investors who hold shares through relevant intermediaries, including Central Provident Fund Investment Schemes (“**CPF Investors**”) and/or Supplementary Retirement Scheme (“**SRS Investors**”) should approach their respective CPF Agent Banks or SRS Operators to submit their votes at least 7 working days before the AGM. CPF/SRS Investors should contact their respective CPF Agent Banks or SRS Operators for any queries they may have with regard to the appointment of proxy for the AGM.
12. Completion and return of the Proxy Form by a member will not prevent him/her from attending, speaking and voting at the AGM if he/she so wishes. The appointment of the proxy(ies) for the AGM will be deemed to be revoked if the member attends the AGM in person and in such event, the Company reserves the right to refuse to admit any person or persons appointed under the relevant instrument appointing a proxy(ies) to the AGM.

General:

The Company shall be entitled to reject the instrument appointing the Chairman of the Meeting if it is incomplete, improperly completed or illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the instrument appointing the Chairman of the Meeting. In addition, in the case of members of the Company whose shares are entered against their names in the Depository Register, the Company may reject any instrument appointing the Chairman of the Meeting lodged if such members are not shown to have shares entered against their names in the Depository Register seventy-two (72) hours before the time appointed for holding the Annual General Meeting as certified by The Central Depository (Pte) Limited to the Company.

Personal Data Privacy

By submitting an instrument appointing a proxy(ies) and/or representative(s), the member accepts and agrees to the personal data privacy terms set out in the Notice of AGM dated 8 October 2025.



PASTURE HOLDINGS LTD.

(COMPANY REGISTRATION NO.: 201731601W)

(INCORPORATED IN THE REPUBLIC OF SINGAPORE ON
3 NOVEMBER 2017)

Address: 2 Corporation Road #03-04/05 Corporation Place
Singapore 618494
Phone: +65 6515 6516
www.pasturegroup.com